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Abstract  
 This thesis presents research into the development of sustainable methodology for the 
synthesis of amides, esters and polypropionate fragments. As well as a literature review of 
efficient natural product synthesis.  
Acylals are a known class of reagent that have been utilized within literature for a wide 
range of synthetic methodologies. Herein we present acylals as new highly active reagents for 
the N-/O-acylation of amines and alcohol nucleophiles for the synthesis of a range of 
formamides, acetamides, formate esters and acetate esters. It has been demonstrated that a 
range of acyl groups can be transferred including short and long chain alkyls, acryloyl, benzoyl, 
phenyl acetyl and biologically important trifluoroacetyl group, thus enabling the synthesis of a 
range of benzylamides and esters. These acylation reagents have also been shown to 
demonstrate inherent N-/O- selectivity towards the amine and alcohol groups of serine methyl 
ester.   
The scope and limitations of these reagents of the use of acylals has been investigated 
through the N-formylation of a range of unprotected amino acids, and for the synthesis of the 
biologically important tripeptide f-MLP. As well as the acylation/formylation of the ω-amino 
residue of a lysine residue within a decapeptide. Finally, it has also been demonstrated that a 
simple switch in pH from basic to acidic conditions for diols can change from O-acylation to 
acetal formation. 
The synthesis of enantiomerically enriched dihydropyrans from the heteo-Diels-Alder 
reaction of 1-alkoxy dienes and ethyl glyoxalate has been presented. A series of stereoselective 
derivatisation reactions were developed including, hydroboration, hydrogenation, epoxidation, 
dihydroxylation and epimerization which procced with stereoselectivity to afford a range of 
complex enantiomerically enriched polypropionate based building blocks, which are ideally 
suited for the synthesis of polyketide natural products through a “plug and play” approach.  
Chemistry has also been presented which makes use of the orthogonally addressable synthetic 
handles of the pyran building blocks. Utilization of either the masked aldehyde character or the 
ester functionality present allows for further elaboration of the pyran building blocks by 
selectively introducing new functionality.   
 
 
III 
 
Acknowledgements  
First and foremost I would like to thanks Prof. Steve Bull who has provided great advice 
and ideas throughout my PhD. He has provided me with unbelievable opportunities over the 
years and for those I will be forever grateful, I look forward to his continued support and 
friendship in the future. Even if it does mean I have to keep letting him beat me at pool on a 
regular basis.  
I would also like to thank the CSCT for giving me the opportunity to achieve this PhD, as 
well as provide me with valuable life experiences and opportunities I would otherwise not have 
had access too. As well as all my cohort who made the MRes year of the process an enjoyable 
experience.  
I was lucky enough to spend three months of my PhD working for Prof. Karl Scheidt at 
Northwestern University in Chicago. It was a brilliant experience and I wish to extend my thanks 
to Karl for allowing me to work in his lab. His group were very welcoming and I made some great 
friends in particular Ben McDonald and Dr Ashley Jaworski.  
I would like to thank my second supervisors Dr Matthew Jones and Dr Pawel Plucinski, 
whose help was always available if I needed it. I would also like to extend my thanks to John 
Lowe for all his NMR help, Dr Heather Parker and Dr Rhodri Owens for their help with the GC, 
Georgina Gregory for help with DFT calculations and Dr Ruth Webster for allowing me to use her 
glovebox.  
Finally, but by no means least I would like thank the past and present members of the 
Bull group who have made my PhD such and enjoyable experience. I would like to thanks Dr 
Marc Hutchby whose help and advice over his postdoc had a great impact on my own work. I 
was lucky enough to work closely on projects with Dr Ruth Lawrence and Dr Lucy Peacock, who 
were both great fun to be around, and led to successful projects. I owe a special thanks to Dr 
Richard Blackburn who, by being a vocal source of controversy and questionable morals allowed 
me to escape under the radar! Thanks also go to Dr Dave Tickell who like me benefitted from 
Richards ability to draw attention. I would also like to thank Dr Sarah Abou-Shehada, Dr Caroline 
Jones, Emma Lampard, Bill Cunningham, Maria Weber, Josh Tibbetts, Liam Stephens, Adam 
Sedgwick and Maria Odyniec who all made coming into work every day a pleasure.  
 
 
IV 
 
Contents 
Abstract ......................................................................................................................................... II 
Acknowledgements ...................................................................................................................... III 
Abbreviations............................................................................................................................... VII 
1.0 Use of Acylals as N- and O- Formylation and Acylation Agents .............................................. 1 
1.1 Introduction ......................................................................................................................... 1 
1.2 Acylation Strategies ............................................................................................................. 2 
1.3 Phenylmethylene Diacetate as an Acylation Reagent ......................................................... 8 
1.4 Synthetic Utility of Phenylmethylene Diacetate ................................................................. 9 
1.5 Acylals as Reagents for the N-Acetylation of Amines ........................................................ 27 
1.51 Acylals for the O-Acetylation of Alcohols ........................................................................ 35 
1.52 Use of Acylals for the N-/O-Acylation of Benzylamine and Benzyl Alcohol .................... 38 
1.6 N-Formylation of Amines................................................................................................... 42 
1.61 An N-Formylation Reaction Performed on Scale ............................................................. 46 
1.62 N-Formylation Reactions of Amino Acid and Peptides ................................................... 48 
1.621 N-Formylation Reactions of α-Amino Acids .................................................................. 48 
1.622 N-Formylation of Peptides ............................................................................................ 50 
1.63 O-Formylation Reactions of Alcohols .............................................................................. 52 
1.64 Investigation into the N-/O- Selectivity Profile of Acylals ............................................... 54 
1.7 Acetalisation of 1,2-Diol and 1,3-Diol Utilizing Acylals ...................................................... 54 
1.8 Preliminary Investigations into the use of Mixed Acylals for N-/O-Acylation Reactions .. 60 
1.9 Future Work ....................................................................................................................... 61 
1.10 Conclusion ....................................................................................................................... 63 
2.0 Efficient Natural Product Synthesis ....................................................................................... 66 
2.1 Introduction ........................................................................................................................... 66 
3.0 Early Natural Product Synthesis ............................................................................................ 66 
3.1 Natural products as drug molecules .................................................................................. 72 
4.0 Protecting Group Free Synthesis ........................................................................................... 92 
V 
 
5.0 Polyketides .......................................................................................................................... 101 
5.1 Introduction to Polyketides ............................................................................................ 101 
5.2 Synthesis of Ionomycin ................................................................................................... 105 
5.3 Synthesis of Pironetin ..................................................................................................... 115 
5.4 Synthesis of Spirodienal A ............................................................................................... 119 
6.0 Conclusion ........................................................................................................................... 127 
7.0 A Protecting Group Free Strategy towards the Sustainable Synthesis of Polypropionate 
Fragments ................................................................................................................................. 128 
7.1 Results and Discussion ........................................................................................................ 128 
7.2 Diene Synthesis ............................................................................................................... 134 
7.3 Hetero-Diels-Alder Chemistry ......................................................................................... 139 
7.31 Dihydropyran Synthesis ................................................................................................ 144 
7.4 Dihydropyran Derivatization ........................................................................................... 150 
7.41 Hydroboration ............................................................................................................... 150 
7.411 Hydroxyl Inversion ...................................................................................................... 153 
7.42 Hydrogenation .............................................................................................................. 156 
7.43 Epoxidation ................................................................................................................... 160 
7.44 Dihydroxylation ............................................................................................................. 164 
7.45 Epimerization ................................................................................................................ 168 
7.451 Computational Studies on Epimerization of Dihydropyran 104.2 .............................. 173 
7.5 Dihydropyran Analogue Synthesis .................................................................................. 174 
7.51 Synthesis of Diene Analogues ....................................................................................... 175 
7.52 Dihydropyran Analogues Synthesis............................................................................... 176 
7.53 Dihydropyran Analogues Derivatisation ....................................................................... 178 
7.6 Further Dihydropyran Derivatization .............................................................................. 184 
8.0 Future Work ........................................................................................................................ 189 
9.0 Conclusion ........................................................................................................................... 192 
Experimental ............................................................................................................................. 196 
VI 
 
References ................................................................................................................................. 263 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VII 
 
Abbreviations 
Ac    Acetyl  
α    Alpha 
Acm    Acetamidomethyl 
app    Apparent 
Ar    Aryl 
β    Beta 
BINAP    (1,1′-Binaphthalene-2,2′-diyl)bis(diphenylphosphine) 
BINOL    1,1′-Bi(2-naphthol) 
br    Broad 
13C NMR   Carbon 13 Nuclear Magnetic Resonance 
J    Coupling constant 
oC    Degrees Centigrade 
δ    Delta, Chemical shift 
CAR    Conformational activity relastionship 
CDCl3    Deuterated Chloroform 
CDMT    2-chloro-4,6-dimethoxy-1,3,5-triazine 
CH2Cl2    Dichloromethane  
d    Doublet 
DBU    1,8-Diazabicyclo[5.4.0]undec-7-ene 
DBN    1,5-Diazabicyclo[4.3.0]non-5-ene 
DEBS    Deoxyerythronolide B synthase  
DFT    Density functional theory  
DDQ    2,3-Dichloro-5,6-dicyano-1,4-benzoquinone 
DIBALH    Diisobutyl aluminium hydride 
DIPEA    Diisopropylethylamine  
DMAP    4-(Dimethylamino)pyridine   
eq    Equivalents 
Et    Ethyl 
f-MLP    N-formylmethionyl-leucyl-phenylalanine 
FGI    Functional group interconversion 
GC    Gas chromatography 
g    Grams 
H2O2    Hydrogen peroxide 
HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-              
b]pyridinium 3-oxid hexafluorophosphate 
HDA    Hetero-Diels-Alder 
Hz    Hertz 
HTP    High through put 
HOMO    Highest occupied molecular orbital 
h    Hours 
IAC    Intramolecular acylal cyclisation  
IR    Infrared  
KHMDS    Potassium bis(trimethylsilyl)amide 
LA    Lewis acid 
LDA    Lithium diisopropylamine  
LHMDS    Lithium bis(trimethylsilyl)amide 
LiAlH4    Lithium aluminium hydride  
LUMO    Lowest unoccupied molecular orbital 
m/z    Mass to charge ratio 
MHz    Megahertz 
VIII 
 
Me    Methyl 
PMB    4-methoxy benzylether 
mCPBA    meta-Chloroperbenzoic acid 
Min    Minutes 
mL    Millilitres  
mmol    Millimoles 
m    Multiplet  
mol%    Mole percent  
Ms/Mesyl   Methanesulfonyl  
nm    Nanometres 
NBS    N-bromosuccinimide 
NCL    Native chemical ligation 
nOe    Nuclear Overhauser Effect 
NADH    Nicotinamide adenine dinucleotide 
NBS    N-Bromosuccinimide  
nBuLi    n-Butyl lithium 
N3    Azide 
NHK    Nozaki-Hiyama-Kishi  
NICE    National institute for clinical excellence  
NMR     Nuclear Magnetic Resonance 
NMM    N-Methylmorpholine  
NMIM    N-Methyl imidazole  
NMO    N-Morpholine-N-oxide 
nuc     Nucleophile 
PKC    Protein kinase C 
PKS    Polyketide synthase 
POCl3    Phosphorus(V) oxide chloride 
ppm    Parts Per Million 
Ph    Phenyl 
PS    Polymer supported 
Py    Pyridine 
PPTS    Pyridinium para-toluenesulfonate  
q    Quartet 
R    Unspecified generic group 
RCM    Ring closing metathesis  
rt    Room temperature 
s    Singlet 
SAR    Structural activity relationship 
SMB    Simulated moving bed   
t    Tertiary 
TBAF    Tetra-n-butylammonium fluoride 
TBDMS    tert-Butyldimethylsilyl 
TCAA    Trichloroacetic anhydride  
TEMPO    2,2,6,6-Tetramethyl-1-piperidinyloxy 
TES    Triethyl silyl  
THF    Tetrahydrofuran 
TLC    Thin layer chromatography 
TMS    Trimethylsilyl 
TCDI    Thiocarbonyl diimidazole 
TRAM    Triarylmethane 
t     Triplet 
IX 
 
Ts/Tosyl   para-Toluenesulfonyl  
UV    Ultra violet 
 
 
1 
 
1.0 Use of Acylals as N- and O- Formylation and Acylation Agents 
 
1.1 Introduction  
Acylation reactions, and in particular acetylation reactions, are some of the most 
significant and widely used transformations in organic synthesis.1-5 The amide bond is ubiquitous 
throughout nature (e.g. peptides, proteins, etc...) and is found in many pharmaceutically active 
molecules (Figure 1), resulting in the N-acylation of amines and O-acylation of alcohols being 
two of the most widely utilized reactions in drug and agrochemical synthesis.1, 6, 7 
 
 
Figure 1. Examples of top selling drugs containing amide or ester acyl groups.7 
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1.2 Acylation Strategies  
Traditionally, N-acylation reactions are carried out utilizing carboxylic acid derivatives, 
namely acid anhydrides 1.2 and acyl chlorides 1.3. Variations of these approaches form the basis 
of the majority of synthetic acylation reactions (Scheme 1).8  
 
 
Scheme 1. Traditional methods of carrying out N-acylation chemistry.  
 
Modern variations on this theme can be performed in a range of organic solvents and 
often utilize acyl transfer agents such as dimethylaminopyridine (DMAP) and its derivatives, as 
well as Lewis acid catalysts.9-11 DMAP 2.3 is able to act as a nucleophilic organocatalyst, which 
attacks an anhydride (or acyl chloride) to generate an activated acyl transfer agent (e.g. 
acetylpyridinium 2.4) which is then more reactive towards amine and alcohol nucleophiles, thus 
facilitating the formation of amides and esters. For example the acylation of sterically hindered 
methylcyclohexanol 2.1 with acetic anhydride to give methylcyclohexyl acetate 2.2 was explored 
by Goe et al., with three additives tested for this reaction. DMAP performed best giving an 89% 
yield, of the desired ester 2.2, whereas N-methyl imidazole (NMIM) and pyridine gave only 15% 
and <5% yields respectively. This increase in yield is attributed to the ability of DMAP to act as a 
nucleophilic catalyst, which generates a resonance stabilized reactive intermediate in situ 
(Scheme 2).10         
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Scheme 2. Use of DMAP as an acyl transfer catalysts.10 
 
However, there are a number of problems associated with the use of acyl chlorides and 
anhydrides for acylation reactions. For example; reaction of amines with acyl chlorides can be 
highly exothermic, while anhydrides can form side products (e.g. imides) when reacted with 
primary amines.12 Acyl chlorides and anhydrides are also known to be moisture sensitive, with 
the high reactivity of acid chlorides meaning they are potentially liable to decomposition and 
competing side reactions.1-4 It is worth noting as well, that while anhydrides and acyl chlorides 
are moisture sensitive, in some cases they have been shown to be stable enough to allow the 
reaction to be performed in aqueous media.13   
Some of these disadvantages have been alleviated through the direct use of carboxylic 
acids as acyl sources, which is of particular interest for peptide synthesis. Whilst an obvious 
solution is to covert the acid to an acyl chloride in situ, this approach is only really applicable to 
relatively simple substrates, with problems often encountered when more complex substrates 
are used. Consequently, a whole suite of coupling reagents have been developed that activate 
carboxylic acids towards nucleophilic addition of amines and alcohols. Coupling reagents based 
on carbodiimide (DCC), N-acylimidazoles (CDI), phosphonium salts (BOP) and guanidinium salts 
(HATU) are regularly used in peptide synthesis, which afford excellent yields for amide bond 
formation and crucially without eveidnece of any racemization (Figure 2).7 However, the use of 
these coupling reagents can be considered to be expensive and wasteful, since they generate 
stoichiometric amount of by-products.   
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Figure 2. Examples of common peptide coupling reagents.  
 
In response to this, a range of acylation reagents have been developed in the literature 
that act directly as acyl transfer agents, rather than relying on the activation of a starting 
material or intermediate in situ (Scheme 3). One of the first acylation reagents were acyl 
cyanides 3.3, which were first reported as an alternative reactant to acyl chlorides in 1954.14 
More recently, Murahashi and Naota have reported an efficient acyl cyanide synthesis utilizing 
a ruthenium catalyzed oxidation of the corresponding cyanohydrins using tert-
butylhydroperoxide as an oxidant.15, 16 These acyl cyanides were shown to be highly 
chemoselective with only N-acylation observed for a number of amino alcohol substrates.  
Kikugawa and co-workers have demonstrated the use of N-methoxydiacetate 3.4 as a highly 
selective N-acylation reagent, that selectively acylated primary amines over both secondary 
amines and alcohols.17 This was developed into the bench stable N-diethylcarbonyl-N-
methoxyformamide 3.5, which acts as a selective N-formylating reagent. N-acyl-2-phenylimino-
oxazolidines 3.6 developed by the Kim group have been shown to be highly active acylation 
agents, demonstrating high yields with a range of primary and secondary amines, as well as 
amino alcohols.18 The Murakami group have developed a range of acylation agents based on 
substituted anilines, including N-acyl-N-(perfluorophenyl)methanesulfonamides 3.7, which have 
been shown to demonstrate high activity towards primary and secondary amines.19 Yoon et al. 
have shown that air stable 2-acyl-4,5-dichloropyridazin-3-ones 3.8 are effective N-acylation 
agents, with the parent 4,5-dichloropyridazin-3-one by-product potentially being isolated and 
recycled.20 This potentially reduces the impact caused through the use of stoichiometric 
reagents. More recently, Singh et al. have shown that N1-N2-diacyl-3,4-dihydropyrimidin-2(1H)-
ones 3.9 are affective acylation agents for a range of substrates, including ammonia, primary 
and secondary amines.21    
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Scheme 3. Representative range of effective acylating agents. 
 
Katritzky and co-workers have extensively researched the use of N-acylbenzotriazoles 
4.4 as stoichiometric acylating reagents. The group have synthesised an impressive number of 
crystalline and bench stable N-acylbenzotriazoles 4.4 over the past 20 years, and have used them 
to acylate a wide range of different nucleophiles. Their original synthesis was performed using 
benzotriazole 4.1 and acyl chlorides, or through the reaction of carboxylic acids with N-
sulfonylbenzotriazoles 4.2. These reagents were then developed further to allow the direct 
reaction of carboxylic acids and benzotriazole, facilitated by thionyl chloride. This modification 
allowed for the use of potentially unstable acyl chlorides as the acyl donor (Scheme 4).22-25    
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Scheme 4. Synthesis of N-acylbenzotriazoles 
 
Summarising their extensive results, N-acylbenzotriazole 4.4 is active against the range 
of nucleophiles shown in Scheme 5. As well as the synthesis of amides 5.1,12 N-
acylbenzotriazoles react with a range of N-substituted hydroxylamines for the synthesis of 
Weinreb amides 5.2.26, 27 N-acylsulphonamides 5.3, which represent a common motif in many 
drug like molecules, can also be accessed through the use of N-acylbenzotriazoles.28 N-
acylbenzotriazoles 4.4 can also act as O-acylation agents. For example, they react with 
amidoximes in ethanol at rt to form O-acylated amidoximes 5.4, which upon heating, cyclise to 
form the corresponding 1,2,4-oxadiazoles 5.5.29 Their effectiveness as S-acylation agents has 
also being demonstrated through the synthesis of a range of thioesters 5.6 (Scheme 5).30  
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Scheme 5. Selective examples of the utility of N-acylbenzotriazole 4.4 as a versatile acylating agent 
 
Bull and co-workers have recently demonstrated N-acyl 1,5-diazobicylco[4.3.0]non-5-
ene (DBN) tetraphenylborate salts 6.1 as acylation reagents. These salts are air stable crystalline 
solids, which are readily synthesised from DBN and the corresponding acyl chloride, allowing for 
easy storage and increased shelf life when compared with the corresponding acyl chlorides or 
acid anhydrides.1 These DBN salts 6.1 have been shown to be active against a range of amines 
to give the corresponding amides 5.1. Alcohols and sulphonamides can also be acylated to give 
the corresponding esters 6.3 and N-acyl sulphonamides 6.2 respectively (Scheme 6).1, 2          
To summarize, while there are a number of acylation reagents and strategies, there is 
still scope to develop new methodologies that afford amide, ester and sulfonamide bonds, since 
they represent some of the most important functional groups in organic and medicinal 
chemistry.5 Furthermore, there is still much demand for milder and racemization free reaction 
conditions, as well as the ability to improve the selectivity of acylation reactions (e.g. N-acylation 
vs O-acylation, reaction of 1° amine over 2° amine).    
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Scheme 6. N-acyl DBN BPh4 salts as acylating agents 
 
 This chapter will now describe our investigations into the potential of using acylals as N- 
and O- acylation agents for amines and alcohols.  
1.3 Phenylmethylene Diacetate as an Acylation Reagent 
The known compound phenylmethylene diacetate 7.2, can be readily synthesized from 
benzaldehyde 7.1 and acetic anhydride 1.2 using para-toluenesulfonic acid (p-TSA) as a Brønsted 
acid catalyst (Scheme 7). These class of compounds have been employed as reagents in a range 
of synthetic methodologies,31 and are referred to as either gem-diacetates, or acylals.32 
 
 
Scheme 7. Synthesis of phenylmethylene diacetate. 
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It is proposed that the mechanism of formation of acylal 7.2 proceeds via an 
intermolecular pathway, with the Brønsted acid first protonating benzaldehyde 7.1 to give 
oxonium 8.1, which then allows for nucleophilic attack of acetic anhydride 1.2 at its carbonyl to 
afford hemiacetal 8.2. A second anhydride equivalent is then able to acylate the alcohol group 
of this hemiacetal intermediate to afford acyl oxonium 8.3. Nucleophilic attack of acetic acid 
then affords the observed phenylmethylene diacetate 7.2 (Scheme 8).33, 34 
   
 
Scheme 8. Proposed mechanism for the formation of acylal 7.2. 
 
We envisaged that these type of acylals might be useful as selective acylating agents, 
and now briefly review the literature to summarize where they have been used presviously as 
versatile reagents for synthesis.  
1.4 Synthetic Utility of Phenylmethylene Diacetate 
 Phenylmethylene diacetate 7.2 (or structural analogues) has been used as a reagent for 
a range of different synthetic methodologies, some of which will now be discussed in detail to 
highlight the versatility of this class of reagents. One use of acylals is as substrates for 
transdithioacetalization reactions to afford cyclic dithianes 9.1.35, 36 Exposure of acylal to dithiols 
under a range of mild acid catalyzed conditions affords cyclic thioacetates 9.1, with the reaction 
procceding under relatively mild conditions with improved reactivity when compared to 
reaction of the parent aldehyde (Scheme 9).35, 36    
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Scheme 9. Use of phenylmethylene diacetate 7.2 in transdithioacetalization reactions35 
 
Acylals have also found application for the synthesis of allylic acetates, with variants of 
this reaction employing allyl silanes, allyl bromides or allyl samarium bromides as the allylating 
source.37-39 For example, Yadav et al. have developed indium catalyzed allylation reactions of 
acylals utilizing either allyl bromides or allyl silanes, to afford a wide range of allylic acetates 
under relatively mild reaction conditions (Scheme 10).    
 
 
Scheme 10. Indium catalysed allylation reaction of acylal 7.237, 38 
 
A further extension of this type of allylation methodology has been shown by Song et al. 
who demonstrated that phenylmethylene diacetate 7.2 could be applied for the synthesis of 
protected homoallylic amines 11.3.40 The reaction is proposed to proceed through iron catalysed 
reaction of CbzNHTMS with diacetate 7.2, to afford immine intermediate 11.2. A Cbz-TMS 
adduct is formed through reaction of Cbz-Cl and HMDS, in situ, which then reacts with an in situ 
formed acyl oxonium species 11.1 to generate the desired imine.  This imine is then able to 
undergo nuclephilic attack of the allyl group to give the desired Cbz-protected homoallylic amine 
11.3.40  
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Scheme 11. Synthesis of protected homoallylic amines40  
 
Acylals have recently been proposed as key intermediates in the Perkin condensation 
reaction for the synthesis of cinnamic acids, whereby benzaldehyde, acetic anhydride, 
potassium acetate, are reacted at 180 °C. The traditionally accepted mechanism for the Perkin 
reaction is proposed to proceed via formation of an anhydride enolate 12.1, which is able to 
undergo nucleophilic attack at benzaldehyde 7.1 to afford the anhydride alkoxide 12.2. 
Intramolecular acyl transfer then occurs to generate carbonate 12.3, which then undergoes 
nucleophilic attack at a second equivalent of acetic anhydride 1.2 to give acetate 12.4. E1cB 
elimination of acetate from 12.4, followed by hydrolysis of anhydride 12.6 then affords the 
observed cinnamic acid 12.7 (Scheme 12). 
However, it has been noted that the reaction conditions employed for the Perkin 
reaction are unlikely to generate enolate 12.1, because a strong base is not present, with the 
mechanism proposed in Scheme 12 requiring that a weakly basic acetate ion function to 
generate the required enolate. Further evidence that the literature mechanism may be 
incorrect, is that the anhydride, when subjected to the reaction conditions in the absence of 
aldehyde remains stable. If the enolate 12.1 is formed under these conditions, then it is likely 
that is would rapidly fragment to afford a ketene under the high temperatures employed 
(Scheme 12).41    
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Scheme 12. Traditional mechanism proposed for the Perkin reaction 
 
Chandrasekhar et al. proposed that the reaction proceeds via formation of an acylal 
intermediate, showing that the Perkin reaction proceeds when acylal 7.2 is used as a 
replacement substrate for benzaldehyde 7.1. They propose that reaction of acylal 7.2 with base 
affords a cyclic orthoester 13.1, which then undergoes nucleophilic attack at benzaldehyde 7.1 
to afford alkoxide 13.2, which then undergoes acyl transfer reaction to generate acetate 13.3 
(intermolecular rather than intramolecular?). Elimination of benzaldehyde from 13.3 then 
occurs to afford carboxylic acid 13.4, which then undergoes E1cB elimination of acetate to give 
the observed cinnamic acid 12.3 (Scheme 13).41 
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Scheme 13. Use of phenylmethylene diacetate as an alternative substrate in the Perkin reaction41 
 
A recent publication by the Sakai group also identified acylal 7.2 as a key intermediate 
in their indium catalyzed Knoevenagel condensation of aldehydes with dimethyl malonate for 
the synthesis of α,β-unsaturated bis-esters 14.1 (Scheme 14).42 
 
 
Scheme 14. Indium catalysed Knoevenagel condensation42 
  
It is proposed that indium catalyzed reaction of benzaldehyde with acetic anhydride 
affords phenylmethylene diacetate 7.2 in situ, which then undergoes indium catalyzed 
14 
 
deacetylation to give acyl oxonium 15.1. Oxonium 15.1 then reacts with an indium generated 
enolate 15.2 to afford tris-ester 15.3, that then undergoes E1cB elimination to afford the desired 
α,β-unsaturated bis-ester 14.1 (Scheme 15).42  
 
 
Scheme 15. Proposed mechanism for indium catalysed Knoevenagel condensation42 
 
As well as these relatively recent examples of the synthetic utility of phenylmethylene 
diacetate 7.2, Sandberg and Sydnes published an earlier series of work looking at the chemistry 
of acylals.43-46 The first publication explored the reactivity of acylals towards Grignard and 
organolithium reagents, with the carbon nucleophile being able to selectively displace one of 
the acyl ester groups to afford a range of substituted esters 16.1 (Scheme 16).43 It is interesting 
to note that acylals demonstrated greater reactivity towards Grignard reagents than aldehydes, 
which was established through a competition experiment between acylal 7.2 (R = p-OMe) and 
4-methoxy benzaldehyde, and 0.5 equiv. of Grignard nucleophile, with only the acylal being 
consumed.43   
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Scheme 16. Reaction of acylals with Grignard and organolithium reagents43 
 
The mechanism is believed to proceed via formation of acyl oxonium 15.1 which is able 
to undergo nucleophilic attack of the Grignard reagent at the oxonium carbonyl to give the 
observed acetate ester 16.1 (Scheme 17). 
 
 
Scheme 17. Mechanism for the reaction of acylals with Grignard reagents.43 
 
Their second report focused on reactivity of acylals towards azide species. In efforts 
originally aimed at performing azide substitution reactions of acylals, they found that reaction 
with TMS-N3 (trimethylsilyl azide) in the presence of a Lewis acid catalyst (titanium(IV) chloride) 
led to the formation of nitriles 18.1 (Scheme 18).44 
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Scheme 18. Reactivity of acylals with TMS-N344 
 
The reaction is believed to proceed via a stepwise route, involving displacement of one 
of the acyl groups by nucleophilic attack of azide to afford acetate 19.1. Evolution of N2 from 
19.1 then generates an unstable nitrene 19.2, with acyl transfer occurring to afford O-acyl oxime 
19.3, that then eliminates acetate to afford the observed nitrile 18.1 (Scheme 19).44 
 
 
Scheme 19. Mechanism of nitrile synthesis from acylals44 
 
Their third contribution explored a similar reaction manifold, investigating the reactivity 
of acylals towards cyanide reagents.45 They found that using TMS-cyanide and titanium(IV) 
chloride as a Lewis acid catalyst gave the best results, synthesizing a range of O-acyl 
cyanohydrins 20.1 in good to excellent yields.45 The use of TMS-cyanide as a nucleophile in the 
reaction resulted in mono substitution of one of the acyl groups, allowing the synthesis of 
cyanohydrin esters 20.1 (Scheme 20).   
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Scheme 20. Synthesis of cyanohydrin esters from acylals45 
 
 The final report by Sydnes and Sandberg explored the reactivity of acylal 7.2 with silyl 
enol ethers 21.1, with boron trifluoride catalyzed reactions leading to the formation of α,α’-
bis(arylmethylidene)cylcoalkanones 21.2 in moderate to excellent yields (Scheme 21).46    
 
 
Scheme 21. BF3·OEt2 catalysed reaction of acylals with silyl enol ethers46 
 
 While no detail of the reaction mechanism was proposed, a reasonable mechanism 
would involve boron trifluoride catalyzed formation of acyl oxonium 15.1. Nucleophilic attack of 
silyl enol ether 21.1 would then afford acetate 22.1, with an acetate elimination reaction 
installing the first alkene unit of silyl enol ether 22.4. Reaction of silyl enol ether 22.4 with a 
second equivalent of acyl oxonium 15.1 would afford acetate 22.5, that could then undergo 
elimination of a second acetate anion equivalent to give oxonium 22.7, which would lose its silyl 
ether group to afford the observed bis-α,β-unsaturated ketone 21.2 (Scheme 22). 
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Scheme 22. Proposed mechanism for the synthesis of bis(arylmethylidene)cycloalkanones 
 
Acylals have also found application for the synthesis of triarylmethanes (TRAMs) 23.2, 
which are important targets in a number of fields, including materials chemistry, medicinal 
applications and for the synthesis of dyes.47 Reaction of acylal 7.2 with para-xylene in the 
presence of an iron catalyst and acetic anhydride led to the formation of TRAM 23.2. The 
reaction was shown to proceed using aldehydes instead of acylals, but the acylal is thought to 
be formed as a more reactive intermediate in situ (Scheme 23).47  
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Scheme 23. Reaction of acylals with p-xylene to afford triarylmethanes47 
 
 No mechanism for the formation of triarylmethane 23.2 was proposed in the paper, 
however, a potential mechanism is suggested in Scheme 24. An iron catalyzed acetate 
elimination would afford acyl oxonium 15.1. This intermediate would then undergo electrophilic 
aromatic substitution of p-xylene 23.1 to give acetate 24.1, with aromaticity being regenerated 
through deprotonation of 24.1 to give bisarylmethylacetate 24.2. Acetate elimination via an SN1 
type mechanism would then lead to the generation of stabilized carbocation 24.3, with a second 
electrophilic aromatic substitution reaction, and subsequent deprotonation event, affording 
triarylmethane 23.2 (Scheme 24).   
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Scheme 24. Proposed mechanism for the formation of TRAMs  
 
 Allyl acylals have proven to be one of the most utilized class of reagent, with this area 
of research being first developed by Trost and coworkers, who published a series of reports on 
the asymmetric alkylation reactions of allylic acylals, and application of this methodology for 
natural product synthesis.48-53 Their initial report described the reaction of allyl diacetate 25.1 
with sodium malonate 25.2 to give the monoalkylated product 25.4 in 92% yield and 95% ee, 
utilizing a palladium catalyst and the chiral bis-phosphine ligand 25.3 (Scheme 25). This 
alkylation reaction proceeds through formation of a Pd-π-allyl complex which allows for 
stereoselective nucleophillic attack of the malonate nucleophile 25.2. The reaction was 
subsequently optimized to accommodate a wide range of allyl acylals and stabilised carbon 
nucleophiles, affording the corresponding monoalkylation products in good yield and excellent 
enantiomeric excess.51, 52     
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Scheme 25. Asymmetric alkylation reaction of allylic acylal49 
 
 Trost et al. subsequently applied this methodology to the synthesis of the natural 
products sphingofungins E and F.50, 53 Both natural products were synthesised from the common 
intermediate allyl acetate 26.1, which was synthesised from O-silyl protected allyl diacetate 26.1 
and oxazolone 26.2 in 70% yield and 87% ee. Allyl acetate 26.3 was used as an advanced 
intermediate for the synthesis of the natural products sphingofungins E and F in 5.1% (17 steps) 
and 17% (15 steps) overall yields respectively (Scheme 26).50, 53       
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Scheme 26. Synthesis of sphingofungins E and F utilizing allylic acylal 26.1 as a carbonyl surrogate50, 53 
  
Acylals have also been applied as a substrate for a number of other natural product 
syntheses, including for the synthesis of roelactamine 27.2 by the Martin group in 2007. The 
acylal containing tertiary amide 27.1 was treated with concentrated methanolic hydrochloric 
acid, resulting in a facile double cyclization reaction to give roelactamine 27.2 in 71% yield 
(Scheme 27).54     
 
 
Scheme 27. Synthesis of roelactamine54 
 
 The reaction is proposed to proceed via acid catalysed formation of acyl oxonium 28.1. 
An intramolecular electrophilic aromatic substitution reaction affords acetate 28.2 which upon 
deprotonation by acetate gives bicycle 28.3. A second acid catalysed intramolecular SN1-like 
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electrophilic aromatic substitution reaction then affords 28.4, which after further deprotonation 
event gives the desired roelactamine product in a 71% yield (Scheme 28).  
 
 
Scheme 28. Proposed mechanism for the synthesis of roelactamine 
 
 A second tandem intramolecular acylal cyclisation (IAC) strategy was developed by the 
Hilton group directed towards the synthesis of erythrina alkaloid derivatives.55 They first 
developed the synthesis of a range of key cyclisation precursors 29.1 (one example shown for 
clarity), which were subjected to a mild BF3 catalysed cyclisation reaction to give the fused 
tricycle 29.2 (Scheme 29).    
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Scheme 29. Intramolecular acylal cyclisation reaction for the synthesis of erythrina alkaloid derivatives55 
 
 The reaction is believed to proceed via intramolecular nucleophilic addition of an 
enamine fragment at an acyl oxonium species 30.1 to afford N-acyl-iminium species 30.2. An 
intramolecular electrophilic aromatic substitution reaction then occurs to afford tricycle 30.3, 
with an alkyl migration reaction leading to ring expansion to generate carbocation 30.4. 
Subsequent, deprotonation then generates the observed tetracyclic product 29.2 in a 60:40 
trans to cis ratio (Scheme 30).    
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Scheme 30. Proposed mechanism for the synthesis of fused tetracycle 29.255 
 
 Allyl acylal substrates have also been utilised by the Krische group for stereoselective 
iridium catalysed alkoxyallylation reactions,56 with allyl gem-benzoate 31.1 affording the highest 
yields and best diastereoselectivities when compared to other acylal substrates. For example, 
benzaldehyde 7.1 reacted with diacyl 31.1 in the presence of the chiral iridium catalyst 31.2 to 
afford the anti-alkoxyallylation product 31.3 in 63% yield and an impressive 99% ee, with a dr 
ratio of 18:1 (Scheme 31).56 The reaction proceeds under iridium catalysed transfer 
hydrogenation conditions with isopropanol as the terminal reductant, which facilitates the 
reductive coupling of the gem-dibenzoate 31.1 and benzaldehyde 7.1.  
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Scheme 31. Use of vinyl acylal as allyl donors in an iridium catalysed anti-alkoxyallylation reactions56 
 
 The reaction is believed to proceed through formation of Ir-π-allyl complex 32.1. The 
iridium migrates to form σ-allyl complex 32.2 (primarily (E)), which then reacts with bezaldehyde 
7.1 via a Zimmerman-Traxler type transistion state to afford anti-diastereomer 32.3. 
Isopropanol then displaces monobenzoyl diol 32.4 from the iridium catalyst, which was 
subsequently reacted with benzoyl chloride to give the desired anti-bis-benzoyl diol product 
31.3 (Scheme 32).    
 
 
Scheme 32. Proposed mechanism for iridium catalysed anti-alkoxylation reaction of vinyl acylals56 
 
As described, phenylmethylene diacetate 7.2 and acylals are versatile synthetic reagents 
that have been applied as substrates in a range of synthetic methodologies. However, 
remarkably and to the best of our knowledge, phenylmethylene diacetate 7.2 had never been 
applied as a simple acylating reagent for nitrogen and oxygen nucleophiles. Consequentially, we 
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now report an investigation into the application of acylals as new, bench stable, acylating 
reagents for the N-/O- acylation of primary and secondary amines and alcohols. 
1.5 Acylals as Reagents for the N-Acetylation of Amines 
In order to employ acylals as potential new N-/O- acylating agents it was first necessary 
to devise a route for their synthesis. The most common methods reported in the literature 
involve reaction of a parent aldehyde with an anhydride in the presence of a suitable catalyst. 
The catalysts utilized are primarily based on Brønsted acids,32, 57-60 Lewis acids,61-70 as well as the 
use of iodine,71 NBS,72 iron-montmorillonite and zeolites.73, 74 All these catalytic systems are 
believed to afford acylals using the same general mechanism described in Scheme 8. The 
conditions that were chosen for the synthesis of acylal 7.2 were those of Manjula et al.32 utilizing 
p-TSA as a Brønsted acid catalyst. These conditions were reported to afford acylal 7.2 in excellent 
yield at rt (Scheme 7). Importantly, no arduous purification steps were required, with high purity 
product obtained after an aqueous sodium carbonate wash, meaning that acylals could 
potentially be accessed in large quantities.       
The choice of parent aldehyde used for the synthesis of the desired acylal was an 
important consideration. Cost of reagents, ease of synthesis and ease of byproduct removal 
were some of the factors that were considered. It was decided that either an aromatic aldehyde, 
or a short chain alkyl aldehyde would best suit our purposes, with benzaldehyde and 
propionaldehyde identified as potential precursors. Acylal synthesis using benzaldehyde 
proceeded smoothly to give high purity acylal 7.2 in good yield after 1 h (Table 1 entry 1). 
However, when propionaldehyde was used as the aldehyde core a number of problems became 
apparent. Under a range of synthetic conditions the resultant acylal proved to be much less 
stable and more temperamental than the benzaldehyde derivative, readily decomposing to 
afford undesired side products, believed to be formed through unwanted elimination or aldol 
side reactions.  
Therefore, while the use of propionaldehyde resulted in 100% conversion, the yield of 
the desired acylal was significantly reduced to 45% (Table 1 entry 2). In an attempt to alleviate 
this issue, alternative conditions were explored using Cu(BF4)2·xH2O as a Lewis acid catalyst (at 
1 mol%).70 Although the crude yield of the desired acylal was greatly improved, the presence of 
multiple minor impurities meant that the acylation reagent required further purification by 
column chromatography that resulted in a significant loss in yield. This was undesirable, and 
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essentially rendered the use of propionaldehyde as the aldehyde core unviable. Consequently 
benzaldehyde was chosen as the core aldehyde for acylal synthesis (Table 1).         
 
Table 1. Synthesis of acylals  
 
Entry Aldehyde Catalyst 
Reaction 
Time 
Aldehyde  
Conversion (%) 
Selectivity 
Towards Acylal 
(%) 
1 
 
p-TSA 1 h 100 95 
2 
 
p-TSA 1 h 100 45 
3 
 
Cu(BF4)2·xH2O 5 min 100 65 
4 
 
Cu(BF4)2·xH2O 1 min 100 68 
Reaction conditions: Entries 1 and 2, aldehyde (1 equiv.), acetic anhydride (2 equiv.), cat (0.1 equiv.). 
Entries 3 and 4, aldehyde (1 equiv.), acetic anhydride (1.5 equiv.), cat (0.01 equiv.).   
 
Acetylation of benzylamine 33.1 using phenylmethylene diacetate 7.2 was the first N-
acylation reaction to be investigated. A range of conditions were screened, encompassing 
solvent, reaction time, reaction temperature and number of equivalents of acylating agent 
(Table 2). As shown in Table 2 the choice of solvent had little effect on the distribution of 
products, with the reaction also found to perform well under solvent free conditions (entry 4). 
However, as shown for entries 1-4, although there was good conversion of benzylamine at rt, 
selectivity for formation of acetamide 34a was poor at around 50%. Unsurprisingly, the major 
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side product formed was due to reaction of benzylamine with benzaldehyde (produced as a 
byproduct of the acetylation reaction) to form imine 33.2 (Scheme 33).  
 
   
Scheme 33. Competing side reaction during acetylation of benzylamine 
 
Imine formation is a reversible process, whereas acetamide formation is irreversible. 
Therefore, it was proposed that the equilibrium for imine formation could be perturbed towards 
acetamide formation under more forcing conditions. To achieve this aim, a number of routes 
were explored. Firstly, the reaction time was extended to 16 h and the amount of acylal 7.2 
employed increased from 1.5 to 5 equivalents, however, this had little or no effect on the ratio 
of amide to imine formed (entries 4-7). Reaction temperature was the next variable to be 
changed, with increased reaction temperature, leading to greater quantities of acetamide being 
produced, with the best results achieved at 70 °C. The optimal conditions were found to be 1.5 
equivalents of acylating agent 7.2 at 70 °C for 16 h solvent free. The crude amide product could 
be purified directly via column chromatography, without the need for any aqueous work up.  
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Table 2. Optimization of N-acetylation reactions of benzylamine 
 
Entry Solvent 
Equiv. gem-
Diacetate 
Reaction 
time (h) 
Temperature  
(°C) 
Amine 
Conversion (%) 
Acetamide:
Imine  
1 EtOAc 1.5 2  rt 95 50:50 
2 Tol 1.5 2  rt 90 48:52 
3 DCM 1.5 2  rt 92 51:49 
4 - 1.5 2  rt 94 53:47 
5 - 1.5 16 rt 99 54:46 
6 - 2 16 rt 98 55:45 
7 - 5 16 rt 99 52:49 
8 - 1.5 16 50 99 65:35 
9 - 1.5 16 60 99 70:30 
10 - 1.5 16 70 99 95:5 
 
With these optimized conditions in hand a range of amines were screened for reaction with 
phenylmethylene diacetate 7.2 affording a range of eleven acetamides 34a-k (Reaction 
conditions; 1 mmol of amine, 1.5 equiv. 7.2, 12 h, 70 °C. atoluene required as solvent. b24 h reaction time. 
Scheme 34). N-acetylation of both primary, secondary and cyclic amines proceeded with 
good conversion to afford their corresponding acetamides in 60-95% isolated yield. It is worth 
noting that typtamine was cleanly N-acetylated to afford 34c in 62% yield, with no acetylation 
of the indole nitrogen being observed. Pleasingly, even sterically hindered branched amines 
gave their corresponding acetamides 34d in 70% yield. Less reactive primary and secondary 
anilines were also efficiently N-acetylated, albeit with slightly reduced isolated yields 60-68% 
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(34e and 34f), including the electron deficient amide 34g which was formed in a 65% yield. For 
amines that proved to be insoluble in acylal 7.2, then toluene was used as a co-solvent to ensure 
a homogeneous reaction mixture.  
 
 
Reaction conditions; 1 mmol of amine, 1.5 equiv. 7.2, 12 h, 70 °C. atoluene required as solvent. b24 h 
reaction time. 
Scheme 34. Scope of N-acetylation reactions of amines with acylal 7.2 
 
 It was proposed that the mechanism of acetamide formation could potentially proceed 
via one of two potential pathways. Pathway A would proceed via nucleophilic attack of amine 
33.1 into one of the carbonyl bonds of the acetate groups of acylal 7.2 to give tetrahedral 
carbinolamine intermediate 35.1. Reformation of the carbonyl bond would then lead to 
formation of acetamide 34a as well as formation of one equivalent of benzaldehyde 7.1 and 
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acetic acid 35.2. Pathway B would proceed through acetate elimination to give acyl oxonium 
15.1, followed by nucleophilic attack of the amine 33.1 at the acyl carbonyl bond to afford the 
observed acetamide 34a, once again resulting in one equivalent of benzaldehyde 7.1 and acetic 
acid 35.2 as by-products (Scheme 35).    
 
 
Scheme 35. Potential mechanisms for the formation of acetamide 34a 
 
In order to investigate which pathway was operating a series of experiments were 
conducted. In both of the proposed reaction pathways, for every equivalent of acetamide 
produced, then an equivalent of acetic acid would also be produced. It would be expected that 
every equivalent of acetic acid produced would react with unreacted amine to form an acetate 
salt, preventing it acting as a nucleophile in the reaction. If this were to happen then the 
maximum conversion would be expected to be only 50% however, complete conversion was 
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clearly being observed at elevated temperatures. When the pH of the reaction was monitored 
overtime the reaction remained neutral (pH 7) throughout the course of the reaction, until the 
end of the reaction when it became acidic in nature. This would suggest that the reaction is self-
buffering. Therefore, it is proposed that the amine acetate salt is indeed being formed in situ, 
but is being formed reversibly allowing for free amine to be continuously generated, in the 
reaction that can then irreversibly react with excess acylal to afford the observed acetamide 
(Scheme 36).       
 
 
Scheme 36. Self-buffering pH control mechanism operating in acetylation reaction 
 
 It is also important to consider the formation of imine by-product. For pathway A it is 
proposed that the imine would be formed by acid catalysed reaction of unreacted amine and 
the benzaldehyde produced. However, for pathway B the imine could also be formed through 
nucleophilic attack of amine at the oxonium carbonyl of intermediate 15.1 to give O-acyl-hemi-
carbinolamine 37.1 (Scheme 37). In order to try and investigate which method of imine 
formation was occurring, the reaction was performed under basic conditions, since conventional 
imine formation from reaction of an amine and an aldehyde, does not generally occur under 
basic conditions. 2 equiv. of K2CO3 was added to the reaction to maintain a basic pH throughout 
the course of the reaction. It was found that imine 33.2 was indeed formed under these basic 
conditions, suggesting that the reaction proceeds via pathway B. It is important to note that 
under basic conditions the reaction did not reach 100% conversion, with the reaction stalling at 
50% acetamide and 50% imine, which is due to the stability of imines under basic conditions.      
 
 
Scheme 37. Pathway B for imine formation 
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 The acetylation reaction of benzylamine 34.1 with acylal 7.2 was followed by 1H NMR 
spectroscopic analysis at 70 °C (in toluene-d8), with the data summarised in Figure 3. As can be 
seen, consumption of the amine occurs within the first 30 minutes (Figure 3). However, imine 
formation occurs slightly faster than acetamide formation reaching 34% after 30 minutes. 
Slowly, over time reversible imine formation regenerates the amine, which reacts with oxonium 
species 15.1 to irreversibly afford acetamide 34a as witnessed by the gradual increase in 
acetamide and decrease in imine (Figure 3). 
 
 
Figure 3. A timeline graph to show acetamide and imine formation during the course of acetylation 
reaction using acylal 7.2. 
 
 With all this information in hand, a possible overall mechanism for the N-acetylation of 
amines by acylal 7.2 is presented below (Scheme 38). Acid catalysed formation of acyl oxonium 
15.1 from acylal 7.2 is coupled with a loss of acetic acid. Nucleophilic attack of amine 38.1 (which 
is in equilibrium with its acetate salt 37.2) into the oxonium carbonyl of acyl oxonium 15.1 would 
lead to the reversible formation of imine 38.2. Alternatively nucleophilic attack of amine 38.1 
can occur at the acyl carbonyl of acyl oxonium 15.1 to irreversibly afford acetamide 38.3 and 
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one equivalent of benzaldehyde 7.1. Benzaldehyde 7.1 is able to further react with one 
equivalent of amine 38.1 to reversibly generate imine 38.2. Both routes that lead to the 
formation of imine 38.2 are reversible, so this allows for the irreversible formation of acetamide 
38.3 that act as a thermodynamic sink, to perturb all the equilibria allowing for total conversion 
of amine 38.1 to acetamide 38.3 (Scheme 38).  
 
 
Scheme 38. Overall mechanism for the N-acetylation of amines by acylal 7.2 
 
1.51 Acylals for the O-Acetylation of Alcohols 
O-acylation reactions of alcohols are also an important synthetic tool, either through 
thier use as a reversible protecting group strategy for alcohols, or for the synthesis of ester 
products.2, 75 Consequently, it was decided to explore whether acylal 7.2 could also be used for 
the O-acetylation of alcohols. The neutral solvent free conditions that were applied for the N-
acylation of amines were unsuccessful for the O-acylation of less nucleophilic alcohols. In the 
absence of the self-buffering nature of the amine (Scheme 36) the acetic acid formed as a by-
product appeared to retard the O-acetylation reaction and degrade acylal 7.2. However, it was 
found that the inclusion of an inorganic base resulted in clean O-acylation of the alcohol, which 
functions to neutralize the acetic acid as it is produced, as well as deprotonating the alcohol to 
increase its nucleophilicity.  
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After a brief optimization study, optimal conditions were found to be an elevated 
reaction temperature to 80 °C, and inclusion of two equivalents of potassium carbonate (K2CO3), 
using 1.5 equivalents of acylal 7.2. These optimized conditions were applied to a range of eleven 
primary and secondary alcohols which gave the corresponding acetate esters in 68-92% yield 
(Scheme 39). Alcohol substrates that were successfully O-acetylated include; cyclic, acyclic, alkyl, 
vinyl, heterocyclic alcohols and diols 39a-l. Although phenols were not acylated under these 
conditions. Important observations to note include the fact that O-acetylation of 2-
pyridinemethanol proceeded to give acetate 39b, with no evidence of products arising from N-
acetylation of the pyridine nitrogen. The diol fragment of benzylidene-protected glucose 
derivative underwent bis-acetylation to give diacetate 39g in 65% yield. Carveol acetate 39l was 
formed with no evidence of any competing base catalyzed elimination reaction having occurred 
to afford diene products. Good yields were obtained for the formation allylic alcohol acetates 
39i-l, which are useful products that are often used as substrates for palladium allyl nucleophilic 
addition chemistry.     
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Reaction conditions; 1 mmol of alcohol, 1.5 equiv. 7.2, 2.0 equiv. K2CO3, 16 h, 80 °C. a24 h reaction time. 
b 3 equiv. 7.2 
Scheme 39. Scope of O-acetylation reactions of alcohols using acylal 7.2 
 
 The mechanism of the O-acetylation of alcohols using acylal 7.2 is believed to proceed 
in a much more simplistic manor than that for the N-acetylation of amines. Nucleophilic attack 
of alcohol 40.1 into the acyl carbonyl of acyl oxonium 15.1 will lead to the formation of of 
protonated ester 40.2. Deprotonation with K2CO3 will lead to formation of ester 40.3, as well as 
formation of one equivalent of benzaldehyde 7.1 and potassium acetate 40.4 (Scheme 40).    
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Scheme 40. Mechanism for the O-acetylation of alcohols with acylal 7.2 
 
1.52 Use of Acylals for the N-/O-Acylation of Benzylamine and Benzyl 
Alcohol 
After carrying out successful N-/O-acetylation reactions of a range of amines and 
alcohols, it was decided to broaden the scope of the acylating reagent to determine whether 
other acyl groups could be transferred in this manner. A range of five acylals 41a-e containing 
different acyl donor groups were synthesized using the same methodology developed previously 
for the synthesis of phenylmethylene diacetate 7.2. Synthesis of the trifluoroacetyl derivative 
41f required more forcing conditions that employed trifluoroacetic acid as a catalyst, which 
afforded an acylal product that was used without further purification. Exposure of acylal 41f to 
water or atmospheric moisture, led to its rapid decomposition (Scheme 41).  
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Reaction conditions; 1 equiv. 7.1, 1.5 equiv. anhydride, 0.1 equiv. p-TSA. a 1 equiv. 7.1, 1.5 equiv. 
anhydride, 0.1 equiv. TFA. 
Scheme 41. Synthesis of a range of acylals 40a-f 
 
These diacyl reagents 41a-f were then used for a series of representative N-/O-acylation 
reactions of benzylamine and benzyl alcohol respectively. N- and O-acylation reactions using this 
range of acylals 41a-f (including short and long chain alkyl, acryloyl, benzoyl, phenyl acetyl and 
trifluoroacetyl groups) proved successful without the need for any further optimization 
affording a range of six benzylamides 42a-f and six benzyl esters 43a-f in 79-96% and 62-94% 
yields respectively (Scheme 42 and Scheme 43).   
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Reaction conditions; 1 mmol of amine, 1.5 equiv. diacylate, 16 h, 70 °C. a1 mmol of amine, 1.5 equiv. 
diacylate, rt 1 h 
Scheme 42. N-acylation reactions of benzylamine using acylals 41a-f 
 
  
Reaction conditions;  1 mmol of alcohol, 1.5 equiv. diacylate, 2.0 equiv. K2CO3, 16 h, 90 °C. a1 mmol of 
alcohol, 1.5 equiv. diacylate, 2.0 equiv. K2CO3, rt 1 h. 
Scheme 43. O-acylation reactions of benzyl alcohol using acylals 41a-f 
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These type of amide and ester compounds have numerous potential applications. For 
example, acrylamides 42c are routinely used as monomers for polymerization chemistry, whilst 
triflouroacetyl amides are privileged medicinal chemistry motifs, which are often used for the 
synthesis of highly active drug molecules. Such as Valrubicin which is used for bladder cancer 
treatment (Figure 4). 
  
 
Figure 4. Structure of Valrubicin 
 
Having demonstrated that acylals could be used for the acylation of amines and 
alcohols, our attention turned to developing an analogous formylating reagent. N-formylation 
of amines is a highly important reaction in organic synthesis and medicinal chemistry, with 
formamides used as versatile synthetic intermediates, and often present as fragments in a 
number of medicinally active compounds.76-78 For example, formylation chemistry has been 
heavily utilized in peptide synthesis due to the ease of carrying out late-stage formyl 
deprotection,76, 77, 79, 80 while formamides have also found widespread application as precursors 
for the synthesis of isocyanides and formamidines.76, 81, 82 With this utility in mind, our efforts 
next turned towards the synthesis of a formyl version of acylal 7.2. As well as the methods 
covered earlier in this report, there a number of techniques for the synthesis of formamides. 
Including the use of chloral, formic acid, formaldehyde and formates as the formyl source.83 
These are either reacted directly or in conjunction with a range of catalsyst including, mild base 
(ammonium carbonate), mild acid (pTSA, MTSA), polymer supported acid/base catalyst and 
metal catalyzed formation.83      
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1.6 N-Formylation of Amines 
It was decided that a gem-diformyl variant was likely to be unviable due to the inherent 
instability of formic anhydride, and so it was decided to attempt to synthesize a mixed 1,1-formyl 
acetate 44.2, reasoning that its more reactive formyl group would be selectively transferred. In 
order to obtain the desired compound our standard synthesis needed to be altered. An 
adaptation of the Chakraborti 1,1-diacetate synthesis was utilized (Scheme 44),70 involving 
treatment of benzaldehyde 7.2 and O-formylacetate 44.1 with a catalytic amount of 
Cu(BF4)2xH2O at -20 °C. This reaction gave a mixture of products containing 
(formyloxy)(phenyl)methyl acetate 44.2, phenylmethylene diacetate 7.2 and gem-diformal 44.3 
in a 16:9:2 ratio (Scheme 44). These products could be easily separated by chromatography to 
afford pure (formyloxy)(phenyl)methyl acetate 44.2 in 59% yield and phenylmethylene 
diacetate 7.2 in 25% yield respectively. Although resonances for gem-diformal 44.3 could be 
seen in 1H NMR spectra of the crude reaction product, is proved to be unstable, as predicted 
decomposing on exposure to silica. The observed formation of a mixture of products is a 
consequence of this reaction proceeding via an intermolecular pathway.33, 34 To the best of our 
knowledge, (formyloxy)(phenyl)methyl acetate 44.2 has only been prepared once previously, 
where it was isolated as a side product of an oxidation reaction in a meagre 8% yield by Syper 
et al. (Scheme 45).84   
 
Scheme 44. Synthesis of (formyloxy)(phenyl)methyl acetate. 
  
 
Scheme 45. Synthesis of (formyloxy)(phenyl)methyl acetate 44.2 by Syper84  
43 
 
 Therefore we decided to investigate the use of (formyloxy)(phenyl)methyl acetate 44.2 
for the N-formylation of amines. The mechanism for the formation of 44.2 is likely to proceed 
as described earlier, with attack of mixed anhydride 44.1 into the carbonyl bond of oxonium 8.1 
affording acyloxonium 46.1. The hydroxy group present in acyloxonium 46.1 is able to attack 
into the formyl fragment of anhydride 44.1 to afford acyl oxonium 46.2. Anhydride regeneration 
then affords the observed (formyloxy)(phenyl)methyl acetate 44.2 (Scheme 46a, shown in 
black). Formation of acylal 7.2 (shown in red) proceeds via a similar mechanism, however, attack 
of the hydroxyl group of 46.1 at anhydride 44.1 occurs at the acyl carbonyl (Scheme 46b). Finally, 
formation of gem-diformal 44.3 (shown in blue) proceeds via attack of the formate half of mixed 
anhydride 44.1 into the carbonyl bond of oxonium 8.1 affording acyloxonium 46.5. The hydroxy 
group present in acyloxonium 46.5 then attacks the formate carbonyl of anhydride 44.1 to afford 
acyl oxonium 46.6. Anhydride regeneration then affords the observed 44.3 (Scheme 46c). 
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Scheme 46. Mechanism for formation of mixture of products 44.2, 7.2 and 44.3 
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Pure (formyloxy)(phenyl)methyl acetate 44.2 was then applied as an N-formylating 
reagent for amines. Pleasingly, (formyloxy)(phenyl)methyl acetate 44.2 proved to be highly 
selective for N-formylation reactions, providing good to excellent yields for N-formylation of a 
range of 16 primary and secondary amines, with no evidence of any competing acyl transfer 
occurring. These formylating reactions afforded a range of 16 formamides 47a-p in 53-95% 
isolated yields. Again, the reactions were able to be purified directly via column 
chromatography, without the need for an aqueous work up. For non-volatile products, removal 
of by-products could be achieved by distillation under high vacuum. It is also worth noting that 
due to the increased reactivity of this formylating agent, these reactions could be carried out at 
rt, with the reaction time reduced to just 1 h (Scheme 47).  
When tryptamine was used as a substrate there was no evidence of competing 
formamide formation at the indole nitrogen (47d). It is also important to note that when (S)-
valine methyl ester was formylated, there was no evidence of any racemization of its 
stereocentre (determined by alpha D for 47g, [α]D20 = -22; Lit = -23.4585), which is often a problem 
with other acylating reagents. The low yield of tert-butylformamide 47h can be ascribed to the 
steric hindrance of the amine and the volatile nature of both the starting amine and product 
formamide. A range of electron deficient anilines were also successfully formylated 47l-p, 
including the sterically hindered N-methyl aniline that gave formamide 47p in 91% yield. In some 
instances where the amine was not soluble in the formylating reagent, EtOAc was added as a 
co-solvent leading to significantly longer reaction times.      
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Reaction conditions; 2 mmol of amine, 1.5 equiv.43.2, 1 h, rt. aEtOAc required as solvent. b24 h reaction 
time. 
Scheme 47. N-formylation reactions of amines using acylal 44.2 
 
1.61 An N-Formylation Reaction Performed on Scale 
The N-acylation and N-formylation reactions described in previous sections were all 
purified via column chromatography, however, this kind of purification approach is clearly not 
compatible to process scale-up. With potential large scale application of these reagents in mind, 
it was decided to develop an alternative purification route that would not rely on 
chromatography. It was found that when the desired amide or formamide products were 
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crystaline, or oils with a suitably high boiling point, then both the acetic acid and benzaldehyde 
by-products could be easily removed by distillation in vacuo. However, when this approach was 
not a viable option (e.g. for volatile 47j), an aqueous work up with saturated NaHCO3 could be 
used to remove the acetic acid, followed by extraction with a solution of saturated NaHSO3 that 
removes the benzaldehyde by-product as its water soluble bisulfite adduct. For example, this 
purification approach was performed on a crude formylation product produced from reaction 
of 5g of benzylamine 33.1 with 9.06 g of formylation agent 44.2 under standard conditions. 1H 
NMR spectroscopic analysis revealed that the reaction afforded a mixture of the desired N-
benzylformamide 47a, benzaldehyde and acetic acid. An aqueous work up with NaHCO3(aq) 
resulted in removal of sodium acetate 48.1. Secondly, a bisulfite extraction then allowed for 
removal of benzaldehyde as its bisulfite adduct 48.2, affording 5.36 g of N-benzylformamide 47a 
in a slightly reduced 85% yield (Scheme 48).       
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Scheme 48. Chromatography free purification of a large scale N-formylation reaction of benzylamine   
1.62 N-Formylation Reactions of Amino Acid and Peptides 
1.621 N-Formylation Reactions of α-Amino Acids  
The direct N-formylation of unprotected α-amino acids remains an attractive goal in 
organic synthesis with only a limited range of synthetic protocols currently available.76, 80, 86, 87 
One of the main issues arises from the poor solubility of amino acids in organic solvents and the 
incompatibility of many formylating reagents with water, which may act as a competing 
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nucleophile. Of the synthetic protocols that are available for N-formylation of unprotected α-
amino acids, the formyl source is either formic acid or formamide, both of which have a high 
tolerance to water. We observed that reagent 44.2 was relatively resistant to hydrolysis by 
water, and therefore it was decided to attempt the direct N-formylation of unprotected α-amino 
acids using water as a solvent. Pleasingly, it was found that (formyloxy)(phenyl)methyl acetate 
44.2 could be used for N-formylation of α-amino acids under aqueous conditions. Formylation 
conditions were optimized for these α-amino acid substrates resulting in the use of 5 equivalents 
of NaHCO3 as a base, extended reactions times of 16 h, and addition of a second 1.5 equivalents 
of (formyloxy)(phenyl)methyl acetate 44.2 after 8 h. This resulted in N-formylation of 
unprotected amino acids proceeding to afford a range of six N-formyl α-amino acids 49a-f with 
good to excellent yields 71-89% (Scheme 49). The purification of N-formyl α-amino acids was 
performed using an aqueous NaHCO3 wash to remove the acetic acid and any unreacted amino 
acid. This was followed by recrystallization of the crude N-formyl-α-amino acid from a mixed 
solvent system of EtOAc and pentane. Comparison of the [α]D20 of 49a-f with those of literature 
revealed no evidence of any racemization having occurred. These type of N-formyl amino acids 
have found numerous applications; for example through conversion to isocyanides as substrates 
for multicomponent reactions, and their use in peptide synthesis.88   
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Reaction conditions; 1 mmol of amino acid, 1.5 equiv 44.2, 5 equiv NaHCO3 16 h, rt (after 8 h 2nd 1.5 
equiv. of 44.2). 
Scheme 49. N-formylation of unprotected amino acids. 
1.622 N-Formylation of Peptides  
Formylation is not only used extensively in peptide synthesis as a protecting group, 
there are a number of naturally occurring and synthetic peptides which contain a formamide 
group that are essential for their biological activity.89 One of the best known examples is N-
formylmethionyl-leucyl-phenylalanine (f-MLP), which is a potent polymorphonuclear leucocyte 
chemotactic factor and macrophage activator.89-91 F-MLP has been used extensively in biological 
and medicinal research,90, 91 therefore its synthesis was identified as a challenging substrate to 
test the scope and limitation of formylating agent 44.2. The tripeptide 50.5 was first synthesized 
according to literature,92 dipeptide 50.3 was formed using DCC coupling of phenylalanine methyl 
ester 50.1 and N-Boc leucine 50.2, followed by N-Boc-deprotection using methanolic HCl. A 
HATU facilitated amide bond formation reaction was then carried out between dipeptide 50.3 
and N-Boc methionine 50.4 to afford the desired N-boc protected tripeptide, which upon 
treatment with methanolic HCl resulted in tripeptide 50.5. This tripeptide was then treated with 
formylating reagent 44.2 in the presence of EtOAc as a co-solvent to afford N-formyl tripeptide 
50.6 in 87% yield. Subsequent ester deprotection through base hydrolysis then afforded f-MLP 
in 93% yield (Scheme 50).   
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Scheme 50. Synthesis of f-MLP. 
 
 It was then decided to further test the limitations of these reagents as formylating and 
acylating agents, for the ω-amino residue of a lysine residue of a more complex peptide. A small 
amount of decapeptide 51.1 with the sequence Ac-ADGIVNGVKA-NH2, whose N-terminus 
protected as an acetamide and whose C-terminus was protected as a primary amide, was 
acquired from Dr Jody Mason (Department of Biology and Biochemistry, University of Bath). This 
peptide was reacted with both the acetylating and formylating reagents 7.2 and 44.2 with the 
aim of selectively acylating the free ω-amino group of its lysine residue. Previous control 
experiments had demonstrated that neither of these reagents could acylate or formylate 
primary amides. The acylation conditions used were altered slightly to accommodate the other 
amino acid residues present in this peptide. To ensure that the ω-amino group of the lysine 
residue was present as its free amine, the reaction was buffered at pH 8. The co-solvent system 
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used was a mixture of MeCN, H2O and a few drops of DMSO. Satisfyingly, both acetylating and 
formylating reactions proceeded to successfully produce formamide peptide 51.2 and 
acetamide peptide 51.3. Formation of both peptide products was confirmed by the presence of 
the correct molecular ions for 51.2 (HRMS (ESI): m/z calculated for C44H74N13O15: requires: 
1025.5433 for [M-H]-; found: 1025.5483) and 51.3 (HRMS (ESI): m/z calculated for C43H73N13O15: 
requires: 1010.5276 for [M-H]-; found: 1010.5292) in their HRMS respectively (Scheme 51).  
 
  
Reaction conditions; a5 equiv 7.2, MeCN/H2O/DMSO pH 8, 50 °C, 24 h. b 5 equiv 43.2, MeCN/H2O/DMSO 
pH 8, rt, 24 h 
Scheme 51. N-Acylation and N-formylation reactions of peptide 51.1 
 
1.63 O-Formylation Reactions of Alcohols 
The corresponding O-formylation reactions of a range of alcohols using reagent 44.2 
were then carried out, for the synthesis of a range of ten formate esters using NaHCO3 as a base, 
at a slightly lower temperature of 60 °C. Pleasingly, these O-formylation reactions were 
compatible with a wide range of alcohols including phenols, primary, secondary and allylic 
alcohols, producing a range of ten formate esters 52a-j in 71-88% yield (Scheme 52). It is known 
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that 4-methoxyphenyl formate 52j is susceptible to hydrolysis due to the low pKa of its resultant 
phenol hydrolysis product, so an isolated 75% yield for 52j highlights the generally mild nature 
of the reaction conditions.  
 
  
Reaction conditions; 1 mmol of alcohol, 1.5 equiv. 44.2, 2 equiv. NaHCO3, 16 h, 60 °C. a24 h reaction 
time. 
Scheme 52. O-formylation reaction of alcohols. 
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1.64 Investigation into the N-/O- Selectivity Profile of Acylals   
The N-/O- selectivity profile of these acylating/formylating agents was then investigated 
utilizing serine methyl ester 53.1 as a bifunctional test substrate. N-acetylation was performed 
under neutral conditions using acylal 7.2 to selectively give N-acetyl-serine methyl ester 53.2 as 
the sole product in 83% yield. O-formylation was then conducted using reagent 44.2 under the 
standard basic conditions to give N-acetyl-O-formylserine methyl ester 53.3 in a 78% yield, with 
no evidence of any N-/O-acyl scrambling having occurred, a phenomenon which has been 
documented previously using acylated serine substrates (Scheme 53).93 There was also no 
evidence of racemization which can be a concern when using protected amino acid esters 
(determined by alpha D, [α]D20 = -9.5; Lit = -10.194 53.2, [α]D20 = +56 53.3). When these reactions 
were attempted in alternative order (formylation followed by acetylation), N-formylation of 
serine methyl ester 53.1 proceeded well, however, the relatively high temperature required for 
O-acetylation led to decomposition of the formamide starting material.    
 
 
Scheme 53. N-/O-selectivity demonstration with serine methyl ester 
 
1.7 Acetalisation of 1,2-Diol and 1,3-Diol Utilizing Acylals 
 In order to further explore the reactivity and utility of acylals it was decided to assess 
their reactivity towards diols under acidic conditions for the potential synthesis of cyclic acetals. 
Reactions to afford acetal and ketal groups are highly important reactions in organic synthesis, 
where they are often used to reversibly protect the functionality of carbonyl groups. This is 
particularly prevalent in natural product syntheses, which often utilize multiple acetal and ketal 
forming reactions to protect diols present in synthetic intermediates. In these more complex 
systems it is important to have mild reaction conditions to introduce the acetal protecting group 
as many natural product intermediates contain functionality that are not stable to strong acids, 
55 
 
or high temperatures. It was proposed that phenylmethylene diacetate 7.2 might serve as a 
useful reagent for the protection of diols as their cyclic benzaldehyde acetals. 
 An initial reaction was performed involving reaction of phenylmethylene diacetate 7.2 
with 1-phenyl-1,3-propandiol 54.1 in CH2Cl2 using a catalytic amount of acetic acid (Scheme 54). 
The reaction proceeded at rt, to afford a modest conversion of 30% for formation of acetal 54.2, 
along with a significant amount of monoacetate 54.3 (10%). This was a promising result that 
warranted further optimization, and so a solvent screen was conducted with the results 
presented in Table 3. Five solvents were screened with acetonitrile and dichloromethane, 
entries 2 and 3, giving the best results, showing 85% and 80% conversion to acetal 54.2 
respectively. Unfortunately formation of monoacetate 54.3 could not be completely suppressed 
(Table 3), however, it is worth noting that the cyclic acetal was formed with total syn-
diastereoselectivity under these conditions, with no evidence of any anti-diastereomer being 
present.   
 
 
Scheme 54. Acetal protection of diol 54.1 
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Table 3. Solvent screen for the optimisation of acetal protection of diol 54.1 
Entry Solvent  
Monoacetate 54.3  
(%) 
Acetal 54.2 
(%) 
1a Dichloromethane 10 30 
2 Toluene 9 7.5 
3 Acetonitrile  13 85 
4 Dichloromethane 10 80 
5 Ethyl Acetate 32 5 
6 Hexane 31 66 
Reaction conditions; 0.5 mmol of diol, 5 equiv. 7.2, 1 mol% AcOH, 3 mL solvent, 12 h, 40 °C a = rt. 
 
In order to investigate the mechanism of this acetalisation reaction a number of control 
experiments were conducted, with some of the key reactions carried out shown below (Scheme 
55). Firstly, it was important to show that benzaldehyde was not acting as the acetalising agent 
under these conditions, since acid catalysed breakdown of phenylmethylene diacetate 7.2 could 
afford benzaldehyde 7.1, which could potentially undergo a normal acid catalyzed acetal 
protection reaction. Pleasingly, as shown in reaction a), no acetal product was produced when 
benzaldehyde 7.1 was substituted in place of acylal 7.2. We next determined whether 
monoacetate 54.3 might be an intermediate in the reaction pathway. Therefore, monoacetate 
54.3 was synthesised separately (from reaction of diol 54.1 with acetic anhydride, isolated from 
a mixture of products) and subjected to the standard reaction conditions. As shown in reaction 
b), these conditions afforded no evidence of any acetal formation. Finally, reaction of 
monoacetate 54.3 with benzaldehyde 7.1 in the presence of acetic acid in MeCN at 40 °C 
(reaction c), once again gave no evidence of any acetal formation (Scheme 55).     
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Scheme 55. Reactions to investigate the mechanism of acetal 52.2 synthesis  
  
Given these results, the reaction is proposed proceed via initial protonation of acylal 7.2 
to afford oxonium 56.1, with elimination of one of its acetate groups to produce O-acyl oxonium 
species 15.1, which is then primed for nucleophilic attack of the primary alcohol functionality of 
diol 54.1 to give acetate 56.2. A second protonation step then occurs to give oxonium 56.3, 
which eliminates a second acetate group to produce alkyl oxonium 56.4. Intramolecular attack 
of the free secondary hydroxyl group of 56.4 then leads to formation of the desired cyclic acetal 
54.2 (Scheme 56).  
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Scheme 56. Proposed mechanism for the formation of acetal 52.2 
 
 It was then decided to investigate the substrate scope of this new acetal protection 
protocol. A small selection of seven 1,2-diols and 1,3-diols were protected as their benzylidene 
acetals, using acylal 7.2 as the acetalising agent in acetonitrile at 40 °C, in the presence of a 
catalytic amount of acetic acid. These acetalisation conditions were applied to a range of diols 
to afford a range of cylic acetals 54.2, 57a-f in 66-88% yield, including substrates containing 
methyl, phenyl and the sterically demanding tert-butyl group. Again, where enantiopure diols 
57c/57f were used, the acetalisation reaction proceeded without racemization ([α]D20 = -100 57f; 
[α]D20 = -33; Lit = +3295 (opposite enantiomer) 57f) (Scheme 57). The 1,3-diols formed 6 
membered ring acetals, with syn-diastereoselectivity, whereas 1,2-diols formed 5 membered 
ring acetals predominantly with anti-diastereoselectivity. 
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The majority of the reactions proceeded to afford a single diastereomer, however, 
acetals 57d and 57e were isolated as a mixture of syn/anti diastereomers. Importantly, acylal 
7.2 could also be used for the synthesis of acyclic acetals such as acetal 57g, albeit with a slight 
reduction in yield when using the alcohol substrate as the limiting reagent.  
 
  
Reaction conditions; 1 mmol of diol, 3 equiv. 7.2, 1 mol% AcOH, 3 mL solvent, 12 h, 40 °C. aProduct 
isolated as a mixture of diastereomers.  
Scheme 57. Acetal protection of diols 
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1.8 Preliminary Investigations into the use of Mixed Acylals for 
N-/O-Acylation Reactions 
One area where this project could be advanced is through the use of a mixed acylal 
reagent that contains a sterically hindered pivaloyl whose steric bulk would ensure that it was 
not transferred as an acyl group. This would allow for the selective transfer of the acyl group of 
choice, allowing for a much more efficient process, especially if a valuble and complex acyl group 
needs to be transferred. Synthesis of a mixed acylal was performed in the same way as for the 
preparation of (formyloxy)(phenyl)methyl acetate 44.2, substituting O-formaylacetate 44.1 for 
acetic pivalic anhydride 58.2. Reaction of this mixed anhydride with benzaldehyde 7.1 gave the 
desired mixed acylal acetoxy(phenyl)methyl pivalate 58.3 in 60% yield (Scheme 58).    
 
 
Scheme 58. Use of mixed gem-diacetate for selective acyl transfer 
 
Two preliminary experiments were carried out to determine whether this approach was 
viable using acetoxy(phenyl)methyl pivalate 58.2 as the acylating agent, in the hope that the 
acetate group would be transferred, due to the steric bulk of the tert-butyl group preventing 
nucleophilic attack at its proximal carbonyl. Pleasingly, these reactions proceeded well, affording 
the desired acetamide 34a in 85% yield, and the corresponding acetate ester 39a in a 83% yield, 
with no evidence of any N-benzylpivalamide or pivalic ester being formed (Scheme 59). It is 
anticipated that this type of mixed acylal reagent will have the most impact, where a more 
complex or expensive acyl group needs to be transferred. However, due to time constraints this 
area could not be fully explored, and further experiments to explore the scope and limitation of 
this approach will be carried out in the near future. 
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Scheme 59. Preliminary example of selective acyl transfer 
1.9 Future Work 
There are a number of potential routes where this project could be taken forward. A key 
area would be to fully explore the use of mixed acylals for acylation reactions. One potential 
powerful application could be the use of a mixed acylal for peptide synthesis. For example, acylal 
60.1 containing a protected amino acid fragment could be used as an acylating agent for a range 
of amines, with acylation of an amino acid methyl ester 60.2 potentially enabling facile dipeptide 
synthesis (Scheme 60).   
 
 
Scheme 60. Proposed use of mixed acylals for peptide synthesis  
 
 These mixed acylals could also be potentially used for labelling the amine/alcohol 
groups of serine/lysine residues of proteins with fluorophores, allowing the targeted protein to 
be visualised within the cell. Labelling using a mixed acylal should be selective for tagging only 
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those residues that are solvent exposed on the surface of the protein. Which should mean that 
the labelling event should not affect the protein activity. Furthermore, transfer of acyl units 
containing alkyne functionality would allow for “click” chemistry to be carried out to modify 
protein surfaces, or for immobilising proteins to surfaces.  
 Another exciting area where acylals could be applied is as potential suicide inhibitors 
(pro-drugs). There are a number of drug molecules which contain aldehyde functionalities. 
However, while this aldehyde functionality accounts for the impressive biological activity they 
possess, it also results in some highly undesirable side effects, usually caused by the toxicity 
related to the high reactivity of an aldehyde group towards nucleophile in a cellular 
environment. One such drug is MG-132 which is a specific, potent, reversible, and cell-
permeable proteasome inhibitor (Figure 5). MG-132 activates c-Jun N-terminal kinase (JNK1), 
which initiates apoptosis, allowing for its use in anti-cancer therapies.  
 
 
Figure 5. MG-132 
 
One way in which the toxicity of this compound could be reduced is to mask the 
aldehyde as an acylal. This acylal could be designed in such a way that the aldehyde functionality 
is only revealed in cells that contain high levels of cell activity (cancer cells which also have an 
acidic pH which would also accelerate acylal clevage). Proteasome cleavage of the phenyl 
alanine motif present in acylal 61.1 could potentially lead to the generation of free amine 61.2. 
This amine would then be able to undergo an intramolecular acylation causing the elimination 
of acetate and generation of the aldehyde functionality of the parent compound MG-132 
(Scheme 61).   
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Scheme 61. Potential use of acylal methodology for the design of a suicide inhibitor 
1.10 Conclusion 
In conclusion a new branch of reactivity has been discovered for acylals which had 
previously been shown to exhibit a wide range of reactivity towards a range of nucleophiles.31, 
35-39, 41-46 We have shown them to be highly active reagents for the N-/O-acylation of amines and 
alcohol nucleophiles for the synthesis of a range of formamides, acetamides, formate esters and 
acetate esters. It has been demonstrated that a range of acyl groups can be transferred including 
short and long chain alkyls, acryloyl, benzoyl, phenyl acetyl and biologically important 
trifluoroacetyl group, thus enabling the synthesis of a range of benzylamides and esters. These 
acylation reagents have also been shown to demonstrate inherent N-/O- selectivity towards the 
amine and alcohol groups of serine methyl ester.   
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To explore further the scope and limitations of these reagents 
(formyloxy)(phenyl)methyl acetate 44.2 has been applied for the N-formylation of a range of 
unprotected amino acids, and for the synthesis of the biologically important tripeptide f-MLP. 
As well as this, both phenylmethylene diacetate 7.2 and (formyloxy)(phenyl)methyl acetate 
44.2, have been applied for the acylation/formylation of the ω-amino residue of a lysine residue 
within a decapeptide. Finally, it has also been demonstrated that a simple switch in pH from 
basic to acidic conditions for diols can change from O-acylation to acetal formation.  
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In conjunction with the research described above, work was also been carried out 
towards A protecting group free strategy for the sustainable synthesis of polyketide natural 
products and their analogues. An introduction into this area will now be presented. 
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2.0 Efficient Natural Product Synthesis 
2.1 Introduction  
 Throughout documented human history chemical substances derived from natural 
sources; plants, animals and microbes have been utilised as medicines in the treatment of 
diseases and ailments.96 However, the first chemical synthesis of a natural product did not occur 
until 1828 with the synthesis of urea from inorganic ammonium cyanate by Wӧhler.97, 98 Wӧhler 
demonstrated that natural products, despite being derived from living organisms, could also be 
synthesised in the laboratory.98 This breakthrough led to the first targeted synthesis of an 
“organic “ natural product; acetic acid in 1884.98, 99 Up until the 1960’s, natural product synthesis 
was predominantly a tool to either confirm, or decipher the structure of the natural product 
under investigation. Common spectroscopic techniques taken for granted today were either in 
their infancy, or yet to be discovered; i.e. UV/vis spectroscopy (1930’s), Infra-Red spectroscopy 
(1940’s) and perhaps the most important, nuclear magnetic resonance (NMR) (1950’s). Before 
this, the total synthesis of a complex molecule from known building blocks to give the proposed 
structure was one of the best methods of structural determination and confirmation. A 
comparison of physical properties with an isolated genuine sample of the natural product was 
then used to confirm that the correct compound had been assigned/synthesised.98  
3.0 Early Natural Product Synthesis 
 An example of early natural product synthesis is the relay synthesis of oestrone; which 
relied on a combination of synthetic techniques from Robinson,100 Bachmann,101 Anner and 
Miescher.102 The synthesis shown in Scheme 62 is known as a “relay”, because it targets a known 
intermediate that could also be generated from degradation of the natural product. For 
example, ketone 62.6 had been previously isolated through the degradation of oestrone, and a 
synthesis of oestrone from ketone 62.6 had been established.98, 100 The synthesis shown is typical 
of the time: the molecular skeleton is formed using reactions that only introduce small changes 
to the overall structure, maintaining a level of control over the desired product, and increasing 
the likelihood that the predicted transformation would occur. This concept relied heavily on the 
use of established skeletal building reactions, resulting in natural product synthesis at the time 
not employing many new “risky” reaction steps.98 In the synthesis of oestrone, the main skeletal 
building step was introduction of malonic ester fragment, followed by C-acylation of the 
malonate intermediate to give ketone 62.2. This intermediate then underwent a series of 
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hydrolysis, cyclisation and elimination reactions to give the diacid 62.3. Decarboxylation of 
diacid 62.3 then occurred, with alkene bond migration affording the more thermodynamically 
stable tetra-substituted alkene 62.4. Alkene hydrogenation, followed by esterification 
generated bis-ester 62.5, which underwent Dieckmann cyclisation to afford bis-ester 62.5, 
whose enolate was methylated to give β-keto-ester 62.6. However, 62.6 was formed as one of 
three racemic diastereomers, which needed to be separated by fractional crystallisation. A 
Reformatsky reaction on the desired diastereomer, followed by dehydration of the resultant β-
hydroxyester, afforded α,β-unsaturated ester 62.7. Alkene hydrogenation, followed by further 
fractional crystallisation purification of the resultant mixture gave the pure diester of 
diastereomers 62.8. Formation of acyl chloride 62.9 was followed by Arndt-Eistert homologation 
to afford C1-homologated ester 62.10, which was then cyclised/decarboxylated to afford 
oestrone 62.11. At the time the Arndt-Eistert homologation was a relatively new reaction, so its 
inclusion as a key step at a late stage of a natural product synthesis was considered quite 
revolutionary. Only the yields for the first four steps are available, therefore comments about 
overall yield cannot be made.  
 While it may seem unfair to compare this synthesis to modern day efforts, by so doing 
it can help demonstrate how far synthesis has evolved over the years, and highlight areas where 
progress is still lacking. Key features of this oestrone synthesis are: 
 Atom economy = 15% 
 9 Functional Group Interconversion (FGI) steps, including a number  of ester 
hydrolysis/esterification steps 
 2 reductive steps 
 Lack of stereocontrol during the cyclisation and hydrogenation steps 
 Use of toxic Pb(CO3)2 as a base 
 Use of toxic/explosive diazomethane in the C1-homologation reaction 
An atom economy of 15% for the synthesis of a complex molecule is relatively good, 
however a more strategic synthetic plan might have resulted in a number of the inherently 
inefficient functional group interconversion (FGI) steps being avoided. A number of reagents 
used would no longer be acceptable by modern industrial standards, Pb(CO3)2 is highly toxic and 
lead regents are avoided where possible, whilst carrying out the cyclisation reaction at 300 °C 
seems excessive. Diazomethane is toxic but also presents an explosion risk, while the use of 
these reagents was common place, a greater awareness of health and safety might result in an 
alternative flow protocol being considered for this step.  
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Scheme 62. An early pioneering synthesis of oestrone98 
 
69 
 
 It is important to remember that during these early years of synthesis, how limited the 
synthetic “tool box” was, with many fewer reactions being available for consideration for natural 
product synthesis. This is particularly highlighted in the creation of stereogenic centres where 
the ability to control steroselectivity in a reaction was much less well developed, often resulting 
in low yielding formation of complex mixtures of racemic diastereomers that were difficult to 
purify. 
 The success or failure of natural product syntheses at this time relied heavily on the 
choice of the original starting material, which meant that each synthesis was ‘bespoke’ relying 
on a level of intuition from the chemist.98, 103  This level of “intuition” is well illustrated in the 
total synthesis of homoeroquinene reported by Woodward and Doering in 1945 (Scheme 63).98, 
104 This achievement generated a lot of interest, both within the scientific community and the 
wider population. This was due to the therapeutic properties of quinine for the treatment of 
malaria, which had become an acute problem, due to the British, Dutch and French Empires 
having expanded their influence into malaria infected territories.98, 103 
 This synthesis was again a relay synthesis based on the work of Kindler105 and Prelog,106 
who had isolated quinotoxine and homoeroquinene from the degradation of quinine, and 
subsequently demonstrated that quinine could be reconstructed from these compounds (Figure 
6).    
 
 
Figure 6. Structural relationship between quinine, quinotoxine and homoeroquinene98, 105, 106 
 
 The choice of the hydroxyquinoline 63.1 as the starting material highlights the shrewd 
thinking of Woodward, as all of the skeletal atoms required for the desired intermediate 
homoeroquinene were already in place from the offset.  
 Initially, the nitrogen containing ring of the hydroxyquinoline 63.1 was selectively 
hydrogenated to give hydroquinoline 63.2. N-Acetylation followed by de-aromatisation gave the 
70 
 
fully saturated hydroquinoline 63.3. Complete control over the facial selectivity of the 
hydrogenation of 63.2 to give the desired cis arrangement was unsuccessful and therefore after 
oxidation to ketone 63.4 a separation of diastereomers was required. The cyclohexanone ring 
was then oxidatively cleaved with ethoxy nitrite to give oxime 63.5, which was subsequently 
reduced and N-methylated to give the quaternary ammonium salt 63.6. Hofmann elimination 
resulted in selective alkene formation followed treatment with potassium isocyanate to give 
urea 63.7 (required for purification), which after acid catalysed hydrolysis of both its urea and 
ester functionalities gave the desired homoeroquinene (Scheme 63). 
Key features of this homoerquinene synthesis are:         
 Atom economy = 17% 
 10 steps, 10% overall yield from 63.1 
 2 oxidation steps (including use of stoichiometric chromium oxidants) 
 3 reductive steps 
 Poor stereocontrol during the hydrogenation step 
 Creation and then destruction of 2 stereocentres  
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Scheme 63. Woodward and Doering synthesis of homoeroquinene.98, 104 
 
 With the development of modern day analytical spectroscopic techniques (UV/vis, IR 
and NMR) and with X-ray crystal structure analysis becoming the established techniques for 
structure elucidation, Synthetic organic chemists were suddenly free to explore more ambitious 
syntheses. This new freedom for natural product synthesis was perhaps best captured by 
Eschenmoser.98, 107 
 “Elimination of the classical function of providing structural proof for natural products 
implied liberation from the restriction that only very well established reactions may be applied 
in a synthesis. Natural product synthesis henceforth provides a challenge to invent and to 
develop novel reactions and to discover novel reactivity patterns.” 
 However, developments in the art of the synthesis were not purely about developing 
new reactions, since access to new reactivity profiles also enabled increasingly complex natural 
product targets to be prepared. These synthetic breakthroughs allowed many new drug 
molecules to be prepared, as well as enabling chemical probes to be synthesised that enabled 
biochemical pathways to be interrogated.108 As soon as a new complex natural product was 
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isolated, then the race was on to achieve its total synthesis, with the research groups of 
internationally renowned scientist such as Danishefsky, Evans and Nicolaou, (and numerous 
others), having achieved impressive syntheses of many different of highly complex natural 
products. 
 This change in direction led to large surge in natural product synthesis research 
culminating in a peak in output during the 1970-90s.96, 98, 108, 109 This increase in interest had a 
dramatic impact on the pharmaceutical industry during this time, with 49% of the 877 new 
molecular entities introduced as drugs between 1981-2001 being derived from natural product 
leads. Indeed this percentage increases further when two of the most crucial therapeutic areas 
are considered; with natural product inspired leads responsible for 60% of the drug molecules 
approved in the areas of anti-cancer and anti-infection during the period 1984-1995.96, 110-113 
3.1 Natural products as drug molecules 
 The inherent biological activity, high structural diversity and specificity profiles of the 
large number of natural products that have been isolated, means that they may be considered 
to be privileged lead molecules for drug discovery purposes.96, 108, 114 However, the complexity 
of many natural products often makes them difficult to modify chemically, which is often 
required when the pharmacokinetic properties of the parent natural product need to be 
modified. Natural products are also often not available in sufficiently large enough quantities 
from renewable natural sources. Instead, advances in increasing the efficiency of synthetic 
organic chemistry protocols are still needed, to help remove perceived barriers associated with 
using natural product derived lead compounds in drug discovery programs.114 Indeed, one of the 
main driving forces in modern natural product synthesis is to develop new reaction protocols 
that address efficiency/sustainability issues, and demonstrate that they can be applied to the 
synthesis of structurally complex structures.108  
 A prominent example of the type of problems that are often faced, is for the multigram 
total synthesis of the potent anticancer marine polyketide natural product (+)-discodermolide 
carried out by Merck process chemists in collaboration with Paterson and co-workers.115-119 The 
demand for this compound could not be met through isolation from its natural source; a marine 
sponge Discodermia sp.,115 with repeated attempts to culture Discodermia sp. expressing the 
correct  symbiotic microorganisms that produce discodermolide having proven unsuccessful to 
date. Therefore, a viable synthetic route to large mulitigram quantities of discodermolide was 
required, with the first total synthesis by the Schreiber group requiring a 32 step synthesis in 
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only 3.2% overall yield.120 While an impressive example of natural product synthesis, the low 
yield rendered this route unviable for the production of (+)-discodermolide on a large scale, and 
as a consequence a new more scalable route was required. Many attempted improvements 
were made to increase the yield of its synthesis,121-127 with the semi-industrial route that was 
eventually devised for the synthesis of multigram quantities of (+)-discodermolide ultimately 
being a hybrid of previous syntheses. 
 Initial efforts focused on the production of the common Weinreb amide intermediate 
64.6 which had been identified as a key synthon by Smith in an earlier synthesis.121-123 This route 
begins with the readily available Roche ester 64.1 which was first O-protected as its p-methoxy-
benzyl ether 64.2. Upon reduction, alcohol 3.3 was obtained which was readily oxidised via a 
TEMPO oxidation to give aldehyde 64.4. This aldehyde 64.4 was then reacted with the boron 
enolate of a chiral N-acyl-oxazolidin-2-one to afford an Evans syn-aldol product 64.5. The aldol 
product 64.5 was purified by recrystallization, hydrolysed, and then subjected to Weinreb amide 
formation using the coupling reagent CDMT. This sequence of reactions gave Weinreb amide 
64.6 in six steps, in large quantities (1.6 kg) and required no chromatographic purification steps 
(Scheme 64).115  
 While this route was clearly compatible for synthesis on a medium scale, there are still, 
a number of areas in which the synthesis of this fragment could be improved. Roche ester 64.1 
is a commercially available starting material, however, at a cost of ~£20/g for the (S) isomer and 
~£30/g for the (R) isomer, it is perhaps not the best choice as starting material for a large scale 
multi-step synthesis of a drug compound. The synthesis of intermediate 64.6 also utilises 
protecting group chemistry in the form of the PMB (p-methoxybenzyl) protecting group which 
accommodates for 37 wt.% of intermediate 64.6.  
Protecting group chemistry continues to be an invaluable tool for organic chemists in 
the synthesis of highly complex compounds, through their ability to mask the reactivity profiles 
of competing functional groups, which offers an increased level of security and predictability.128 
However, the use of a protecting group introduces at least two additional synthetic steps,129 
which greatly reduces the atom efficiency of the synthesis, as well as impacting overall yield, 
since quantitative yields are  rarely possible.128 The atom efficiency for this five step sequence 
from Roche’s ester 64.1 to the common intermediate 64.6 is very low at only 1.33%, and it still 
has a PMB protecting group in place. The use of a chiral auxiliary also has a large impact on atom 
efficiency as it involves incorporation and removal of a stoichiometric chiral unit, although 
efficient recycling of the auxiliary can potentially mitigate these concerns. Furthermore, global 
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ester reduction of an ester group to alcohol 64.3, followed by an oxidation step to afford an 
aldehyde is inherently inefficient.    
 
 
Scheme 64. Paterson et al. synthesis of common intermediate 64.6115 
  
 Once intermediate 64.6 was obtained in synthetically useful quantities it was used as a 
core intermediate for the divergent synthesis of the three key compounds; alkene 65.2, acetal 
65.5 and ketone 65.7 in four, seven and five steps respectively.121-123, 126, 127 Alkene 65.1   was 
prepared via O-TBS protection, and Weinreb amide reduction reactions to afford aldehyde 65.1 
in 61% yield over two steps. Wittig olefination of aldehyde 65.1 using iodoethyl 
triphenylphosphonium ylide then gave iodo-(Z)-alkene 65.2 in a low 30% yield.  
Acetal 65.4 synthesis began with a DDQ catalysed oxidative cyclisation reaction to form 
acetal 65.3, which represents a clever way to manipulate a protecting group, whilst changing its 
overall oxidation state (e.g. alcohol to aldehyde). Weinreb amide reduction to aldehyde, was 
followed by an Evans-aldol reaction to generate syn-aldol 65.4. O-silyl protection of 65.4, was 
followed by reductive auxiliary cleavage with LiBH4, with the resultant alcohol then subjected to 
an iodide mediated Appel reaction to afford acetal 65.5. 
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Ketone 65.2 synthesis also started with a TBS protection, followed by PMB deprotection 
to afford alcohol 65.6. Subsequent alcohol oxidation of 65.6 to its corresponding aldehyde, 
followed by Grignard addition of MeMgBr and secondary alcohol oxidation generated ketone 
65.2 in 66% yield from Weinreb amide 64.6 (Scheme 65).       
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Scheme 65. Key intermediate synthesis  
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Alkene 65.2 and acetal 65.5 were then combined and functionalised in an 11 step 
process to give diene 66.5. The initial reaction proceeds through metalation of iodide and 
reaction with 9-MeOBBN to afford borane 66.1 that underwent a Suzuki-type cross-coupling 
reaction with vinyl iodide 65.2 to generate trisubstituted alkene 66.2. Selective reductive 
cleavage of the PMB group of 66.3 with DIBAL-H and subsequent oxidation of the resultant 
alcohol gave an aldehyde which was subjected to a Nozaki-Hiyama allylation reaction with 2-
TMS-allyl bromide to afford diene 66.3. Deprotection of both-PMB groups of 5.3 with DDQ, was 
followed by TEMPO oxidation to afford an aldehyde that was reacted with the potassium anion 
of bis-2,2,2-trifluoroethyl-phosphonoacetic acid methyl ester utilising a Still-Gennari variation of 
the Horner-Wadsworth-Emmons reaction gave vinyl ester 66.4. The free secondary alcohol of 
66.4 was derivatised with isocyanate ClCCON=C=O to afford a carbamate whose ester group was 
reduced with DIBAL-H followed by alcohol oxidation to afford α,β-unsaturated aldehyde 66.5 in 
27% yield over 11 steps.  
(+)-DIP-Cl boron was then used to generate the boron enolate of ketone 65.7 which 
underwent an aldol reaction with α,β-unsaturated aldehyde 66.5 ,  followed by ketone 
reduction, lactonization and global silyl deprotection to give the final compound (+)-
discodermolide in a total of 39 steps, achieving a final mass of >60 g of (+)-discodermolide 
(Scheme 66).115-119 
 The synthetic steps presented in Scheme 65 and Scheme 66 follow the same general 
trend as those in the synthesis of common intermediate 64.6: 
 Use of numerous protection/deprotection steps;  
 A series of ester reduction reactions to afford alcohol intermediates that were then 
oxidised to afford reactive aldehyde group;  
 Use of stoichiometric amounts of chiral auxiliaries/reagents to induce stereocontrol 
Finally, the question could be posed whether this synthesis could ever really be used to 
commercialise (+)-discodermolide for clinical use, since the cost of treatment would likely be 
too expensive to prevent its widespread use for treatment of cancer in the wider population  
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Scheme 66. Convergent synthesis of (+)discodermolide.115 
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 Contemporary drug discovery is often based on the high throughput (HTP) screening of 
small molecules for biological activities associated with their ability to selectively bind to specific 
target proteins.96, 98, 108 Given the limitless number of small molecule structures that are 
accessible for screening, it is important that chemical libraries are designed to address as broad 
a range of chemical space as possible, and that they contain functional groups that are biased 
towards biological compatibility and drug likeness. Consideration of these requirements can 
lead to the identification of “privileged” structures from which a whole host of compounds can 
then be developed for optimisation.  
 As mentioned earlier, natural products, can be viewed as an entire population of 
“privileged” structures, since they have been selected by evolutionary pressure to be able to 
interact with proteins, and other biological targets.96, 114 The application of Nature’s library of 
structures to identify lead compounds, has already led to a large number of natural products 
and their derivatives being used as drug compounds, a few of which are shown below. 
Vancomycin is a clinically relevant antibiotic; stauroporine was used as a lead compound for 
development of the indolecarbazole structure of anticancer drugs; rapamycin is a protein kinase 
inhibitor used for immunosuppression; and Taxol® is a highly potent anti-cancer drug (Figure 
7).96, 98, 108, 110-113  
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Figure 7. Natural product drug molecules108 
 
 Compared to purely synthetic drug molecules, natural products derived leads often have 
a far greater level of complexity in terms of the number of stereogenic centres, number of 
rotatable bonds, number of sp3 hybridised stereogenic carbons that are present, and they often  
contain significantly fewer nitrogen, sulfur and halogen containing groups. They also normally 
contain a higher number of oxygen atoms and have a lower ratio of aromatic rings to heavy 
atoms when compared to their purely synthetic counterparts.96, 108, 130, 131 Natural products are 
also typically larger than synthetic drugs, with molecular weights >500 increasingly common. 
Indeed most natural product derived drugs do not comply at all with Lipinski’s “rule of five”:132 
a general rule based on analysis of the structure of current drug molecules that is often used to 
predict the likelihood of a drug being orally bioavailable. However, despite these considerations, 
the current prevalence of natural product derived drugs with two or more “rule of five” 
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violations is still relatively low at around 10%, approximately equal to the incidence of current 
synthetic drugs.96, 131, 133  
 There are many challenges facing natural product synthesis in the 21st century. One of 
these is to push the boundaries of what many would consider to be beyond the scope of 
traditional natural product synthesis, with chemists becoming increasingly more daring in 
tackling the size and complexity of target molecules. An example of this, is the quite remarkable 
glycoprotein synthesis described by the Danishefsky group.98, 134 Through targeted synthesis, 
Danishefsky and co-workers were able to synthesise the β-subunit of the human follicle-
stimulating hormone, which is a glycoprotein with a molecular mass of 17868, setting a new 
benchmark for peptide synthesis.  
The β-subunit of the human follicle-stimulating hormone contains 111 amino acids with 
two N-linked dodecasaccharides at Asn7 and Asn24, with the high number of cysteine residues 
present in the peptide backbone allowing for the use of native chemical ligation (NCL) to 
assemble the protein.135 The β-subunit was split into smaller fragments which were synthesised 
through Fmoc-based solid phase peptide synthesis (SPPS), with each C-terminus functionalised 
as a thioester ready for NCL. The cysteine residues not required for NCL were protected as 
acetamidomethyl (Acm) groups to prevent unwanted cross linkages being formed. The anomeric 
hydroxyl group of the dodecasaccharide was converted to a primary amine group using 
Kochetkov amination conditions, allowing for a Lansbury aspartylation reaction to be used to 
link the dodecasaccharide to the desired fragments. The dodecasaccharide was prepared 
through a highly convergent series of glycosylation reactions linking known monosaccharide 
building blocks. In each case, protecting groups were carefully selected to maximize 
stereoselectivity during glycosidic bond formation and to minimize the number of deprotection 
steps necessary to complete the synthesis. Subsequent deprotection and sequential NCL steps 
resulted in the synthesis of the β-subunit of the human follicle-stimulating hormone, which 
represents the largest glycoprotein to have been synthesized in a homogeneous state, using 
strictly chemical methods (Figure 8).134    
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Figure 8. Retrosynthetic strategy developed by Danishefsky for the construction of the fully elaborated 
β-subunit of hFSH (2). HATU=O-(7-azabenzotriazol-1-yl)-tetramethyluronium hexafluorophosphate.134 
 
 Another area of development is the emergence of divergent total syntheses for the 
rapid synthesis of structurally complex lead compounds for screening purposes, which has the 
potential to have a large impact on the drug-discovery process. Specific intermediates generated 
during a natural product synthesis contain partial structural elements of the parent compound 
that can be used to help define which fragments of the natural product are necessary for 
biological activity.136 This presents an opportunity to improve on the original compound through 
synthetic divergence from key intermediates,98 whilst also interrogating which functionality is 
required to elicit the observed biological activity.  
One example of this type of synthesis has been recently reviewed by the Taylor group.137 
They illustrated how the use of conformational-activity relationships (CAR), could be used to 
understand how natural products induce their biological activity, by exploring how the most 
active conformer of a complex natural product is bound to its biological target. This structural 
information could then be used to design simpler structural analogues that are easier to prepare 
and still demonstrate high levels of biological activity.  
An impressive example of this approach has been reported for development of 
conformational mimics of bryostatin (Figure 9). Bryostatin is a polyketide natural product that 
elicits a wide array of biological responses, such as restoring apoptotic function in cancer cells, 
improving memory in animal models, and inducing latent HIV activation.137 This impressive 
range of biological activities is believed to be due to the ability of bryostatin to activate protein 
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kinase C (PKC) by binding to its C1 domain. However, limited access to sufficient quantities of 
bryostatin has hindered its advancement into clinical trials. Synthetic techniques, while elegant, 
have only been successful in producing limited amounts, and isolation from its natural source is 
environmentally unviable (18 g of bryostatin from 40,000 L of wet bryozoan!).137  Wender and 
co-workers have instead approached this problem in a different manner, using conformational 
analysis of bryostatin to gain an understanding of how it binds to PKC. They then employed this 
information to propose structural changes to bryostatin that would simplify its synthesis, whilst 
maintaining biological activity.138-140 Their work culminated in the synthesis of a salicylate 
analogue of bryostatin (Figure 9), which still bound to PKC in low nanomolar concentrations, 
approaching the affinity of bryostatin itself. As is evident from considering the two structures, 
the salicylate analogue of bryostatin is synthetically a lot easier to access, resulting in this 
compound being used as a promising lead for further functionalisation and development.137, 139 
  
    
Figure 9. Bryostatin and its salicylate analogue developed through CAR studies  
 
Halaven® (eribulin mesylate) is a potent antitumor agent that is a derivative of the 
structurally complex marine natural product halichondrin B (Figure 10).141-146 It can be seen, that 
while Halaven® has a simplified polyether structure when compared to halichondrin B, it is still 
a highly complex molecule that is difficult to access in large quantities. However, due to the 
impressive biological activity observed when Halaven® was screened in clinical trials, a viable 
synthetic route to significant amounts of this compound was necessary. The Kishi group and 
Eisai Inc. embarked on this daunting undertaking, leading to a truly impressive synthetic route 
which allows for the synthesis of 200-300 g batches of the complex natural product derived 
Halaven®.142-145, 147   
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Figure 10. Halichondrin B and Halaven® 
 
 The synthesis of Halaven® proceeds through the generation of three key intermediates, 
aldehyde 67.8, vinyl triflate 68.9 and vinyl iodide 69.5. Synthesis of aldehyde 67.8 begins with 
the readily available D-glucurono-3,6-lactone 67.1, involving ketal formation followed by α-
chlorination and subsequent reductive dehalogenation to afford lactone 67.2 as a crystalline 
solid. DIBAL-H reduction of lactone 67.2 followed by addition of TMSCH2MgCl provides a β-
hydroxysilane adduct which eliminates on treatment with KHMDS to afford alkene 67.3. 
Protection of the alcohol group of alkene 67.3 with benzyl bromide and base afforded a benzylic 
ether, which underwent a Sharpless asymmetric dihydroxylation reaction, with the resultant diol 
group then protected as their benzoyl esters to afford pyran 67.4. A titanium catalysed C-
glycosidation reaction of pyran 67.4 using allyltrimethylsilane, was followed by modified Moffat 
oxidation (DMSO-trichloroacetic anhydride) of its secondary alcohol functionality to afford 
ketone 67.5. Horner-Wadsworth-Emmons reaction of ketone 67.5 was then used to introduce a 
vinyl sulfone functionality followed by benzyl ether cleavage using iodomethylsilane to afford 
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alcohol 67.6. Hydroxyl-directed conjugate reduction reaction of the vinyl sulfone fragment of 
67.6, was followed by base mediated cleavage of both its benzoyl groups to afford a crystalline 
triol intermediate that could be purified to homogeneity. This triol intermediate was then re-
protected to afford acetonide 67.7. The alcohol functionality of 67.7 was then methylated, 
followed by a further protecting group swap to afford vicinal TBS ethers was then required to 
create protecting group uniformity later in the synthesis (vide supra). Ozonolysis of the terminal 
alkene using a reductive workup (Lindlars catalyst) then afforded crystalline aldehyde 67.8 
(Scheme 67).142, 145 While the use of a biorenewable sugar based starting material represents an 
admirable feature of this synthesis it should be noted that chiral sugars are highly functionalised 
substrates that often require multiple synthetic steps to remove redundant functionality.  
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Scheme 67. Synthesis of aldehyde 67.8 
 
 The synthesis of triflate 68.9 began with acid catalysed hydration of dihydrofuran 68.1, 
followed by a tin-mediated 2-bromoallylation reaction to afford a crystalline racemic diol, whose 
primary alcohol was selectively O-silyl protected to afford vinyl bromide 68.2. The enantiomers 
of 68.2 were resolved through chiral-simulated moving bed (SMB) chromatography using 
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Chiralpak OD as a chiral stationary phase, affording the desired (R)-alcohol 68.2 in >98% ee. The 
unwanted (S)-enantiomer could then be inverted to the desired (R)-enantiomer through the use 
of Mitsunobu chemistry. Tosylation of alcohol 68.2 using tosyl chloride and DMAP afforded vinyl 
bromide 68.3, that underwent a Nozaki–Hiyama–Kishi (NHK) Ni(II) catalysed cross-coupling 
reaction with Weinreb amide 68.6 (obtained in 7 steps from epoxide 68.4), to afford a coupled 
allylic alcohol that was treated with SiO2 in iso-propanol, resulting in cyclisation with loss of its 
tosyl group to generate the tetrahydrofuran ring of 68.7. Grignard addition of MeMgBr to 
Weinreb amide 68.7 generated a ketone, which when treated with KHMDS and phenyl triflimide 
gave its kinetic enol triflate that was O-silyl deprotected to give alcohol 68.8. Subsequent O-
pivaloyl and O-mesyl protections led to the synthesis of vinyl triflate 68.9 in 2.1% yield over a 
total of 15 steps (Scheme 68).145    
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Scheme 68. Synthesis of triflate 68.9 
 
Synthesis of aldehyde 69.6 began with acid catalysed bis-diol protection of D-
gluconolactone 69.1 with cyclohexanone to afford a bis-cyclohexylidene lactone, with 
subsequent DIBAL-H reduction of its lactone functionality generating lactol 69.2. A series of 
transformations including Wittig reaction of MeOCH2PPh3+Cl–, dihydroxylation reaction of the 
resultant alkene, and bis-acetylation led to the formation of bis-acetate 69.3. A key Lewis acid 
catalysed C-glycosidation reaction of bis-acetate 69.3 was carried out with 3-trimethylsilyl-4-
pentenoate to give the important fused pyran functionality of ester 69.4. Periodate mediated 
cleavage of the diol fragment of 69.4 was followed by subsequent NHK reaction of the resultant 
aldehyde with 1-bromo-2-trimethylsilylethene afforded allylic alcohol 69.5. A protecting group 
swap from cyclohexylidene to tert-butyldimethylsilyl ether groups, was then followed by 
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conversion of the vinyl-silane fragment into a vinyl-iodide group  to generate >3 Kg of vinyl iodide 
69.6 (Scheme 69).146   
 
Scheme 69. Synthesis of aldehyde 69.5 
  
Aldehyde 67.8 and vinyl triflate 68.9 (prepared in 15 steps) were then combined utilising 
a third NHK Ni(II) catalysed cross-coupling reaction, with subsequent cyclic etherification to 
afford the pyran ring being achieved through titration with KHMDS, which resulted in 
intramolecular mesylate displacement by its -alkoxide substituent. Reductive cleavage of the 
pivolate with DIBAL-H then afforded alcohol 70.1, which was prepared on a 1.85 kg scale. 
Coupling of of the sulfonyl anion of alcohol 70.1 with the aldehyde functionality of vinyl iodide 
69.6 (prepared on a 3.04 kg scale in 12 steps), was followed by alcohol oxidation and samarium 
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iodide mediated reduction of the sulphonyl group to afford ketone 70.2. An intramolecular NHK 
reaction and subsequent alcohol oxidation was then followed by global O-Silyl deprotection and 
intramolecular ketalization reactions to afford diol 70.3. Introduction of the amine functionality 
was then achieved by tosylation of the primary alcohol, allowing for in situ epoxide formation. 
Epoxide opening with ammonium hydroxide, and generation of a stable mesylate salt afforded 
Halaven® in 200-300 g batches (Scheme 70).142, 145, 147  
A highly convergent approach combined with a strategy for targeting crystalline 
intermediates, were key factors in bringing this incredible syntheses to fruition, and ultimately 
generating usable quantities of Halaven® to allow for biological testing in the clinic. These trials 
proved successful and Halaven® is currently used as a cancer therapy drug for patients suffering 
with advanced breast cancers and inoperable liposarcoma. However, the National Institute for 
Clinical Excellence (NICE) originally rejected its availability on the NHS, with its cost of >£10,000 
for a 6 month treatment programme for only an average 3 month life expectancy extension 
deemed too costly. However, public pressure eventually forced NICE to reverse their decision 
and this drug is now available in the UK. 
This synthesis is of course an incredible achievement of organic chemistry, however, as 
mentioned above there are a number of protection/deprotection steps and inherently 
inefficient protecting group swaps. This results in an additional 17 synthetic steps, and as the art 
of organic synthesis evolves, it is hoped that these kind of wasteful, but currently necessary, 
protecting group processes may ultimately be removed completely.  
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Scheme 70. Synthesis of Halaven® 
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 The emergence of divergent total synthesis and the recent decrease in new 
pharmaceutical leads based on natural products, potentially highlights some of the perceived 
shortcomings of natural product synthesis. It has long been argued that semi-synthesis is the 
only way to produce sufficiently large enough amounts of naturally occurring materials for drug-
discovery applications. However, it must be accepted that this promise is rarely met.98 
Therefore, it can be argued that natural product synthesis in the 21st century should always seek 
to provide the target compound in multigram quantities, with synthesis on this scale presenting 
many challenges associated with logistics, the sustainable use of reagent and disposal of side 
products and waste.147 In this respect the defined principles and metrics of green and 
sustainable chemistry are likely to be increasingly used as a tool to devise efficient syntheses 
that meet these demands.148-153  
4.0 Protecting Group Free Synthesis  
 As mentioned earlier the use of protecting groups are common place in many complex 
synthetic routes towards natural products. However, their use is acknowledged as a necessary 
evil, “synthetic chemists would dearly like to be able to work without protecting groups, but they 
are very glad that they exist” (P. Kocienski).154 The disadvantages associated with the use of 
protecting groups are obvious, an increase in the number of synthetic steps, a reduction in 
overall yield, and an increase in the amount of waste produced. However, the reason that their 
use is so prolific is because of the inherent security and predictability that they confer, allowing 
for increased functional group compatibility that allows for a vast increase in the completion 
rate of structurally complex targets.128, 129 Therefore, organic synthesis faces an enormous 
challenge in trying to change this reliance and move towards more efficient protecting group 
free synthetic protocols. However, this can also be seen as a “opportunity for invention”.128 New 
reactions, regents and catalysts will need to be developed with a focus on chemoselectivity and 
functional group compatibility if this challenge is to be met. While this is clearly a daunting task 
there are a number of research groups that are embracing this challenge, resulting in the 
number of reported protecting group free syntheses of natural products increasing significantly 
over the past decade or more.128, 129, 155  
An impressive early landmark example of a protecting group free synthesis, where 
protecting groups were deliberately avoided through synthetic design, rather than being found 
to be unnecessary, was the synthesis of (+)-hapalindole Q by Baran and Richter in 2004 (Scheme 
71).155  
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 Their synthesis began by inventing a new reaction to couple together the naturally 
available starting materials indole 71.1 and carvone 71.2. Deprotonation of both reagents, gave 
the aza-anion of indole and the enolate of carvone, which were subjected to copper mediated 
oxidation to afford their corresponding radicals that underwent radical coupling to give the 3-
substituted indole 71.3. Deprotonation of indole followed by conjugate reduction of the 
resultant aza-anion with L-selectride, afforded an enolate intermediate 71.4, treatment with 
acetaldehyde gave aldol 71.5. The secondary alcohol functionality of 71.5 was then dehydrated 
using Martin’s Sulfurane to give bis-alkene 71.6. Reductive amination of the ketone  functionality 
of 71.6 resulted in primary amine 71.7 which was converted into its corresponding 
isothiocyanate via treatment with thiocarbonyldiimidazole to give the final compound (+)-
hapalindole Q.155 This synthesis is not only a great example of protecting group free natural 
product synthesis, but also an example where natural product synthesis served as a driving force 
for the development of a new indole coupling reaction.128, 155  
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Scheme 71. Protecting group free synthesis of hapalindole Q155 
 
 Since this outstanding demonstration of protecting group free synthesis, interest in this 
area has increased steadily, resulting in the publication of some exciting and inspiring natural 
product syntheses.128, 129, 156-166 This report will now focus  on a few recent examples of protecting 
group free natural product synthesis, starting with a discussion of a formal synthesis of (-)-
platencin (Figure 11).  
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Figure 11. (-)-Platencin 
 
 (-)-Platencin is a potent, broad spectrum Gram-positive antibiotic.167 The first total 
synthesis by Nicolaou et al.167 in 2008 followed a traditional protecting group strategy in 23 
steps, however, this publication was quickly followed by an efficient “protecting group free” 
formal synthesis by Tiefenbacher and Mulzer affording platencin in 13 steps from perillaldehyde 
(Scheme 72).168   
 Their formal synthesis began with a Diels-Alder cyclisation of Rawal diene 72.1 and (-)-
perillaldehyde 72.2 to give α,β-unsaturated ketone 72.3. A selective Wittig reaction of the 
aldehyde group was then performed to give a bis-terminal alkene which upon treatment with 
Grubbs 2nd generation catalyst, resulted in a ring closing metathesis reaction to afford fused 
tricycle 72.4. Alkene bond migration was performed via bromoalkene formation with NBS, which 
upon treatment with CrCl3 and LiAlH4 gave the desired tricycle 72.5, containing an exocyclic 
alkene bond which was a common intermediate in both syntheses (Scheme 72).167, 168 The 
remaining synthetic steps (shown in red) show the completion of the synthesis according 
Nicolaou’s methodology.167 Sequential enolate alkylation with methyl iodide and allyl iodide 
afforded triene 72.6, which underwent regioselective cross-metathesis with vinyl boronate 
using a 2nd generation Hoveyda–Grubbs catalyst and benzoquinone to afford boronate 72.7. 
Boronate oxidation (using Me3NO), followed by Pinnick oxidation of the resultant alcohol 
afforded carboxylic acid 72.8. This acid then underwent an amide bond coupling reaction with 
aniline 72.9, using a HATU facilitated coupling agent, followed by acid deprotection to afford      
(-)-Platencin (Scheme 72).167    
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Scheme 72. Formal synthesis towards the synthesis of (-)-platencin168 
 
 (±)-Hippolachnin A is a recently isolated marine polyketide, possessing an intriguing 
fused molecular framework that displays promising antifungal activity.157 The first total synthesis 
of (±)-hippolachnin A was completed in 2015 by the Carreira group, who described a protecting 
group free synthesis of (±)-hippolachnin A in nine linear steps and an overall yield of 9%. The 
synthesis began with commercially available cyclopentenone 73.1 which was irradiated with 
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hex-3-yne at λ>270 nm, undergoing a [2+2] photocycloaddition reaction to afford 
bicyclo[4.2.0]heptanone 73.2. This photoadduct was found to be susceptible to elimination 
during purification, therefore it was reacted directly with K2CO3 to generate enone 73.3. 1,4-
cuprate addition of an ethyl fragment, followed by 1,2-Grignard addition of a second ethyl 
fragment afforded alcohol 73.5 with complete exo diastereoselectivity. Treatment of alcohol 
73.5 with methyl acrylate in the presence of pyridinium para-toluenesulfonate (PPTS) then gave 
ester 73.6 as a cyclisation precursor. Reaction of ester 73.6 with BF3·2AcOH resulted in an ene 
cyclization reaction occurring to give the desired tricyclic annulated product 73.7 in a 6:1 
diastereomeric ratio. Heterogeneous platinum catalysed hydrogenation of 73.7 then gave the 
exo product 73.8. The synthesis of (±)-hippolachnin A was completed by α-phenylselenylation 
of the enolate of the ester functionality of 73.8, followed by oxidation of the crude reaction 
mixture with concomitant selenoxide elimination to afford the desired alkene (Scheme 73).157       
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Scheme 73. Synthesis of Hippolachnin A 
 
 The pallambins are terpene natural products, that whilst exhibiting no known 
bioactivity, possess a fascinating structural architecture, containing 4-6 rings and 7-10 
contiguous stereocentres.156 A recent report by the Baran group has demonstrated a highly 
strategic and protecting group free synthesis of pallambins C and D, with their syntheses having 
been intentionally designed to eliminate extraneous redox operations and functional group 
interconversions.  
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 The synthesis began with the abundant feed stock chemical furfuyl alcohol 74.1 which 
is sourced from furfural that is a major biorewable feedstock obtained from sugar cane bagasse. 
Tandem Eschenmoser-Claisen rearrangement and reduction of the resultant amide was carried 
out in a one-pot reaction to afford aldehyde 74.2 (a significant improvement on the previous 
synthesis of aldehyde 74.2). A Robinson annulation of aldehyde 74.2 with ethyl vinyl ketone was 
then used to generate cyclohexenone 74.3. 1,4-Vinyl cuprate addition of 74.3, was followed by 
work-up with TMSCl to afford the activated TMS-enol ether 74.4. Photosensitised 
chemoselective oxidative cleavage of the furan heterocycle resulted in keto-aldehdye 74.5 
which was used in its crude form in the next step, as decomposition occurred during attempted 
purification. A titanium catalysed Mukaiyama aldol cyclisation of the TMS-enol ether fragment 
of 74.5 onto its ketone fragment generated the pivotal bicyclo[3.2.1]octane skeleton of 74.6. It 
is believed that the reaction proceeds via reaction at the less electrophilic methyl ketone group 
due to geometric constraints preventing the enol ether engaging with the aldehyde group. 
Intramolecular BF3 catalysed acetal formation led to the spontaneous generation of the pyran 
ring to afford a mixed acetal, which on treatment with AcBr furnished bromide 74.7. Halogen 
removal via treatment with AIBN/Bu3SnH then afforded alkene 74.8. Treatment of 74.8 with 
LiHMDS and PhSeCl, followed by oxidation, afforded a selenoxide that underwent spontaneous 
elimination to afford α,β-unsaturated ketone 74.9. Subsequent acid catalysed methanol 
elimination then afforded the sensitive, but thermally stable dihydrofuran 74.10. A new enol-
ether difunctionalisation reaction, involving reaction of the tin-enolate of dimethyl malonate 
with dihydrofuran 74.10, followed by addition of I2 afforded the desired iodo-diester 74.11. The 
final cyclisation sequence to generate the desired fused tetracycle was performed utilising a one 
pot sequence: (i) alkaline hydrolysis of the esters (2 M NaOH); (ii) Et3N-induced lactonisation and 
decarboxylation; (iii) aldol addition to acetaldehyde, and (iv) elimination of the -hydroxyl group 
using MsCl/NEt3 to give the desired pallambin C (Z alkene) and pallambin D (E alkene) in a 1:2 
ratio (Scheme 74). This impressive synthesis was completed in just 16 steps (11 one pot 
reactions), with only two steps not being involved in forming bonds present in the final natural 
products. While this is an elegant and efficient synthesis, it does however, utilise some 
undesirable reaction conditions. In particular the tin based reagents (Bu3SnH, SnCl4) are highly 
toxic and should be avoided wherever possible, while the use of phenylselenyl chloride is also 
highly toxic, leads to generation of stoichiometric amounts of toxic waste.    
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Scheme 74. Synthesis of Pallambins C and D 
 
101 
 
In conclusion, although protecting group free syntheses often require reaction 
ingenuity, invention and significant reaction optimisation, the end results more than justify the 
effort required, due to the significant reduction in the number of  steps required, the 
improvement in atom economy and the reduction in the number of redox steps required.128, 129 
However, while there are many elegant protecting group free publications emerging, it should 
be noted that the vast majority of these natural product syntheses do not contain multiple free 
hydroxyl groups, or other functional groups that have highly acidic protons. This clearly 
highlights an area of natural product synthesis where there is still room for further development.  
5.0 Polyketides  
5.1 Introduction to Polyketides  
 Polyketides are an enormous class of natural products synthesised by a wide range of 
organisms; bacteria, fungi and plants.169, 170 They are biosynthesised through a series of 
polycondensation reactions using simple carboxylic acid donors in the form of their 
corresponding thioesters; acetyl-SCoA, propionyl-SCoA and malonyl-SCoA. These 
polycondensation reactions are performed by a range of polyketide synthases (PKS) to form a 
series of acyclic or cyclic molecules, containing contiguous stereocentres, with a simplified 
representation of their biosynthesis shown below (Scheme 75).169-171  
 
Scheme 75. Biosynthetic pathway to polyketides 
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In order to further exemplify this complex process, a ‘cartoon’ version of the 
erythromycin PKS assembly line is shown in Figure 12, in which circles depict enzymatic domains 
whose linker regions have been omitted for clarity. From this figure it can be seen that each of 
the DEBS (6-deoxyerythronolide B synthase) proteins contains two functional units or modules. 
Each module contains the three domains required to catalyse one cycle of chain extension 
(ketosynthase (KS), acyltransferase (AT) and acyl carrier protein (ACP)) as well as a variable set 
of domains (ketoreductase (KR), dehydratase (DH) and enoyl reductase (ER)) associated with 
functional group modification. Throughout the entire biosynthetic sequence, the polyketide 
chains remain bound to the PKS. The three essential domains KS, AT and ACP, co-operate to 
catalyse carbon–carbon bond formation by Claisen condensation, which results in a β-keto ester 
intermediate. The variable set of domains positioned between the AT and ACP (depicted as a 
loop above the line of essential domains) carry out reductive modification of the keto group 
before the next round of chain extension.  
Once the acyclic polyketides are synthesised, further enzymatic transformations can be 
performed to produce a bewildering array of natural products, including those containing cyclic, 
acyclic, small, large, simple, aromatic, and highly complex structures (Figure 12 and Figure 
13).169, 171  
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Figure 12. Domain organisation of the erythromycin polyketide synthase171 
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Figure 13. Examples of naturally occurring polyketides169  
 
 Due to the large variety in thier structure, polyketides exhibit a wide range of biological 
activities including; antibiotic, cancer chemotherapeutic, antifungal and cholesterol lowering 
agents.169 There are around 10000 known polyketide structure, however, this number is ever 
increasing with new natural product sources being discovered almost daily. Of these compounds 
about 1% have been shown to possess useful drug activity, which is about five times higher than 
the average normally found for natural products. This highlights that polyketides are a 
potentially excellent source of lead compounds for the discovery of future drug molecules.169, 172 
 Polyketides can be grouped into three smaller subclasses; fatty acids, polypropionates 
and aromatic polyketides.169 Although these groups are structurally diverse, there are several 
structural features which are common among many polyketides, including the stereotetrad 
motif shown in Figure 14.     
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Figure 14. General structure of a stereotetrad 
 
 The presence of four contiguous stereogenic centres gives rise to the possibility of eight 
stereoisomeric combinations occurring as fragments within the structure of a polyketide natural 
products (Figure 15). Indeed, all of these tetrad combinations are known to be present in 
polyketide natural products.169  
 
 
Figure 15. Possible diastereomeric combinations of the stereotetrad  
 
 Although, polyketides containing these stereotetrad fragments are abundant in nature, 
their stereoselective synthesis still represents a formidable challenge to chemists, who have 
developed an armamentarium of synthetic strategies that they currently employ for their 
preparation. Consequently, the following section briefly reviews methodology that has been 
employed for the synthesis of representative polyketide natural products. 
5.2 Synthesis of Ionomycin 
 Ionomycin (Figure 16) is a polyether antibiotic containing an anti, anti, anti stereotetrad 
which was first isolated in 1978 from the fermentation broths of Steptomyces congoblatus.173, 
174 Ionomycin is able to chelate to inorganic cations, with a particular affinity for calcium. This 
allows ionomycin to act as an ionophore to transfer cations across cell membranes,169, 175, 176 
which has made it an important molecule in neurochemical research.169     
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Figure 16. Structure of ionomycin 
 
 There have been a number of total syntheses of ionomycin starting in 1990 by the Evans 
group177 which based their synthesis on the use of chiral auxiliaries to achieve stereocontrol. The 
Evans auxiliary methodology utilises an iterative approach to build up vicinal stereocentres, 
whereby small fragments are gradually lengthened and functionalised through addition and 
removal of chiral auxiliaries to confer stereocontrol to aldol/alkylation reactions. This 
methodology allows for high levels of stereocontrol of these aldol reactions, and as such has 
become one of the most widely used methods for the synthesis of highly complex acyclic 
polyketides. However, it must be recognised that it is inherently wasteful due to the use of 
multiple stoichiometric auxiliary steps. Which cause extra steps introducing and removing the 
chiral auxiliary fragment (Scheme 76).  
The synthesis of key fragment 76.11 that was employed for the synthesis of ionomycin 
can be used to illustrate this. The boron enolate of norephedrine-based auxiliary 76.1 was 
reacted with acetaldehyde to afford aldol adduct 76.2 in 93% yield and >98% de. The secondary 
alcohol was then O-silyl protected prior to auxiliary removal, via treatment with LiOBn to afford 
benzyl ester 76.3. The ester functionality was then reduced to the primary alcohol and 
subsequently re-oxidised to the aldehyde 76.4. Wittig olefination of 76.4 with ylide 76.5, 
followed by ester reduction and subsequent iodination gave alkyl iodide 76.6. Alkylation of the 
sodium enolate of N-propionyl-oxazolidin-2one 76.1 afforded carboximide 76.7, the auxiliary 
fragment of which was then reduced to give primary alcohol 76.8. A Swern oxidation and Wittig 
olefination with ylide 76.9 then afforded diene 76.10. Silyl ether cleavage with HF(aq), was then 
followed by a stereoselective rhodium catalysed hydrogenation reaction to reduce the alkene 
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functionality, with a final alcohol oxidation step then affording the key C1-C10 fragment 76.11 
(Scheme 76). This part of the synthesis if a good example of how Evans auxiliaries are deployed 
in natural product synthesis. While they offer excellent diastereoselctive control, their inclusion 
and removal considerably lengthens the synthesis. Furthermore, there are normally a number 
of redox manipulations (5 in a 15 step synthesis), including the global reduction of an ester 
followed by re-oxidation back to the aldehyde. While this approach can keep the yield high it is 
an incredibly wasteful method.                 
 
 
Scheme 76. Evans auxiliary methodology used for the synthesis of a key fragment 76.11 used for the 
synthesis of ionomycin 
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A more recent synthesis by Lautens et al. in 2002175 based their stereotetrad 
methodology on ring opening strategies which are shown below in Scheme 77-Scheme 80. Their 
synthesis began with the symmetric oxabicyclic-[3.2.1]-alkenes 77.1 and 78.1 whose synthesis 
had previously been developed within their group, with each bicycle being used to synthesise 
separate fragments of the final compound. Oxabicyclic-[3.2.1]-alkene 77.1 was treated with a 
chiral nickel BINAP system to reductively desymmetrise the oxabicyclic ring to give alkene 77.2 
in excellent yield (95%) and 93-95% ee. The alcohol stereocentre was then inverted via a 2-step 
oxidation/reduction protocol, followed by O-PMB protection to afford the protected diol 77.3. 
Cleavage of the alkene via ozonolysis, followed by aldehyde reduction afforded acyclic diol 77.4. 
Oxidative cyclisation of 77.4 using DDQ (2,3-Dichloro-5,6-dicyano-1,4-benzoquinone) gave cyclic 
PMP acetal 77.5. The remaining unprotected primary alcohol was then O-trityl protected, and 
the acetal reductively cleaved to give alcohol 77.6, which was then oxidised using a Swern 
oxidation reaction to give the desired aldehyde 77.7 (Scheme 77).    
 
 
Scheme 77. Synthesis of aldehyde fragment 77.7175 
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 Synthesis of the ketone fragment 78.11 began with the symmetrical unprotected 
alcohol 78.1 that was also used as a substrate for reductive desymmetrisation. A palladium 
catalysed asymmetric ring opening reaction afforded diol 78.2 in high yield (80%) and excellent 
94% ee. The alcohol groups of diol 78.2 were then selectively protected with silyl and PMB 
protecting groups to give protected diol 78.3, with ozonolysis followed by reduction affording 
acyclic -diol 78.4. Oxidative cyclisation to afford a cyclic PMP acetal, followed by O-silyl 
deprotection gave acetal 78.5. Treatment of acetal 78.5 with TCDI (thiocarbonyl diimidazole) 
protected the 1,3-diol fragment to afford cyclic thiocarbonate 78.6. A radical mediated 
reduction reaction selectively gave primary alcohol 78.7; which was then oxidised to its 
corresponding aldehyde followed by a Wittig reaction to give α,β-unsaturated ester 78.8. 
Hydrogenation of 78.8 resulted in both the alkene bond being reduced and cleavage of the PMP 
acetal to give diol 78.9. A second thiocarbonate formation and radical catalysed deoxygenation 
then reaction gave primary alcohol 78.10. Subsequent oxidation of 78.10, Grignard addition of 
MeMgBr and a further oxidation step then gave the desired ketone fragment 78.11 (Scheme 
78).    
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Scheme 78. Synthesis of the ketone fragment 17.11175 
 
 The Lautens synthesis also required synthesis of the key furan fragment 79.7. Its 
synthesis began with allylic oxidation of the terminal methyl group of geranyl acetate 79.1 using 
SeO2, followed by Appel bromination of the resultant alcohol to give allyl bromide 79.2. 
Alkylation of the enolate of a sulfone with allyl bromide 79.2 with concomitant removal of its 
acetate group, gave alcohol 79.3.Sharpless asymmetric epoxidation reaction and tosyl 
protection of the primary alcohol afforded tosylate 79.4. Acid catalysed epoxide ring opening 
and secondary alcohol O-silyl protection then afforded the protected triol 79.5. A vanadium 
catalysed oxidative furan ring forming reaction was then carried out to afford tetrahydrofuran 
79.6. Iodination and subsequent radical catalysed dehalogenation was then followed by alcohol 
silyl protection to give the key sulfone fragment 79.7 (Scheme 79).      
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Scheme 79. Synthesis of tetrahydrofuran 18.7 
  
Once these fragments had been prepared, then they were combined to give ionomycin. 
The enolate of sulfone 79.7 underwent coupling with aldehyde 77.7 to give the alcohol 80.1 
which was then oxidised to afford ketone 80.2. The sulfone moiety of 80.2 was then reductively 
cleaved using samarium iodide, followed by DDQ mediated PMB deprotection to obtain alcohol 
80.4. Treatment with samarium iodide and benzaldehyde gave β-hydroxy benzoate 80.5, with 
no other regioisomer being formed. The alcohol group of 80.5 was then activated for cyclisation 
by tosylation, followed by O-TMS deprotection, to afford a crude hydroxy tosylate that was 
treated with sodium hydride to construct the second ring of bis-tetrahydrofuran compound 
80.6. Trityl deprotection, followed by oxidation then afforded aldehyde 80.7, which underwent 
a modified Julia coupling with sulfonamide 80.8 to give alkene 80.9. PMB deprotection of 80.9 
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gave alcohol 80.10, followed by Swern oxidation to a ketone, and aldol coupling with the boron 
enolate of ketone 78.11, with a further alcohol oxidation step then affording hydroxy alkene 
80.11. Subsequent removal of the remaining three protecting groups, followed by ester 
hydrolysis afforded ionomycin (Scheme 80) in a 5.6% overall yield.    
 While the Lauten synthesis of the complex natural product ionomycin is highly 
impressive, utilising a wide range of elegant chemistry, the synthetic route is clearly not perfect. 
It has a heavy reliance on protecting group chemistry, with the use of 25 
protection/deprotection steps dramatically increasing the number of synthetic steps and 
amount of waste and by-products produced. It is also a very redox reliant synthesis, with a large 
number of oxidation and reduction steps being employed, with a number of redox processes 
occurring at the same carbon position! During the synthesis of ketone fragment 78.11 there are 
also two deoxygenation steps to give alcohols 78.7 and 78.10 respectively, with this process 
involving removal of previously installed stereocentres.  
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Scheme 80. Synthesis of ionomycin175 
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 The recent ionomycin synthesis by the Kocienski group in 2009176 is similar to the 
Lautens synthesis with respect to the strategy of assembling ionomycin from four very similar 
fragments, however, these fragments were obtained in a much more efficient manner (Figure 
17).  
 
Figure 17. Kocienski retrosynthetic fragmentation of ionomycin176 
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The most impressive fragment synthesis was that employed for the preparation of bis-
hydrofuran 81.4, which was constructed in the following manner. Allene 81.2 was obtained from 
alkyne 81.1 via a stereoselective copper(I)-mediated anti-selective SN2’ reaction, which after 
deprotection of the tetrahydropyranyl group using PPTS (pyridinium p-toluenesulfonate) gave 
diol 81.3. Diol 81.3 then underwent highly stereoselective gold(III) catalysed cycloisomerisation 
of its α-hydroxyallene fragment to afford 2,5-dihydrofuran 81.4 (Scheme 81). This catalytic 
construction of the second hydrofuran ring was far more efficient than approaches employed in 
previous syntheses (Scheme 79).    
    
 
Scheme 81. Construction of the bis-hydrofuran moiety by Kocienski176 
 
 While this synthesis clearly is an improvement upon previous attempts, it still cannot be 
considered to really provide a viable route for the large scale production of ionomycin, with an 
overall yield of only 0.68% being achieved over the 33 step synthesis.   
5.3 Synthesis of Pironetin 
 Pironetin (Figure 18) was first isolated independently, by two Japanese groups in 1993 
from the fermentation broths of both Streptomyces sp. NK10958 and Streptomyces prunicolor 
PA-48153.178-180 Pironetin is an unsaturated δ-lactone attached to a syn, anti, syn. stereotetrad. 
It was  originally of interest due to its plant growth regulatory and immunosuppressive activities, 
however, more recently it has also been identified as a strong antitumor agent.181 It has been 
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synthesised a number of times, the first of which was by Yasui et al.178 in 1995 (shown in red). 
This first synthesis was then quickly followed by those of Gurjar et al. (shown in green)182 and 
Chida et al. (shown in blue)183    
 
 
Figure 18. Selected syntheses of Pironetin 
  
 A  more recent impressive synthesis of pironetin is that by the Cossy group.181 Compared 
to previous syntheses it is much more concise, achieving the final product in only 14 steps from 
the commercially available starting material (S)-Roche ester 82.1 (Scheme 82). 
 (S)-Roche ester 82.1 was tosyl protected followed by reduction of its ester functionality 
with DIBALH which afforded aldehyde 82.2. This aldehyde was then subjected to a diastereo- 
and enantioselective crotonylation reaction using chiral titanium complex [Ti]1* to generate the 
homoallylic alcohol, which was subsequently O-methylated to give alkene 82.3. Ozonolysis of 
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the alkene bond of 82.5 followed by a further diastereoselective allylation reaction using chiral 
titanium complex [Ti]2* gave alcohol 82.4. O-Silyl alcohol protection was followed by treatment 
with a lithium acetylide ethylenediamine complex to introduce the terminal alkyne functionality 
of alkyne 82.5. Once the terminal lithium anion of alkyne 82.5 was methylated, its alkene 
functionality was dihydroxylated with osmium tetroxide to afford a diol which was then 
oxidatively cleaved with sodium periodate to give aldehyde 82.6. A stereoselective boron-
mediated pentenylation reaction using cis-2-pentene was then carried out to afford alkene 82.7, 
acylation of its alcohol gave bis-alkene 82.8. The diene functionality of 82.8 then underwent a 
ruthenium catalysed hydrosilylation reaction, followed by a RCM (ring closing metathesis) 
reaction and acid mediated protodesilylation to give pironetin in an impressive overall yield of 
8.2%     
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Scheme 82. Cossy synthesis of pironetin181 
 
 While this is clearly an impressive synthesis there are still a number of steps that are still 
less than ideal. For example, the two diastereo- and enantioselective crotonylation steps to 
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obtain 82.3 and 82.4 proceed through the use of a stoichiometric amounts of chiral titanium and 
boron reagents, which considering their level of complexity and cost would prevent this 
synthesis from being conducted on a large scale. Furthermore, allylation of 82.2 is immediately 
followed by ozonolysis, resulting in the cleavage of a C1 carbon fragment, which had previously 
been installed as part of a C3-allyl unit. There is also a loss of ethylene associated with the RCM 
reaction, which also affects the overall atom economy of the synthesis. The synthesis also 
contains an alkyne hydrosilylation reaction and subsequent protodesilylation step for this RCM 
strategy to be effective. All of these requirements have a considerable impact on the efficiency 
and cost of this synthesis, resulting is an overall atom economy for this synthesis of only 6.6%.   
5.4 Synthesis of Spirodienal A 
 Spriodienal A (Figure 19) is a spiroketal that was isolated from fermentation broths of 
the myxobacteria Sorangium cellulosum in 2009,184 which was shown to exhibit potent antibiotic 
and cytotoxic activity.184   
 
 
Figure 19. Spirodienal A 
 
 The first total synthesis of spirodienal A was completed by the Ley group in 2014.185 
Synthesis was conducted predominantly in flow systems which were proposed to allow for high 
levels of control and the use of otherwise ‘challenging’ conditions; including high pressure; the 
use of gaseous reagents; and the use of highly toxic reagents – all of which led to a highly 
convergent and efficient approach.185 
 Synthesis began with 2,3-butane diacetal protected aldehyde 83.1 which underwent a 
solid supported Wittig reaction, where the ylid reagent 83.2 was supported on a monolith. This 
120 
 
approach meant that upon reaction completion, the triphenylphosphine oxide by-product was 
left attached to the monolith and could be simply filtered off, vastly improving the ease of 
purification. The resultant α,β-unsaturated ester 83.3, was then hydrogenated at 20 bar utilising 
Pfaltz’s iridium catalyst to afford methyl ester 83.4. A protecting group switch led to the 
formation of acetal 83.5. The methyl ester of 83.5 was then reduced to aldehyde 83.6 using 
DIBALH which was immediately reacted with the stoichiometric amounts of chiral tartrate 
derived crotylation reagent (R, R)-83.7, to give the key homoallylic alcohol intermediate 83.8. 
All of the reactions from aldehyde 83.1 to alkene 83.8 were conducted entirely in flow in an 
overall 73% yield (Scheme 83).   
 
Scheme 83. Flow synthesis of key intermediate 83.8185 
 
 With homoallylic alcohol 83.8 in hand, the synthesis then diverged into a parallel 
synthesis, to form the two coupling partners aldehyde 84.10 and dialkyne 85.8 (Scheme 84 and 
Scheme 85).  
 To acquire aldehyde 84.10, the homoallylic alcohol 83.8 was O-silyl protected and then 
subjected to ozonolysis to give aldehyde 84.1. This was then reacted with the crotylation reagent 
(S, S)-83.7 to give the homoallylic alcohol 84.2. Silyl deprotection and acetal protection of the 
resultant diol fragment were performed simultaneously through the use of polymer supported 
sulfonic acid to give the diacetal 84.3. Ozonolysis, followed by borohydride reduction afforded 
alcohol 84.4, which was then O-silyl protected to give the fully protected polyol 84.5. A two-step 
batch sequence was then required to achieve aldehyde 84.6 involving selective hydrolysis of the 
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external acetal to afford the corresponding vicinal diol, which then underwent periodate 
oxidative cleavage to afford aldehyde 84.6. This aldehyde 84.6 was then subjected to a Seyferth-
Gilbert homologation reaction through use of the Bestmann-Ohira reagent (dimethyl 
(diazomethyl)phosphonate) to afford alkyne 84.7. A copper catalysed hydrosilylation reaction 
on 84.7 gave the corresponding alkene 84.8, which underwent silyl-iodide exchange to give the 
corresponding allyl iodide, that was then subjected to a Pd(0) mediated Negishi cross-coupling  
with Me2Zn to give alkene 84.9. Silyl deprotection of 84.9 was followed by TEMPO ((2,2,6,6-
tetramethylpiperidin-1-yl)oxidanyl) catalysed oxidation to afford the desired aldehyde 84.10 
(Scheme 84).  
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Scheme 84. Flow synthesis of coupling partner 84.10185 
 
 O-Silyl protection of intermediate homoallylic alcohol 83.8 with TESOTf/DIPEA resulted 
in cleavage of the acetonide ring to afford a primary silyl protected alcohol and secondary enol 
ether in situ (of the acetonide). The resulting alkene was then subjected to ozonolysis to 
oxidatively cleave the enol ether and terminal alkene to afford aldehyde 85.1. Propargylic 
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mesylate 85.2 was then used as a substrate to generate a chiral allenylzinc reagent in situ which 
was reacted with aldehyde 85.1 through an SE2’ mechanism to afford alkyne 85.3. Silyl 
deprotection using polymer supported sulfonic acid and selective protection of the two 
secondary alcohols via acetal formation, was followed by a TEMPO oxidation of the terminal 
alcohol to afford aldehyde 85.4. A monolith supported Wittig olefination was then carried out 
to afford dibromo alkene 85.6. Reductive acetate cleavage followed by further silyl deprotection 
afforded acetal 85.7, which upon treatment with n-BuLi gave the desired bis-alkyne functionality 
of 85.8 via a Corey-Fuchs reaction (Scheme 85).    
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Scheme 85. Synthesis of coupling partner 24.8185 
 
 Of all the previous steps used to the coupling intermediates, all except 5 tranformations 
were conducted in flow (marked in schemes), however, some synthetic steps were unable to be 
conducted in flow and were instead completed using traditional “batch” conditions. However, 
it can also be argued that this synthesis represents one of the worst cases of the ‘abuse’ of 
protecting group usage, with 14 of the 26 synthetic steps used to generate coupling 
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intermediates 84.10  and 85.8 involving either formation or removal of a protecting group! There 
are also 10 oxidation/reduction reactions, and this along with the high use of protecting groups, 
obviously has a huge detrimental effect on the efficiency and sustainability of the synthesis.    
 The synthesis of spirodienal A was completed through the use of the following batch 
techniques. Treatment of the bis-alkyne 85.8 with n-BuLi followed by addition of aldehyde 23.10 
gave alcohol 86.1, which was subsequently oxidised to the ynone and stereoselectively reduced 
using the chiral Corey-Bakshi-Shibata reagent 86.2. The chiral ynol was then methylated 
followed by global deprotection via sequential treatment with TBAF and a polymer supported 
acid to afford pentol 86.3. Spiroketalization was then induced using gold catalysis to give 
spiroketal 86.4 in only moderate yield (30%). This kind of low yield towards the end of a natrual 
product synthesis can be disastrous, as it results in the loss of 70% of painstakinly made material. 
Spiroketal 86.4 then underwent a Sonogashira reaction with vinyl iodide 86.5 to give alcohol 
86.6. Which was subjected to a mixed metal (Zn/Cu) catalysed cis-selective alkyne reduction 
reaction to afford a diene fragment, followed by alcohol oxidation to afford the aldehyde 
functionality of spirodienal A (Scheme 86).     
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Scheme 86. Spirodienal A synthesis185 
 
 This synthesis of spirodienal A was conducted in a divergent manner to try and maximise 
efficiency by which analogues of the parent natural product could be synthesised. This synthesis 
by the Ley group is an exciting example of modern natural product synthesis that illustrates the 
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potential of using flow synthesis for the preparation of complex molecules. However, the use of 
these expensive flow-systems is currently limited to academia and research labs. With few 
syntheses having been reported ‘on-scale’. Furthermore, their use can be restrictively 
expensive, with liquid-liquid extraction equipment being expensive and having a high running 
cost, whilst optimisation of flow transformations can be lengthy and consume a lot of substrate. 
A necessity of flow chemistry is the use of scavenger or polymer supported reagents to ensure 
that material of sufficient purity is available to be taken on to the next step. This potentially 
creates a stoichiometric amount of waste, and whilst these scavenger and polymer supported 
reagents can be regenerated, these processes often comes with a large energy and commercial 
cost. 
6.0 Conclusion 
Huge advances have been made since the dawn of natural product synthesis, with 
organic chemists given enough time, resource and manpower now being able to synthesise even 
the most complex molecules. However there is still room for improvement, particularly in the 
efficiency of reactions, and design of syntheses to embrace the ethos of sustainable chemistry, 
with the aim of minimising the number of protection/deprotection steps and maximising the 
number of catalytic rather than stoichiometric reactions used. There are also a number of other 
aspects that should be considered when trying to move towards a “perfect” synthesis. These 
include minimising the number of redox steps, maximising yield, use of biorenewable substrates, 
development of convergent synthetic strategies, invention of new reactions, and the target of 
crystalline intermediates to facilitate purification. A focus should also be placed on performing 
reactions at room temperature, under atmospheric conditions using “green” solvents.109 
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7.0 A Protecting Group Free Strategy towards the 
Sustainable Synthesis of Polypropionate Fragments   
7.1 Results and Discussion  
Organic synthesis has evolved immensely over the last 100 years to afford an impressive 
arsenal of reactions and techniques for the synthesis of a wide range of complex molecules. As 
described in the preceding chapter, this has led to many ‘state-of-the-art’ syntheses of 
important medicinally active compounds that can be considered to be at the forefront of 21st 
century scientific development. However, despite the elegance of many of these synthetic 
protocols, methods for the synthesis of polyketide derivatives are far from optimal, with 
multistep synthetic routes often requiring protecting groups, stoichiometric and/or undesirable 
reagents, and harsh reaction conditions that afford low yields.98, 109, 172  
This offers the opportunity to develop alternative more efficient ‘protecting group free’ 
strategies for the synthesis of chiral building blocks for polyketide natural products. As 
mentioned earlier a key structural feature of polyketides are the presence of polypropionate 
(stereotetrad) fragments, with these structural motifs having been the target of a number of 
synthetic methodologies (Figure 20). One of the most important of these is the aldol reaction, 
with extensive work by Evans186-190 and Paterson191-194 allowing for regio-, stereo-, and 
enantioselective carbon-carbon bond forming reactions to be performed under either chiral 
auxiliary or substrate control (e.g. through the use of boron enolates for Evans aldol reactions 
and for Paterson anti-aldol reactions). A further use of the aldol reaction is the Mukaiyama aldol 
addition,195 utilising silyl enolates of ketones that add to aldehydes with excellent levels of 
stereocontrol. 
As well as the aldol reaction there are a number of other well established methodologies 
for the construction of polypropionate fragments, including, the reductive aldol reaction,196-200 
crotylation,201-208 allenylation,209-212 epoxide ring opening,213-216 thiopyran chemistry,217, 218 [2+2] 
cycloaddition reactions,219-223 and sequential substitution reactions (Figure 20).224-227     
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Figure 20. Established methodology for the synthesis of polypropionate fragments228 
  
The aim of this project was to develop a sustainable synthetic route to polyketide 
natural product fragments using a protecting group free strategy. Based on the use of a Lewis 
acid (LA) catalysed enantioselective hetero-Diels-Alder (HDA) reaction to construct a six-
membered dihydropyran ring. This ring could then be derivatized in a number of ways, one of 
which would be hydroboration to afford a chiral pyran as a masked stereotetrad containing four 
contiguous stereocentres that was ideally suited for natural product synthesis (Scheme 87). It 
was envisaged that derivatisation of dihydropyran 87.3 using a range of different chemistries 
would result in a range of useful chiral building blocks. These could then be used for the synthesis 
of a range of polyketide natural products (and their analogues), in a “plug and play” manner. 
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Scheme 87. Proposed hetero-Diels-Alder strategy for the synthesis of polyketide fragments 
 
 This strategy was inspired by some of the ground breaking work carried out by the 
Danishefsky group. Their work also focused on development of new synthetic methodology for 
the synthesis of polyproionates, based on cyclo-addition reactions of Danishefsky type dienes 
88.1 with an appropriate aldehyde, which gave rise to silyl enol ether 88.3, or α,β-unsaturated 
ketone 88.4. They showed that application of a series of selective derivatisation reactions to 
88.3 and 88.4, enabled a series of highly functional pyran rings 88.5, containing four chiral 
centres to be prepared (Scheme 88).  
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Scheme 88. Danishefsky’s strategy for the synthesis of polypropionates229, 230 
 
This elegant methodology has since been applied to a range of syntheses, including 
complex polyketide natural products and saccharides, where stereochemical control is achieved 
through derivatisation of cyclic structures using simple reagents, which would not be possible 
using an acyclic substrate.229-241 Once the derivatized pyran has been constructed cleavage of 
the ring can be easily achieved by exploiting the masked aldehyde character of the hemi-acetal 
linkage. “Hence both the construction and the disassembly of the cyclic edifice need not add steps 
to the total program and, therefore, need not be regarded as contrivances” (S. Danishefski).229 
Two examples of where this methodology has been applied for the synthesis of polypropionate 
fragments towards natural product synthesis are shown below.  
The first example is the synthesis of lactone 89.6, which is a subunit of monensin (a 
polyether antibiotic). A ytterbium catalysed cycloaddition reaction of aldehyde 89.1 and 
Danishefsky diene 89.2, affords silyl enol ether 89.3. Treatment of 89.3 with HF resulted in silyl 
deprotection to afford ketone 89.4, which was then reduced to its corresponding alcohol. 
Methylation of this alcohol followed by acetal cleavage gave lactol 89.5. Treatment of lactol 89.5 
with catalytic ruthenium dioxide in the presence of NaIO4 afforded a crude lactone acid which 
was then esterified with diazomethane to afford racemic lactone 89.6 (Scheme 89).      
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Scheme 89. Synthesis of racemic polypropionate fragment 89.6229 
 
 A second selected example is the synthesis of aldehyde 90.6, as a masked 
polypropionate fragment present in migrastatin, which is a natural product that has anti-cancer 
properties. A titanium catalysed diene aldehyde cyclocondensation reaction of aldehyde 90.1 (4 
steps from dimethyl tartrate) and Danishefsky diene 90.2 gave α,β-unsaturated ketone 90.3. 
Luche reduction of ketone 90.3 afforded an allylic alcohol which underwent an aqueous Ferrier 
arrangement to give lactol 90.4. Reduction of lactol 90.4 with LiBH4 afforded the acyclic diol 90.5, 
with selective acetate protection of the primary alcohol functionality being followed by O-silyl 
protection of the secondary alcohol. Acetate removal and subsequent alcohol oxidation then 
afforded the core polypropionate fragment 90.6 (Scheme 90).239  
 
133 
 
 
Scheme 90. Substrate controlled synthesis of polypropionate fragment 90.6239 
 
 It was proposed to modify this powerful methodology for the synthesis of a range of 
complex enantiomerically enriched pyran based building blocks, that could be accessed in a 
highly efficient manner, that would be ideally suited for the synthesis of polyketide natural 
products through a “plug and play” approach. If the structure of the advanced alcohol 
intermediate 90.5 is considered, then a retrosynthetic analysis can be performed to highlight 
how our proposed methodology was envisaged to proceed. Lactol 90.4 could potentially be 
accessed from dihydropyran 91.1, with the presence of the terminal alkene allowing for late 
stage derivatisation. This alkene unit could be introduced via addition of a vinyl Grignard reagent 
to the corresponding aldehyde 91.2. Aldehyde 91.2 could then be accessible directly from an 
enantioselective HDA reaction of 1-alkoxy diene 91.3 with methyl glyoxalate, the ester group of 
which would function as a synthetic handle for subsequent derivatization (Scheme 91). 
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Scheme 91. Retrosynthetic analysis of alcohol 90.5 
 
7.2 Diene Synthesis  
 The diene 91.3 shown below (Figure 21) was identified as the target starting material 
for this methodology, however, a review of the literature revealed that routes for the 
preparation of 1-alkoxy dienes were somewhat limited. This resulted in the synthesis of this 
target diene becoming problematic, and significant effort was expended to identify an efficient 
route for their synthesis.   
 
 
Figure 21. Target diene 91.3 
 
 Initial attempts were based on the use of a strong electrophilic methylating agent, such 
as Meerwein’s salt (Me3OBF4), which we hoped would react with the α,β-unsaturated aldehyde 
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in the presence of base, to form the desired enol ether. However, this proved to be unsuccessful 
with no product formation being observed via 1H NMR analysis (Scheme 92). 
 
 
Scheme 92. Unsuccessful synthesis of diene 91.3  
 
 Multiple attempts were made along these lines with no success, with attempts at other 
elimination strategies also proving fruitless. Examination of the literature revealed that one 
successful approach for the synthesis of small diene molecules was the use of Wittig 
olefination.242 From this precedent, two carbonyl species were identified as potential targets, 
93.1 and 93.2, with the aim of using them as substrates for a Wittig olefination reaction to obtain 
the desired diene 91.3 (Scheme 93).      
 
 
Scheme 93. Proposed Wittig synthesis of diene 91.3 
 
 It was decided proceed with diene synthesis using an anolouge of aldehyde 93.1, since 
protocols for the synthesis of 3-ethoxy-2-methyl-2-propenal 94.2 were known in the literature. 
3-Ethoxy-2-methyl-2-propenal 94.2 was formed by the reaction of propionaldehyde diethyl 
acetal 94.1 with POCl3 via a Vilsmeier-type reaction (Scheme 94).243, 244    
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Scheme 94. Synthesis of 3-ethoxy-2-methyl-2-propenal 
 
 This reaction is proposed to proceed via a similar mechanism to the classical Vilsmeier 
reaction. Protonation of acetal 94.1 is followed by elimination of ethanol to give vinyl ether 95.3, 
which then reacts with chloroiminium 95.2, to afford oxonium 95.4. This oxonium spicies 95.4 
then eliminates chloride to give iminium species 95.5, which is then hydrolysed to afford 
aldehyde 94.2 (Scheme 95).    
 
 
Scheme 95. Mechanism of Vilsmeier reaction 
 
 In our hands, formation of aldehyde 94.2 proceeded with 100% E-selectivity, with this 
aldehyde then being carried forward to complete the desired diene synthesis via Wittig 
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olefination with ethyltriphenylphosphonium bromide in the presence of LDA as a strong base. 
Purification by distillation gave the desired diene 96.1 in good yield and in a ratio of 15:1 
(1E,3E):(1E,3Z), as assigned by 1H NMR spectroscopic analysis (E, E)-isomer (δ 5.45 (qd, J = 6.6, 
15.1 Hz, 1 H, CH=CHCH3)) (E, Z)-isomer (δ 5.31 (qd, J = 7.2, 11.7 Hz, 1 H, CH=CHCH3)).  However, 
to our delight, when this mixture of geometric isomers was left at room temperature for two 
days, it was found to equilibrate in favour of its thermodynamically favourable (1E,3E)-isomer in 
a ratio of 50:1.     
 
 
Scheme 96. Synthesis of (1E,3E)-1-ethoxy-2-methylpenta-1,3-diene 
 
 Concurrent to the syntheses described above, an alternative synthetic strategy to diene 
96.1 was investigated. An interesting report from the literature caught our attention involving 
the synthesis of acetal and carbonyl substituted allyl chlorides from α,β-unsaturated acetals,245 
which was proposed to proceed through alkoxy diene 97.2 (Scheme 97). It was reported that 
treatment of α,β-unsaturated acetal 97.1 with an excess of n-butyl lithium and potassium tert-
butoxide (known as LICKOR), afforded diene 97.2, which in the presence of excess base and 
methyl iodide gave the substituted diene 97.4. Addition of N-chlorosuccinimide, base and 
methanol then gave the acetal substituted allyl chloride 97.5.  
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Scheme 97. Synthesis of acetal substituted allyl chloride 97.5245 
 
 It was hoped that the first step of this methodology (97.1 to 97.2) could be applied for 
the synthesis of our target diene 96.1. Therefore, synthesis of α,β-unsaturated acetal 98.2 from 
α,β-unsaturated aldehyde 98.1 was achieved through treatment of α,β-unsaturated ketone 98.1 
with triethyl orthoformate and ammonium nitrate, in 95% yield. The conditions of the LICKOR 
mediated elimination reaction were adjusted for use with α,β-unsaturated acetal 98.2; with 
increased amounts of base, extended reaction time and elevated temperatures required, when 
compared to the literature procedure (Scheme 98). Diene 96.1 was isolated in 60% yield, 
affording a second viable route to the necessary diene. This route proved to be a significant 
improvement, with many of the reagents employed for synthesis accessible from biorenewable 
starting materials.     
 
 
Scheme 98. Alternative synthesis of (1E,3E)-1-ethoxy-2-methylpenta-1,3-diene 
 
 For example, propionaldehyde 99.1 is readily obtained from biorenewable propanol. 
Consequently, an aldol self-condensation reaction was carried out to afford α,β-unsaturated 
aldehyde 98.1 in 85% yield, with the reaction proceeding as a biphasic mixture, allowing for easy 
work up and purification. Acetal formation was achieved in the same manner as above, through 
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the use of ammonium nitrate which is commonly used as a high nitrogen fertiliser, and as such 
is available at large quantities and in low cost. More benign conditions were then developed to 
carry out elimination of 98.1 to 96.1. It has been reported that use of solutions of potassium 
tert-butoxide in dimethyl sulfoxide results in a highly basic system.246, 247 This is believed to occur 
due to the solvent strongly complexing with the potassium cations, producing an activated 
ligand-separated and dissociated tert-butoxide anion in a medium of high dielectric constant.246 
This base system is known to be a powerful reagent for carrying out β-elimination reactions,246, 
247 and its application to the elimination of 98.2 proved successful affording diene 96.1 in 80% 
yield (Scheme 99).  
 
 
Scheme 99. Synthesis of diene 96.1 from biorenewable sources  
 
 With diene 96.1 obtained in synthetically useful quantities, our attention then turned to 
development of asymmetric hetero-Diels-Alder methodology to synthesise dihydropyran 87.3. 
7.3 Hetero-Diels-Alder Chemistry 
  Since its discovery in 1928, by Otto Diels and his then student Kurt Alder,248-250 the Diels-
Alder reaction has become one of the cornerstone reactions of organic chemistry for the 
construction of six membered rings.249 The conventional Diels-Alder reaction is a [4+2] 
cycloaddition reaction of a conjugated diene 100.1 and a dieneophile 100.2 (usually an electron 
deficient alkene) to form a cyclohexene ring 100.3 (Scheme 100). 
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Scheme 100. Diels-Alder reaction 
 
 Since its discovery, an understanding of the molecular orbital theory developed by 
Woodward and Hoffmann,251 has enabled the Diels-Alde reaction to be used for the asymmetric 
synthesis of compounds, with reactions often proceeding with excellent levels of region- and 
stereocontrol.252-254 A prominent example of this is the use of copper bisoxazoline catalyst 101.3, 
for the enantioselective Diels-Alder reaction of acrylimide 101.1 and furan 101.2 to afford 
cycloadduct 101.4 in 67% yield, which was achieved in 80:20 endo selectivity and 97% ee.253 It 
is proposed that the chiral ligand of complex 101.3 is able to create a stereoselective 
environment around the metal centre, that forces the furan dienophile to approach the diene 
from “below” the ligand, as shown for transition state 101.5.    
 
 
Scheme 101. An enantioselective example of Diels-Alder reaction253, 254 
 
141 
 
A further development in Diels-Alder methodology was replacing the alkene as the 
dieneophile with a heteroatom containing dieneophile, in what has become known as the 
hetero-Diels-Alder (HDA) reaction. The HDA reaction is less well investigated than the original 
Diels-Alder reaction, but its synthetic utility is becoming increasingly recognised.249, 255 One of 
the most notable areas where the HDA reaction has been well utilised is for the synthesis of 
monosaccharides,233-235, 256-259 which was pioneered by the Danishefsky group, who developed 
HDA methodology for their synthesis using Danishefsky type dienes, summarised in Figure 22.  
 
 
Figure 22. Danishefsky’s route to totally synthetic hexoses234 
 
 An excellent example where this methodology has been applied to natural product 
synthesis is for the total synthesis of avermectin A1A.235, 260, 261 A transition metal catalysed HDA 
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reaction of diene 102.1 (using L-phenylmenthol as a chiral auxiliary to introduce stereocontrol) 
and acetaldehyde 102.2 afforded the cycloadduct 102.3, which was oxidised with Mn(OAc)3 to 
give dihydropyranone 102.4. Pyranone reduction with sodium borohydride in the presence of 
CeCl3, afforded a vinyl alcohol that was O-methylated followed by acetate hydrolysis to afford 
alcohol 102.5. Methoxybromination of 102.5 followed by debromination (using Bu3SnH) 
afforded methyl glycoside 102.6. Reaction of methyl glycoside 102.6 with dihydropyran 102.7 
(obtained from 102.4) with N-iodosuccinimide afforded the protected disaccharide 102.8, that 
proved to be a crucial fragment for the synthesis of the disaccharide fragment of avermectin A1A.     
   
 
Scheme 102. Total synthesis of avermectin A1A using HDA chemistry235, 260, 261 
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HDA reactions involving a diene and a carbonyl dienophile proceed with normal electron 
demand, (HOMO of the diene overlap with LUMO of the dienophile Figure 23), however, hetero 
atom containing dieneophiles are generally not as reactive as alkenes for Diels-Alder chemistry. 
To overcome this, Lewis acids (LA) are often required to catalyse the reaction by improving 
overlap of the HOMO and LUMO orbitals of the respective diene and heterodienophile (Figure 
24). The LA coordinates to a lone pair of the hetero atom of the dinenophile acting as an electron 
withdrawing group to lower the energy of the LUMO orbital. This the energy of the LUMO of the 
dieneophile closer to the HOMO of the diene allowing for more efficient overlap and cyclisation 
to occur.   
 
 
 Figure 23. Hetero-Diels-Alder reaction 
 
 
Figure 24. Frontier molecular orbitals of Lewis acid catalysed HDA reaction 
 
 The LA may not only act as a catalyst to facilitate the HDA reaction, but also presents an 
opportunity to confer further control over the reaction, with extensive work having been 
conducted into using chiral auxiliaries and chiral catalysts for achieving enantio- and 
diastereoselective control.249 
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7.31 Dihydropyran Synthesis 
 Initial HDA studies were performed with the commercially available Jacobsen bidentate 
catalyst 103.1. This catalysts was chosen not only for the convenience of being commercially 
available, but it has also been shown in literature to be active for a range of asymmetric HDA 
reactions.262 It had been reported that HDA reaction between Danishefsky's diene 90.2 and 
benzaldehyde 7.1 using this catalyst, followed by O-silyl cleavage with TBAF (tetra-n-
butylammonium fluoride), gave chiral ketone 103.3 in 85% yield and 87% ee (Scheme 103). This 
reaction was successfully repeated to ensure the integrity of the commercial catalyst, 
successfully affording α,β-unsaturated ketone 103.2 in 80% yield and 85% ee.    
 
 
Scheme 103. Literature example of using Jacobsen catalyst for an enantioselective HDA reaction262 
 
 1-Alkoxy dienes are known to be generally deactivated towards cycloaddition 
reactions,263 whilst diene 96.1 lacks the activating silyl enol ether fragment of diene 90.1, so 
therefore the choice of a reactive carbonyl reaction partner was important. Consequently, the 
carbonyl substrate chosen for HDA reaction with diene 96.1 was the activated aldehyde ethyl 
glyoxalate 104.1; which we proposed would afford a HDA adduct 104.2 that would be ideally 
suited for further synthetic elaboration.     
  The reaction proceeded with good diastereoselectivity producing two diastereomers 
104.2 and 104.3 in a ratio of 11:1, the two diastereomers, which were separable by column 
chromatography allowing the single major diastereomer 104.2 to be obtained in 86% yield 
(Scheme 104).    
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Scheme 104. Synthesis of dihydropyan 104.2  
 
 The relative stereochemistry of the major diastereomer 104.2 was predicted to be syn, 
due to the endo selectivity normally observed for Diels-Alder reactions. However, confirmation 
was needed, the first piece of evidence was the difference in the coupling constants of Hd and 
He in the two isolated diastereomers 104.2 (J = 3.5 Hz) and 104.3 (J = 10.4 Hz). A large coupling 
constant of Jd,e = 10.4 Hz for dihydropyran 104.3 is characteristic of an axial-axial relationship, 
which would require both groups to be anti to each other. A small coupling constant on the 
other hand, such as Jd,e = 3.5 Hz for dihydropyran 104.2 is characteristic of a axial-equatorial 
relationship that would be expected if the protons had a syn-relationship. Another way of 
obtaining evidence of relative stereochemistry is through nOe (nuclear Overhauser effect) NMR 
experiments. If, as expected, the three protons Ha, Hd and He of the major diastereomer had a 
syn geometry, then nOe interactions would be expected between them, as represented for the 
major ring conformer shown in Scheme 105. Since nOe interactions occur by through space 
interactions between protons, these interactions would only be possible if the protons of the 
dihydropyran ring were on the same face (Figure 26). The use of coupling constants can also 
help assign relative stereochemistry.  
 
 
Scheme 105. Dihydropyran 104.2 ring conformation 
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 In order to determine the relative stereochemistry by nOe NMR it is necessary that 1H 
NMR of the compound in question is fully assigned. The full assignment of dihydropyran 104.2 
is presented below (Figure 25). 1H NMR (500 MHz, CDCl3) δ 5.71 - 5.68 (m, 1H, Hc), 5.09 (s, 1H, 
Ha), 4.34 (d, J = 3.5 Hz, 1H, He), 4.28 - 4.22 (m, 2H, CH21), 3.87 (dq, J = 9.6, 7.0 Hz, 1H, Hg), 3.66 
(dq, J = 9.5, 7.1 Hz, 1H, Hf), 2.48 - 2.42 (m, 1H, Hd), 1.66 (s, 3H, Me1), 1.30 (t, J = 7.1 Hz, 3H, Me3), 
1.25 (t, J = 7.1 Hz, 3H, Me4), 1.01 (d, J = 6.9 Hz, 3H, Me2). Due to restricted rotation, the acetal 
ethoxy protons Hf and Hg of dihydropyran 104.2 are diastereotopic. This is confirmed by analysis 
of the NOESY spectrum which reveals an interaction between Ha and Hg. Once full assignment 
has been made then inspection of the nOe spectrum allows the relative stereochemistry to be 
assigned.    
 
 
Figure 25. Assaingment of 1H NMR of dihydropyran 104.1 
 
 
 
147 
 
 
 
 
Figure 26. NOESY NMR of dihydropyran 104.2 
 
 With the relative stereochemistry of dihydropyran 104.2 confirmed the enantiopurity 
was then determined. A genuine racemic sample of 104.2 was prepared using a racemic sample 
of catalyst 103.1.  Enantiomeric excess was then determined using chiral GC, using a β-Dex 
column as the stationary phase. Unfortunately, the enantiomeric excess measured was found 
to be low at only 15% ee. In an attempt to improve this ee a number of changes were made to 
the reaction conditions, with an ultimately important modification being prior purification of 
ethyl glyoxalate 104.1. Ethyl glyoxalate 104.1 is commercially available as 50% solution in 
toluene. However, the glyoxalate is commercially available predominantly as its polymeric 
hydrate, rather than its aldehyde form. Consequently the glyoxalate was distilled/cracked under 
nitrogen and stored as a 50% solution in anhydrous CH2Cl2 at -20 °C to ensure it was present as 
its reactive aldehyde form. However, this change in this instance (and numerous other 
modifications), gave no improvement in ee.  
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These results were highly disappointing, and with the critical need to improve ee of the 
HDA reaction it was decided to investigate a different chiral catalyst. A catalytic system that had 
been used on a paramount, similar system was titanium-BINOL 106.3,242 which had been 
reported to catalyse the reaction of diene 106.1 and methyl glyoxalate 106.2, to afford the 
cycloadduct 106.4 in 77% yield and 94% ee.   
 
 
Scheme 106. Mikami et al. HDA reaction using Ti-BINOL 106.3242 
 
Catalyst 106.3 was synthesised by addition of diisopropoxytitanium dichloride 107.1 to 
a stirred mixture of BINOL 107.2 and 4 Å molecular sieves in anhydrous CH2Cl2. The reaction was 
stirred for 1 h and the molecular sieves allowed to settle overnight. The solution was then 
decanted from the molecular sieves utilizing Schlenk techniques, concentrated and the resultant 
residue was suspended in anhydrous pentane. The pentane was then removed via syringe and 
the residue dried under vacuum to give the titanium-BINOL complex 106.3, which was stored 
under an inert atmosphere and used without further purification (Scheme 107).242 Complete 
removal of the molecular sieves was shown in the original paper to be essential to achieve good 
enantioselective control over the reaction.      
 
 
Scheme 107. Synthesis of titanium-BINOL catalyst 106.3 
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This new catalyst was then applied to the HDA reaction of diene 96.1 and purified ethyl 
glyoxalate 104.1, pleasingly this change had the desired effect, with very high enantioselectivity 
achieved of 99% ee. A small optimization study was carried out, which identified that use of 
diene 96.1 as the limiting reagent, resulted in the reaction proceeding to 104.2 as a single 
diastereomer in 65% yield and most importantly, in 99% ee (Scheme 108).       
 
 
Scheme 108. Enantioselective synthesis of dihydropyran 104.2 
 
Enantioselective induction from the BINOL ligand is believed to result from binding of 
the when the Ti-BINOL complex to glyoxalate to create a highly chiral environment around the 
aldehyde. This only allows the diene to approach from one face of the aldehyde, resulting in 
formation of both a single diastereomer and a single enantiomer (Figure 27).  
 
 
Figure 27. Ti-Binol-glyoxalate transition state for the enantioselective synthesis of dihydropyran 104.2. 
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However, while this was an important step forward in validating this HDA project, it was 
found that different batches of Ti-BINOL 106.3 resulted in widely different ee’s of dihydropyran 
104.2, ranging from 99% to 0% ee! In order to address this issue of reproducibility it was decided 
to subsequently synthesise Ti-BINOL catalyst 106.3 in a glove box to ensure the quality of the 
catalyst produced. This change was made under the assumption that the reaction and 
performance of the catalyst were highly sensitive to the presence of adventitious water. 
Pleasingly, this change in synthetic procedure rectified the reproducibility issue associated with 
using catalyst 106.3 in our HDA reaction, enabling access to gram quantities of enantiomerically 
enriched dihydropyran 104.2. Consequently our attention then switched to employing 104.2 as 
a chiral template for carrying out a series of diastereoselective derivatisation reactions to afford 
a library of chiral building blocks.  
7.4 Dihydropyran Derivatization 
 It was proposed that subsequent reactions performed on the dihydropyran ring should 
proceed with a high level of diastereoselectivity due to its cyclic conformation, which ideally 
would mean that chiral reagents would not be necessary, with all the stereocontrol ultimately 
being controlled by the original enantioselective HDA reaction.  
7.41 Hydroboration 
The first reaction considered was hydroboration of the alkene functionality of 104.2; 
which would lead to the introduction of the desired hydroxyl group and the generation of two 
new stereocentres. There are a number of similar literature examples that suggested that this 
hydroboration reaction would occur with good facial selectivity. In particular, the seminal work 
of Danishefsky has demonstrated that good selectivity could be achieved for hydroboration 
reactions of dihydropyran 109.2, using simple hydroborating reagents such as borane (Scheme 
109).237  
 
 
Scheme 109. Stereoselective hydroboration reaction of dihydropyran 109.2237 
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 The hydroboration reaction of dihydropyran 104.2 proved to be successful and 
proceeded with good selectivity, affording a single diastereomer in 85% yield (Scheme 110).  
 
Scheme 110. Stereoselective hydroboration of dihydropyran 104.2  
 
 The borane approaches the alkene via its least hindered face and undergoes anti-
Markovnikov addition, which upon oxidative workup affords pyran 110.1, whose hydroxyl group 
has a anti relationship relative to the other substituents, with the relative stereochemistry again 
being confirmed by NOESY NMR spectroscopic studies. Key nOe interactions between Ha, Hb, Hd 
and He confirm that all four protons are on the same face of the pyran ring, with Hc not 
interacting with any of the other pyran protons other than Hd due to their vicinal equatorial 
relationship (Figure 28).     
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Figure 28. NOESY NMR of pyran 110.1 
  
The incorporation of a hydroxyl group not only creates two new stereocentres, but also 
gives the potential for further derivatization reactions towards the synthesis of a wide range of 
natural products, potentially making it a highly valuable building block. Hydroboration also 
results in the generation of a stereotetrad, which as mentioned previously is a highly common 
structural motif in polyketide natural products.169 For example, the diastereomer of pyran 110.1 
produced is stereochemically equivalent to the stereotetrad containing a syn, syn, syn relative 
stereochemistry, which is present in polyketide natural products such as Erythromycin A (Figure 
29).   
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Figure 29. Erythromycin A. 
 
7.411 Hydroxyl Inversion 
 However, in order to gain complementary access to another diastereomeric tetrad it 
was decided to oxidise the hydroxyl group of 110.1 and then subsequently reduce the resulting 
ketone to afford an inverted hydroxyl functionality. The success of this method would rely on 
the inverted hydroxyl group product being produced via attack of the hydride from the least 
hindered face of the ketone functionality of pyranone 111.1. Therefore, alcohol 110.1 was 
oxidised to ketone 111.1 under Swern conditions, with the reaction proceeding well to afford 
pyranone 111.1 in 80% isolated yield. The ketone reduction was performed with sodium 
borohydride in ethanol at 0 °C to give the inverted alcohol 111.2 in a 95% yield (Scheme 111). 
Pleasingly, this reduction reaction proceeded to give a single diastereomer, confirming that 
pyran 111.2 could be successfully accessed as a sole diastereomer under kinetic control. Access 
to ketone 111.1 potentially presents an opportunity for carrying out other derivatisation 
reactions, via treatment with different nucleophiles to afford a range of natural and non-natural 
synthons.        
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Scheme 111. Inversion of hydroxyl group on pyran 110.1  
 
 The relative stereochemistry of pyran 111.2 was again confirmed by nOe NMR 
spectroscopic studies, with key nOe interactions between Ha, Hb, Hc, Hd and He confirming that 
they are all present the same face of the pyran ring, and therefore have and  all syn-relationship 
(Figure 30).     
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Figure 30. NOESY Spectra of pyran 111.2 
 
 The tetrad stereochemistry of pyran 111.2 produced is equivalent to the anti, anti, syn 
relative stereochemistry, which is found as a pair of enantiomeric fragments present in the 
natural product Aplyronine A (one of each enantiomer) (Figure 31). 
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Figure 31. Aplyronine A  
 
7.42 Hydrogenation  
We next targeted another derivatization reaction of dihydropyran 104.2 involving 
hydrogenation of the alkene functionality. This transformation was expected to proceed with 
good stereoselectively, due to the mechanism of hydrogenation reaction; whereby the alkene 
substrate is adsorbed onto the heterogeneous metal catalyst surface, followed by syn addition 
of hydrogen across the double bond. However, initial hydrogenation attempts proved to be 
unsuccessful, instead unexpectedly affording acyclic bis-ester 112.1 as the sole product from the 
reaction (Scheme 112).   
 
 
Scheme 112. Hydrogenation of 104.2 affording bis-ester 112.1 
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 A proposed mechanism for this unexpected transformation is shown below in Scheme 
113. Pd-H addition across the alkene bond of dihydropyran 104.2 affords a syn adduct 113.1. 
However, at low pressures of hydrogen, this process is reversible, enabling competing 
elimination of the Ha proton to afford alkene 113.2. Stereoselective protonation of the enol 
ether fragment of 113.1 affords an oxacarbenium species 113.3, which is then hydrolysed to 
give bis-ester 112.1 (Scheme 113).  
 
 
Scheme 113. Proposed mechanism for the formation of bis-ester 112.1 
 
 As a consequence of this unexpected reaction, it was decided to perform the 
hydrogenation reaction in an aprotic solvent under a high pressure of Hydrogen, since a related 
literature example by the Danishefsky group suggested this might be successful.237, 241 It was 
reported that when alkene 114.1 was subjected to a H2 atmosphere of 50 PSI in the presence of 
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a palladium on alumina catalysts, it afforded the fully saturated pyran 114.2 in 80% yield 
(Scheme 114). 
 
 
Scheme 114. Literature hydrogenation example237  
   
Under these conditions, the hydrogenation of dihydropyran 104.2 with palladium on 
alumina under an atmosphere of 50 PSI hydrogen for 24 h afforded tetrahydropyran 112.2 as a 
single diastereomer in 85% yield (Scheme 115).  
 
 
Scheme 115. Synthesis of pyran 112.2 
   
 The relative stereochemistry of pyran 112.2 was once again confirmed by nOe 
interactions. The key nOe interactions that confirm the assignment of the configuration of the 
methyl group, are that of Hb which is shown to interact with both Ha and He confirming the 
relative stereochemistry of pyran 112.2 (Figure 32). Pyran 112.2 has been previously synthesised 
by the Evans group as its enantiomer,264 with a comparison of the analytical data confirming the 
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structure of pyran 112.2, as well as a comparison of the optical purity ([α]D20 = +82, literature 
[α]D20 -88 for opposite enantiomer264). 
 
 
 
 
 
Figure 32. NOESY NMR of pyran 112.1 
 
Pyran 112.2 contains a polydeoxypropionate fragment which is also present in many 
natural products, with a tetrad fragment with the same relative configuration being present in 
the natural product bourgeanic acid (Figure 33).265   
 
 
160 
 
 
 
Figure 33. Bourgeanic acid 
 
7.43 Epoxidation 
 Epoxidation of alkenes is an important reaction in synthetic chemistry not only for 
generation of epoxides, but also for their synthetic capacity to introduce further functionality 
into a molecule. One of the most utilized methods of epoxidation is through the use of m-
chloroperbenzoic acid (mCPBA). Initial attempts to epoxidise dihydropyran 104.2 were made 
using mCPBA, with the reaction proceeding well at 0 °C in four hours, using potassium carbonate 
as a buffer to prevent the chlorobenzoic acid by-product from ring the opening epoxide 116.1 
product (Scheme 116). The relative stereochemistry of the resultant epoxide 116.1 can be 
explained due to the mCPBA approaching the double bond from the least hindered face. 
However, this methodology proved unreliable, with yields varying considerably when the 
reaction was repeated on scale, and with isolation of epoxide 116.1 proving problematic.  
 
 
Scheme 116. Epoxidation of dihydropyran 104.2 using mCPBA 
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 Due to these issues it was decided to try and identify an alternative epoxidation method 
for trisubstituted alkenes. An example that came to our attention was the methodology 
bescribed by Venturello and Noyori,266, 267 who have both published excellent methods 
employing H2O2 and in situ-generated, or preformed metal complexes. The most commonly 
employed catalyst is a tungstate complex, composed of quaternary ammonium 
tetrakis(diperoxotungsto)phosphates (-3), which not only acts as the epoxidation catalyst, but 
also acts as a phase transfer catalyst. The reaction utilises H2O2 as the oxidant, which is one of 
the greenest oxidants available, producing water as a by-product. The method chosen to follow 
was using a preformed tungstate complex as described by Venturello,266 which was prepared by 
heating tungstic acid in 30% H2O2 at 60 °C until the reaction becomes homogeneous. The 
reaction was then cooled to rt and 40% phosphoric acid solution added, and the reaction diluted 
with H2O followed by the addition of Aliquat 336. Aqueous work-up followed by concentration 
en vacuo then provided the desired tungstate complex. The epoxidation reaction of 
dihydropyran 104.2 proceeded in excellent yield at rt in 4 h, under solvent free conditions, to 
give epoxide 116.1 in a 95% yield as a single diastereomer (Scheme 117). The reaction was 
demonstrated to have excellent reproducibility, and was a significant improvement on the 
original mCPBA epoxidation conditions. 
 
 
Scheme 117. Venturello catalyst epoxidation of dihydropyran 104.2 
 
 Reduction of epoxide 116.1 with LiAlH4 proceeded well to give the expected 
Markovnikov tertiary alcohol 118.1 in 90% yield after 1 h, with the ester functionality also being 
reduced to a primary alcohol to afford diol 118.1 (Scheme 118), containing orthogonally 
addressable groups for further derivatization. This reduction reaction proceeds via an SN2 type 
mechanism, because the reaction in performed in a polar aprotic solvent, which results in the 
hydride nucleophile approaching the epoxide with an axial trajectory at the least hindered 
carbon.     
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Scheme 118. Reduction of epoxide 30.1 with LiAlH4  
  
 Attempts were also made to access the opposite diastereomer of epoxide 116.1 through 
base mediated ring-closure of bromohydrin 119.1. Dihydropyran 104.2 was subjected to 
standard bromohydrin synthesis conditions utilising N-bromosuccinimide (NBS) and water. 
However, rather than producing the expected bromohydrin 119.1 via approach of NBS from the 
least hindered face, it was found that bromohydrin 119.2 was generated as the only product in 
86% yield (Scheme 119). Fortunately, the bromohydrin produced could be isolated as a 
crystalline solid which allowed for confirmation of its structure by single crystal X-ray 
crystallography (Figure 34).    
 
 
Scheme 119. Synthesis of bromohydrin 119.1  
Figure 34. X-ray crystal structure of bromohydrin 119.1 (hydrogens omitted for clarity) 
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As confirmation that the epoxide generated using the Venturello conditions had been 
assigned correctly, bromohydrin 119.1 was cyclised using potassium carbonate as base to afford 
epoxide 116.1 in 90% yield (Scheme 120). Comparison of the 1H NMR and 13C NMR spectra of 
both synthesised epoxides and a mixed NMR sample provided confirmation that both routes 
had led to generation of the same epoxide diastereomer 116.1.  
 
 
Scheme 120. Ring closing to form epoxide 116.1 
 
 This unexpected bromohydrin result is proposed to be due to two contributing factors. 
Firstly, electrophilic bromination of an alkene double bond is known to proceed via reversible 
formation of a bromonium ion.268-271 Secondly, the trans-diaxial effect (Fürst-Plattner rule),272 
states that nucleophilic attack of cyclohexyl derivatives such as epoxides, imines and halonium 
ions occurs to preferentially afford trans-diaxial product.272, 273  
If formation of bromohydrin 119.2 is considered, the bromonium ion would be expected 
to arise from approach of Br+ from the least hindered face, resulting in formation of bromonium 
ion 121.1. If this is considered as a “bow-tie” conformation, then hydroxyl attack of the 
bromonium ion to produce a trans-diaxial product would proceed via a highly disfavoured “twist 
boat” conformation. However, since bromonium ion formation is potentially reversible, small 
quantities of the more sterically hindered bromonium ion 121.2 may also be formed. Hydroxyl 
attack of bromonium ion 121.2 could then proceed smoothly to give the “chair” conformation 
of the bromohydrin, which acts as a “thermodynamic sink” to afford the unexpected 
bromohydrin 119.1 (Scheme 121). 
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Scheme 121. Proposed route to unexpected bromohydrin 119.1 
 
7.44 Dihydroxylation 
 Reactions of osmium tetroxide with alkenes to give syn-vicinal diols was discovered in 
the early 1900’s and was first published by Makowka in 1908.274 Since then, this methodology 
has undergone incredible development with the introduction of a number of catalytic methods 
aimed at minimising the amount expensive and toxic osmium employed.275 One of the most 
well-known and successful examples of employing catalytic amount of OsO4 is the Upjohn 
process, which regenerates the active osmium species through the use of stoichiometric 
amounts of N-methylmorpholine N-oxide (NMO) as a sacrificial oxidant.276 In the 1980’s 
Sharpless developed an asymmetric dihydroxylation protocol on the basis of this earlier work, 
based on observations by Criegee that tertiary amines (e.g. pyridine) accelerated the reaction of 
osmium tetroxide with alkenes.277-282 Continued development of their asymmetric methodology 
eventually led to a commercially available mixture of chiral ligand, oxidant and an osmium 
source being made available. These reagents are collectively known as AD-mix α and Ad-mix β, 
with opposite enantiomers of the (DHQ)2PHAL ligand potentially allowing for synthesis of the 
diol enantiomer of choice (Figure 35).   
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Figure 35. AD-mix α and AD-mix β 
 
 It was proposed that the use of AD-mix α or Ad-mix β for dihydroxylation of 
dihydropyran 104.2 could potentially afford both diastereomers of syn-diol 122.1 under catalyst 
control. However, it was found that irrespective of which Ad-mix was used, the same diol 
diastereomer 122.1 was obtained, indicating that substrate control overrides the ligand 
directiving effect of the AD-mix reagents (Scheme 122). As seems to be common for use of AD-
mix, the dihydroxylation reaction was slow, taking 4 days to afford diol 122.1 in only 45% isolated 
yield.      
 
 
Scheme 122. Synthesis of diol 122.1 
 
 The relative stereochemistry of diol 122.1 was assigned by NOESY NMR, with Hc 
demonstrating interactions with Hd due to the fact that they are both equatorial, whilst 
displaying no nOe interactions with Ha or He (Figure 36). 
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Figure 36. NOESY of diol 122.1 
 
In order to provide further confirmation of the configuration of the diol produced, it was 
decided to synthesise the more structurally rigid acetonide 123.1, which was formed via 
treatment with dimethylacetal and pTSA in acetone in 95% yield (Scheme 123).  
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Scheme 123. Synthesis of acetonidel 123.1 
 
nOe analysis confirmed the relative stereochemistry as previously assigned with Hc 
having nOe interactions with Hd due to thier equatorial relationship, and no other interactions 
with any other protons of the pyran ring (Figure 37). The low coupling constant of 1.8 Hz for Hc 
and Hd also denotes an anti-relationship, with this low coupling constant value characteristic of 
an equatorial-equatorial relationship.    
 
 
 
Figure 37. NOESY NMR of acetonide 123.1 
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 Dihydroxylation of dihydropyran 104.2 to give diol 123.1 gives rise to a stereotetrad 
containing a quaternary carbon centre, which is present as a stereotetrad fragment in the 
natural product yokonolide B, which is a novel inhibitor of auxin signalling (Figure 38).283  
 
 
Figure 38. Yokonolide B 
7.45 Epimerization  
 The aim of this project was to not only gain access to a library of chiral building blocks 
for polyketide synthesis, but also enable access to other possible diastereomeric tetrad 
combinations. An obvious simple change, which would double the current number of 
diastereomers accessible, would be to synthesise the anti-hetero Diels-Alder product, as 
opposed to the syn-hetero Diels-Alder product 104.2. A publication by Terada in 2009 reported 
that use of chiral phosphoric acid 124.2, as a chiral catalyst had afforded an anti-
diastereoselective and enantioselective hetero-Diels-Alder reaction to be carried out.284 In this 
instance, silyloxy diene 124.1 was coupled with ethyl glyoxalate 104.1 to give dihydropyran 
124.3 in 95% yield with >99:1 anti:syn selectivity and 99% ee (Scheme 124).     
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Scheme 124. A chiral phosphoric acid catalysed anti-selective HDA reaction284 
  
It was decided to synthesise chiral phosphoric acid 124.2 and apply this methodology to 
our system, with the synthesis of chiral phosphoric acid 124.2 beingperformed utilising the 
protocols of Kobayashi and Gestwicki as shown in Scheme 125.285, 286  
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Scheme 125. Synthesis of chiral phosphoric acid 124.2 
 
However, while Terada was able to demonstrate that this catalytic system was active 
for 1-alkoxy dienes for the formation of anti-HDA products, in our hands its HDA reactions 
proceeded to give the same syn-diastereomer 104.2 obtained previously observed using the Ti-
BINOL catalyst 106.3.  
 Therefore, it was decided instead to tackle this problem using a different approach. A 
literature search revealed that an epimerization protocol could potentially be a solution to this 
problem, since the Evans group had previously reported selective epimerization of pyran 126.1 
(enantiomer of pyran 112.2) through the use of potassium tert-butoxide as base at -50 °C in THF 
to give its epimer 126.2 in quantitative yield (Scheme 126).264      
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Scheme 126. Evans’ selective epimerisation protocol264 
 
 This epimerisation protocol was applied to dihydropyran 104.2, which on treatment 
with potassium tert-butoxide at 0 °C in THF for 2 h gave epimer 104.3 in 96% yield (Scheme 127).  
 
 
Scheme 127. Epimerization of dihydropyran 104.2 
 
 nOe analysis of dihydropyran 104.3 confirmed that epimerization had occured (when 
compared to the nOe of dihydropyran 104.2), with the key proton-proton interactions that 
would indicate a syn-geometric relationship having disappeared (Figure 39). The analytical data 
for 104.3 also matches that for the minor diastereomer originally synthesised previously (see 
Scheme 104). 
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Figure 39. NOESY NMR of dihydropyran 104.3 
 
 To demonstrate that the epimerization of this stereocentre does not affect the 
stereoselectivity of subsequent reactions, dihydropyran 104.3 was epoxidised to give epoxide 
128.1 in 96% yield as the sole diastereomer. This result shows that the previous diastereoslective 
hydroboration/hydrodenation/dihydroxylation methods developed for dihydropyran 104.2 
should also be applicable to dihydropyran 104.3 (Scheme 128).  
    
 
Scheme 128. Epoxidation of dihydropyran 104.1 
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 To further understand this epimerization reaction a deuterium experiment was 
performed. The reaction was conducted in deuterated THF with KOtBu at room temperature, 
after 5 min a small amount of D2O was then added to the NMR tube, with 1H NMR spectroscopic 
analysis showing a 20% deuterium incorporation (Scheme 129). This results suggests that the 
epimerization proceeds through deprotonation at the ester proton, it also suggests that the 
deprotonation event of the epimerized dihydropyran 104.3 occurs at a much slower rate than 
for dihydropyran 104.2, as shown by the low deuterium incorporation.   
 
 
Scheme 129. Deuterium incorporation experiment for dihydropyran 104.2  
7.451 Computational Studies on Epimerization of Dihydropyran 104.2 
 In an attempt to fully understand how this epimerization process is able to achieve 
complete stereocentre inversion, density functional theory (DFT) computational studies on the 
two diastereomers 104.2 and 104.3 were undertaken.  
All calculations were performed using the Gaussian09 suite of codes (revision D.01).287 
Geometries were fully optimised without any symmetry or geometry constraints. The 
calculations were all carried out using a temperature of 298 K and solvent effects in 
tetrahydrofuran considered using conductor-like polarisable continuum model (CPCM). The 
nature of all the stationary points as minima were verified by calculations of the vibrational 
frequency spectrum. Free energies were calculated within the harmonic approximation for 
vibrational frequencies. 
Figure 40 shows a summary of the data gained from these computational analysis, with 
the Gibbs free energy of pyran 104.3 set to zero so that a comparison to the other three 
conformers can be made. As can be seen both the low energy syn-conformers of dihydropyran 
104.2 possess Gibbs free energies significantly higher than the epimerized product 104.3 (Figure 
41).  
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Figure 40. Computed Gibbs free energies at the 6-311++G(d, p)/B3LYP/cpcm=THF/298 K level of theory 
for the epimerization of dihydropyran 104.2 
 
 
Figure 41. Lowest energy conformers of dihydropyran 104.2 and 104.3  
7.5 Dihydropyran Analogue Synthesis  
 While the stereotetrad is present in a wide range of polyketide natural products, access 
to other motifs such as deoxy-1,3-methyl-methyl substitution would also be useful to access 
other types of polyketide natural product targets (Figure 42). Furthermore, access to this type 
of methodology would potentially allow for structure activity relationships (SAR) study to be 
performed to help decipher which structural elements in a natural product were responsible for 
their biological activity, by allowing facile access to non-natural analogues.   
 
104.3 104.2 
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Figure 42. Dihydropyran analogues 
7.51 Synthesis of Diene Analogues 
 In order to access these dihydropyran analogues the diene utilized in the hetero-Diels-
Alder methodology had to be altered. Diene 130.1 was first targeted as it could be accessed 
from aldehyde 94.2 which was an intermediate that had been generated previously on route to 
diene 96.1. Employing methyltriphenylphonsphonium bromide in the Wittig reaction of 94.2 
enabled the desired diene 130.1 to be prepared in 70% yield (Scheme 130).    
 
 
Scheme 130. Synthesis of diene 130.1 
 
 Wittig chemistry was also utilized for the synthesis of diene 131.2, with crotonaldehyde 
131.1 being reacted with (ethoxymethyl)triphenylphosphonium chloride under standard Wittig 
conditions to afford (E. E)-diene 131.2 in 75% yield (Scheme 131)  
 
 
Scheme 131. Synthesis of (E. E)-diene 131.2 
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7.52 Dihydropyran Analogues Synthesis  
 Dienes 130.1 and 131.2 were then subjected to the catalytic enantioselective hetero-
Diels-Alder conditions previously utilized for the synthesis of dihydropyran 104.2 in 99% ee. The 
HDA reaction of diene 130.1 proceeded in 68% yield with poor diastereoselectivity to afford an 
epimeric mixture of 132.1 and 132.2 in a ratio of 1:1. However, it was found that over time, this 
mixture readily epimerized to give a single diastereomer assigned as dihydropyran 132.2 in 68% 
yield and 76% ee (Scheme 132).  
 
 
Scheme 132. Synthesis of dihydropyran 132.2 
 
 The configuration of dihydropyran formed after epimerization was assigned as the anti-
diastereomer 132.2, from consideration of its nOe NMR spectrum. As shown in Figure 43, the 
key nOe interactions between Ha and He which would denote a syn relationship as if present in 
the nOe of dihydropyran 104.2 were not present, suggesting that the anti-diastereomer is the 
final product of this HDA/epimerisation protocol.  
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Figure 43. NOESY NMR of dihydropyran 132.2 
 
The HDA reaction of diene 131.2 proceeded with good diastereoselectivity to give a 
single diastereomer of dihydropyran 133.1 in 55% yield and 74% ee (Scheme 133). 
 
 
Scheme 133. Synthesis of dihydropyran 133.1 
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Once again the relative stereochemistry of this diastereomer was confirmed by nOe 
NMR with the key interactions between Ha, Hc and He confirming the syn geometry, and with 
the Jd,e coupling constant of 3.5 Hz being indicative of a syn-relationship.    
 
 
 
Figure 44. NOESY NMR of dihydropyran 133.1 
  
The ee’s of both dihydropyran 132.2 and 133.1 of 76% and 74% ee were relatively low 
when compared to the parent dihydropyran 104.2, which was formed in 99% ee. It is believed 
that with further optimization the ee of both these reactions should be able to be increased to 
a level much closer to that of dihydropyran 104.2, however, due to time constraints this 
optimisation study will be conducted in the near future.     
7.53 Dihydropyran Analogues Derivatisation  
 As with the original chiral dihydropyran template 104.2, it was hoped that all 
subsequent derivatization reactions performed on analogues 132.2 and 133.1 would proceed 
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stereoselectively to afford a single diastereomer. Hydroboration of dihydropyran 132.2 
proceeded well to afford a single diastereomer in 65% yield (Scheme 134). Surprisingly upon 
further characterisation is appeared that the syn-diastereomer had been formed. This would 
suggest that hydroboration had occurred in conjunction with an epimerisation event. This could 
potentially occur in solution either before borane addition, or after the hydroboration step had 
occurred. It is believed to be the first option, where epimerisation of dihydropyran 132.2 occurs 
before borane addition. This is due to evidence of unreacted dihydropyran 132.1 being present 
in the crude 1H NMR (Scheme 134).          
 
 
Scheme 134. Hydroboration of dihydropyran 132.2 
 
 Examination of the nOe NMR confirms the syn relative stereochemistry, with key 
interactions between Ha and Hf showing that these two protons are present on the same face 
of pyran ring, confirming their syn-relationship. Importantly, as well Hc shows no interactions 
with Ha, Hb and crucially Hf, confirming its anti-relationship to other protons (Figure 45). 
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Figure 45. NOESY of pyran 134.1 
 
 Pyran 134.1 contains a sterotriad with syn-syn relative stereochemistry, which contains 
the same relative stereochemistry as that present in the recently discovered marine polyhydroxy 
polyketides nahuoic acid D and nahuoic acid E (Figure 46).288  
 
Figure 46. Nahuoic acid D and nahuoic acid E288 
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 Epoxidation of dihydropyran 132.2, using the Venturello conditions used previously, 
resulted in a mixture of syn-epoxide 135.1 and anti-epoxide 135.2. The two epoxides were 
produced in 80% yield and a diastereomeric ratio of 85:15 in favour of the syn-epoxide 135.1 
(Scheme 135).    
 
 
Scheme 135. Epoxidation of dihydropyran 132.2 
 
Examination of the nOe NMR confirmed the all syn relative stereochemistry of the major 
diastereomer, with key interactions between Ha and He showing that these two protons are 
present on the same face of the pyran ring, thus confirming their syn-relationship (Figure 47). 
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Figure 47. NOESY of epoxide 135.2 
 
Hydroboration of dihydropyran 133.1 led to the formation of two regioisomers pyran 
136.1 and pyran 136.2 in a 3:2 ratio in an overall yield of 75% (Scheme 136). This loss of 
regiocontrol is due to the absence of the alkene methyl groups that were present in 
dihydropyrans 104.2 and 132.2. Pyran 136.1 was formed as a single diastereomer, showing that 
the directive nature of the cyclic system is still effective. However, the minor pyran 136.2 was 
formed as a 1:1 mixture of diastereomers (unassigned), as evidenced by doubling of the peaks 
present in both the 1H and 13C NMR spectra.        
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Scheme 136. Hydroboration of pyran 133.1 
 
 COSY NMR was used to help identify the structure of pyran 136.1, which revealed that 
Hb1 and Hb2 showed coupling to each other and with Hc (the hydroxyl proton) (Figure 48).   
 
 
 
 
 
Figure 48. COSY NMR of pyran 136.1 
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7.6 Further Dihydropyran Derivatization  
 By gaining access to enantiomerically enriched dihydropyrans 104.2, 132.2 and 133.1 as 
the well as their subsequent derivatives, methodology has been developed to allow for rapid 
derivatisation of chiral templates with potential for the synthesis of polyketides. These 
dihydropyran compounds possess bi-functional aldehyde and ester groups at their termini, 
which can potentially be functionalised in a selective manner. This would potentially allow 
access to the “plug and play” approach originally devised at the outset of this project, with a 
representative range of transformations that could be utilised to achieve this aim presented in 
Scheme 137.   
 Hydrolytic cleavage of the masked acetal of dihydropyran 104.2 would give access to a 
“sugar” analogue 137.1, that would exist in both its cyclic hemi-acetal form 137.1 and also as its 
acyclic aldehyde 137.2. This aldehyde represents a highly reactive functional handle that can be 
derivatized in a number of ways, such as through the use of Wittig olefination chemistry to give 
diene 137.3. Another method of utilising this aldehyde functionality would be through titanium 
salen catalysed asymmetric synthesis of cyanohydrin ethyl carbonates,289 which would 
potentially give access to β-aminoalcohols and γ-azido-α,β-unsaturated nitriles. This aldehyde 
functionality could also be utilised to carry out boron or silicon allylation chemistry to allow 
access homoallylic alcohol 137.5, which are a highly prized class of synthetic intermediates for 
the construction of a wide variety of complex polyketides.290 Sugar compound 137.1 can also be 
utilised as a synthetic reagent in its own right, utilising carbohydrate chemistry to form glycosidic 
bonds to natural sugars, to give rise to potentially exciting polyketide-sugar hybrids 137.6. 
 The ester functional handle present in dihydropyran 104.2 can also be utilised in a 
number of ways. Global reduction would give rise to primary alcohol 137.7, with activation as 
its mesylate/tosylate (or as a halogen via Appel reaction), enabling a wide range of nucleophiles 
to be introduced into the compound. However, use of a mild selective reducing agent such as 
lithium diisobutyl-tert-butoxyaluminium hydride (LDBBA) which is formed through a 
combination of tBuOH, nBuLi and DIBAL-H, might allow access to aldehyde 137.8, which could 
then be subjected to the wide range of derivatization chemistries available for aldehyde 137.2. 
A further more complex elaboration of dihydropyran 104.2 would be to utilise the chemistry 
developed for epimerization of pyran 104.2. Therefore, deprotonation of pyran 104.2 at its C6-
position would afford an enolate, which could be alkylated with a range of electrophiles. 
Hydrolysis of the ester functionality to afford carboxylic acid 137.9, would then allow for 
implementation of photoredox decarboxylation chemistry. Decarboxylation of carboxylic acid 
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137.9 through irradiation of an Ir/Ni catalytic system, would potentially afford advanced pyran 
intermediates 137.10 containing different side-chains with high levels of diastereocontrol. The 
stereoselectivity of this process would be controlled by the formation of an antiperiplanar 
radical intermediate preferentially adopting a trans-diaxial orientation due to the anomeric 
effect. While the example shown replaces the carboxylic acid with a proton, this could also be 
used as an opportunity to introduce a wide range of new functionality. For example, recent 
reports by MacMillan and Waser have demonstrated how photoredox chemistry can be used to 
replace carboxylic acids groups with alkene and alkynyl groups,291, 292 which would represent a 
highly efficient way of joining together fragments enroute to a complex natural product (Scheme 
137).     
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Scheme 137. Potential synthetic elaborations of dihydropyran 104.2 
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 As proof of concept that these dihydropyrans could be further elaborated, it was 
decided to pick two of these examples shown for the further derivatization of dihydropyran 
104.2. It was decided to first investigate utilization of the masked aldehyde functionality, of 
104.2 through a Wittig-olefination reaction. Treatment of dihydropyran 104.2 with mild acid at 
50 °C led to formation of sugar-like intermediate, which exists in both its cyclic lactol 137.1 form 
and an acyclic aldehyde 137.2. The aldehyde group was then intercepted by treatment with 
phosphonium ylide 138.1 to give diene 138.2 in a 70% yield over the two steps. Diene 138.2 was 
formed as an inseparable 2:1 ratio of E:Z geometric isomers, which contained orthogonally 
addressable ester groups that would allow for selective derivatisation (Scheme 138). 
 
 
Scheme 138. Exploiting the masked aldehyde functionality of 104.2 for the synthesis of diene 138.4 
 
 It was hoped that diene 138.2 would be set up, to allow for the utilization of Evans 
methodology for the diastereoselective synthesis of a protected syn 1,3-Diols.293 The Evans 
methodology proceeds through formation of an acetal alkoxide which is then able to act as 
tethered oxygen nucleophile. This nucleophile is then able to undergo diastereoselective 
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intramolecular conjugate addition to a Michael acceptor in a stereoselective manner to afford a 
benzylidene acetal 139.2 (Scheme 139). This methodology represents a potentially exciting way 
of installing a hydroxyl group (through subsequent hydrolysis of the benzylidene acetal) in a 
stereoselective manner. 
 
Scheme 139. Evans methodology for diastereoselective synthesis of protected syn 1,3-diols.293   
 
 It was hoped that this Evans’ methodology could be applied to vinylogous diene 138.2, 
where it was proposed that this conjugated system would also be able to undergo a similar 
intramolecular conjugate addition. However, this reaction proved to be unsuccessful (Scheme 
140), which is believed to be due to the fact that the distal alkene is not sufficiently conjugated, 
and may possess more “normal” electron rich alkene character. Evidence of this can be seen 
when similar diene systems are subjected to dihydroxylation conditions, with only the remote 
alkene group undergoing dihydroxylation.294 It is hoped that with more investigation this 
methodology could be applied to diene 138.2, however, due to time constraints this was beyond 
the current scope of this thesis.  
 
Scheme 140. Unsuccessful attempt at employing Evans methodology for the diastereoselective synthesis 
of protected syn 1,3-diols 
 
 Finally, as a method of showing the utility of the ester functionality it was decided to 
perform a global reduction, and then demonstrated that the resultant alcohol could be activated 
for further derivatisation. Reduction of ester 104.2 through treatment with LiAlH4 afforded 
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alcohol 137.7 in 95% yield, leaving the hemi-acetal and alkene functionality untouched. This 
alcohol presents an excellent intermediate for further elaboration, via its corresponding tosylate 
141.1, which was prepared in 82% yield using standard (Scheme 141). Tosylate 141.1 is a key 
compound to demonstrate how these chiral building blocks could be implemented into a 
synthetic route, since it can be reacted with a range of nucleophiles to provide advanced 
intermediates for polyketide synthesis.     
 
 
Scheme 141. Route to exploiting the ester functionality  
8.0 Future Work  
 There are a number of ways in which this research project could be taken forward. An 
obvious choice would be to identify a late stage synthetic intermediate of a polyketide natural 
product and conduct a formal synthesis where the methodology developed leads to a significant 
reduction in step count and a more efficient synthesis. However, an equally important 
application where this methodology could have a large impact is in the field of precursor 
directed biosynthesis.295-298 For example, the Khosla and Cane groups have conducted extensive 
research into precursor-directed biosynthesis of 16-membered macrolides by the erythromycin 
polyketide synthase. They were able to utilize a range of SNAC thioester precursors (such as 
alkene 142.1) as substrates for deoxyerythronolide B synthase (DEBS) a polyketide synthase. The 
synthase was shown to be able to use these substrates to construct a series of macrolides. By 
varying the diastereomer and functionality of the substrate used, a range of natural and non-
natural polyketides could be synthesised (Scheme 142).295-298        
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Scheme 142. Precursor-directed biosynthesis of macrolide 142.2 
 
 By utilizing the methodology developed throughout this project, quick and efficient 
access to this type of substrate could be achieved, that would allow variation of the functionality 
and diastereoselectivity incorporated into the corresponding macrolide. Shown below is a 
proposed route for the synthesis of SNAC thioester precursor 142.1. Substitution of the tosyl 
group of pyran 142.1 with a carbon nucleophile (e.g. Me2CuLi) could then afford alkene 143.1. 
Hemi-acetal formation, followed by oxidation would generate lactone 143.3, which if treated 
with N-Acetylcysteamine 143.4 would generate thioester 142.1 as a precursor for feeding 
studies (Scheme 143).   
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Scheme 143. Proposed route to biosynthetic precursor 142.1 
 
Further development of diene synthesis might also be considered, with a potential route 
to attempt to utilise flow technology shown in Scheme 144. For example, treatment of 
propionaldehyde 99.1 with a solid-supported base ‘in-flow’ should generate an enolate species 
144.1 that will be flowed into the stream of another aldehyde (shown propionaldehyde 99.1) to 
afford a homo-aldol product 144.2 that could then be dehydrated via contact with base to afford 
an enone 98.1, that could be reacted with EtOH/H+ to afford diene 96.1 (Scheme 144).  
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Scheme 144. Proposed “in flow” diene synthesis 
9.0 Conclusion 
 A potential route towards the synthesis of a library of building blocks for the synthesis 
of polyketide natural products has been presented. Two reliable synthetic routes to multigram 
quantities of substituted 1-alkoxy dienes have been established. The first of these approaches 
utilises a non-aromatic Vilsmeier reaction, followed by Wittig chemistry to construct the 
conjugated diene. The second more efficient route involves acetal formation, followed by base 
facilitated elimination resulting in diene formation.      
 
 
Scheme 145. Diene synthesis 
 
 These dienes have been shown to be active in HDA chemistry with the reaction 
proceeding with good enantiomeric and diastereoselective control around the dihydropyran 
ring, using a titanium-BINOL catalyst developed by Mikami et al. 
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Scheme 146. Enantioselective synthesis of dihydropyran 18.2 
 
 A series of stereoselective derivatisation reactions were then conducted on pyran 104.2 
including, hydroboration, hydrogenation, epoxidation, dihydroxylation and epimerization to 
afford a range of complex enantiomerically pure pyran based building blocks, which are ideally 
suited for the synthesis of polyketide natural products through a “plug and play” approach. All 
the performed derivatization reactions proceed with good selectively producing a single 
diastereomer in good yield. This represents a highly efficient route to the generation of up to 
five contiguous stereocentres that are a common feature of polyketide natural products 
(Scheme 147).  
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Scheme 147. Range of diastereoselective derivatisation reactions of dihydropyran 104.2 
 
Methodology has also been developed to allow further elaboration of the pyran 
structure through exploiting the masked aldehyde character of the hemi-acetal, and through 
utilization of the ester functionality.    
 This HDA chemistry was also applied to two other diene analogues which gave rise to a 
new series of mono-methyldihydropyrans 132.2 and 133.1, which differ in position of their 
methyl groups around the ring. By gaining access to analogues of this motif, through substitution 
of the methyl groups for protons, a greater number of potential natural product targets can 
potentially be reached. Furthermore, this approach could potentially allow for structure activity 
relationship (SAR) studies to be performed, to help decipher which structural elements within a 
natural product are responsible for its biological activity, by allowing access to non-natural 
isomers.   
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Figure 49. Dihydropyran analogues  
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Experimental 
General conditions 
 Infrared spectra (4000 cm-1 to 650 cm-1) were recorded on a Perkin Elmer Spectrum 100 
FT-IR spectrometer using a Universal ATR accessory for sampling. The machine has internal 
calibration and only selected peaks are quoted in ν (wavenumbers, cm-1). 
 Proton magnetic resonance spectra were recorded at 300.22 MHz on a Bruker Avance 
300 spectrometer unless otherwise stated. Chemical shifts (δH) are quoted in parts per million 
(ppm) and are referenced to the residual solvent peak. The multiplicities and general 
assignments of spectroscopic data are denoted as: singlet (s), doublet (d), triplet (t), quartet (q), 
doublet of doublets (dd), triplet of doublets (td), quartet of doublets (qd), triplet of triplets (tt), 
multiplet (m), aromatic (Ar), and apparent (app.). Coupling constants (J) are quoted to the 
nearest 0.1 Hz. Carbon magnetic resonance spectra were recorded at 75.5 MHz on a Bruker 
Avance 300 spectrometer unless otherwise stated. Chemical shifts (δC) are quoted in parts per 
million (ppm) and are referenced to the residual solvent peak. Coupling constants (J) are quoted 
to the nearest 0.1 Hz. 
 Mass spectra were recorded on a Bruker Daltonics micrOTOF electrospray time-of-flight 
(ESITOF) mass spectrometer. Samples were introduced either by syringe pump or flow injection 
using an auto-sampler. Samples were diluted in either methanol or acetonitrile. 
 All capillary melting point determinations were carried out using Büchi 535 melting point 
apparatus and reported to the nearest degree Celsius (° C). 
 Analytical thin layer chromatography was carried out using commercially available 
polyethylene backed plates coated with Merck Kieselgel 60 GF254. Plates were visualised under 
UV light (at 254 nm) or by staining with potassium permanganate, p-anisaldehyde or 
phosphomolybdic acid followed by heating. Flash chromatography was performed under 
medium pressure using Merck 60 H silica gel (35-75 μm). Samples were loaded as saturated 
solutions in an appropriate solvent. 
 Reactions requiring anhydrous conditions were performed under nitrogen in oven-dried 
apparatus, which was allowed to cool under nitrogen prior to use. Anhydrous solvents were 
obtained by passing through anhydrous alumina columns using an Innovative Technology Inc. 
PS-400-7 solvent purification system. Petrol refers to the fraction of petroleum ether boiling at 
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40-60 °C. Ether refers to diethyl ether. Hexanes refer to the hexane fraction of petroleum. 
Solvents were evaporated on a Büchi Rotorvapor. 
 All commercially available compounds were used as obtained from the chemical 
suppliers, unless otherwise stated. All temperatures quoted are external. 
General Procedures General Procedure A: N-Acetylation of amines 
Amine (1.0 mmol) was added to phenylmethylene diacetate 7.2 (0.291 g, 1.5 mmol) the 
reaction was stirred at 70 °C for 16 h. The crude reaction mixture was then directly purified by 
column chromatography to give the isolated acetamide. Where the reaction mixture was not 
homogeneous 2 mL of EtOAc was added at the start of the reaction. 
General Procedure B: O-Acetylation of alcohols 
Alcohol (1.0 mmol) was added to phenylmethylene diacetate 7.2 (0.291 g, 1.5 mmol) 
and K2CO3 (0.270 g, 2.0 mmol) the reaction was stirred at 80 °C for 16 h. the crude reaction 
mixture was then directly purified by column chromatography to give the isolated ester. Where 
the alcohol was a solid at 60 °C 2 mL of toluene was added at the start of the reaction. 
General Procedure C: Synthesis of acylation reagents  
para-Toluenesulphonic acid (mono hydrate) (0.18 g, 0.94 mmol) was added to a mixture 
of benzladehyde (1.0 g, 9.4 mmol) and anhydride (18.8 mmol) at rt. The reaction was stirred for 
12 h and then diluted with Et2O (50 mL) and washed with saturated Na2CO3 (3 x 20 mL). The 
organics were dried (MgSO4) and concentrated in vacuo to give the title compound which was 
used in subsequent steps without further purification unless otherwise stated.  
General Procedure D: N-acylation of amines  
Amine (1.0 mmol) was added to the acylation reagent (1.5 mmol) the reaction was 
stirred at 70 °C for 16 h. the crude reaction mixture was then directly purified by column 
chromatography to give the isolated amide.  
General Procedure E: O-acylation of alcohols  
Alcohol (1.0 mmol) was added to the acylation reagent (1.5 mmol) and K2CO3 (0.270 g, 
2.0 mmol). The reaction was stirred at 90 °C for 16 h. The crude reaction mixture was then 
directly purified by column chromatography to give the isolated ester.  
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General Procedure F: N-formylation of amines  
Amine (2.0 mmol) was added to (Formyloxy)(phenyl)methyl acetate 44.2 (0.582 g, 3.0 
mmol), the reaction was stirred at rt for 1 h. The crude reaction mixture was then directly 
purified by column chromatography to give the isolated formamide. Where the reaction mixture 
was not homogeneous 2 mL of EtOAc was added at the start of the reaction. 
General Procedure G: N-formylation of α-amino acids 
(Formyloxy)(phenyl)methyl acetate 44.2 (0.291 g, 1.5 mmol) was added to a mixture of 
amino acid (1.0 mmol) and NaHCO3 in H2O (4 mL). The reaction was stirred at rt for 16 h. The 
reaction mixture when then made acidic with 1 M HCl and extracted with CH2Cl2 (3x 10 mL), the 
organics were combined, dried (MgSO4) and concentrated in vacuo. The residue was then 
purified via recrystallization with EtOAc and petroleum ether to give the isolated formyl 
carboxylic acid. 
General Procedure H: O-formylation of alcohols   
Alcohol (1.0 mmol) was added to (Formyloxy)(phenyl)methyl acetate  44.2 (0.291 g, 1.5 
mmol) and NaHCO3 (0.168 g, 2.0 mmol), the reaction was stirred at 60 °C for 16 h. The crude 
reaction mixture was then directly purified by column chromatography to give the isolated 
formate ester. Where the alcohol was a solid at 60 °C, 2 mL of EtOAc was added at the start of 
the reaction. 
General Procedure I: Acetal synthesis from 1,2- and 1,3-diols   
Diol (1.0 mmol) and acetic acid (0.65 μL, 0.01 mmol) were added to phenylmethylene 
diacetate 7.2 (0.582 g, 3.0 mmol) in MeCN (3 mL) and heated to 40 °C for 12 h. The crude reaction 
mixture was concentrated under vacuum and the resulting residue was purified by column 
chromatography to give the isolated acetal.    
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Phenylmethylene diacetate 7.2 
 
General procedure C was followed to afford the title compound as a clear oil in 98% 
yield (1.92 g, 9.21 mmol). 1H NMR (300 MHz, CDCl3) δ 7.7 (s, 1H, CH(OAc)2), 7.6 – 7.5 (m, 2H, 
ArH), 7.5 – 7.4 (m, 3H. ArH), 2.1 (s, 6H, 2 x CH3). 13C NMR (75 MHz, CDCl3) δ 169.0, 135.6, 129.9, 
128.8, 126.8, 89.8, 21.0. I.R (thinfilm) ν max (cm-1): 2981 (ArC-H), 1746 (C=O); HRMS (ESI): m/z 
calculated for C11H12O4: requires: 231.0633 for [M+Na]+; found: 231.0683. 
N-Benzylacetamide 34a 
 
General procedure A was followed. Eluent 30% EtOAc in CH2Cl2 the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a cream solid in 86% yield (0.128 g, 0.86 mmol). 1H NMR (300 MHz, CDCl3); δ 
7.4 – 7.2 (m, 5H, ArH), 5.9 (s, 1H, NH), 4.4 (d, J = 5.7 Hz, 2H, CH2), 2.0 (s, 3H, CH3). 13C NMR (75 
MHz, CDCl3) δ 170.0, 138.3, 128.8, 128.0, 127.7, 43.9, 23.4. 
Analytical data in accordance with literature.299 
N-(pyridin-4-ylmethyl)acetamide 34b 
 
General procedure A was followed. Eluent 30% EtOAc and 1% NEt3 in CH2Cl2 the fractions 
containing product were combined and the solvent was evaporated under reduced pressure to 
give the title compound as a orange oil in 84% yield (0.126 g, 0.84 mmol). 1H NMR (300 MHz, 
CDCl3) δ 8.6 – 8.5 (m, 2H, ArH), 7.2 – 7.1 (m, 2H, ArH), 6.1 (s, 1H, NH), 4.4 (d, J = 6.1 Hz, 2H, CH2), 
2.1 (s, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 170.4, 150.1, 147.5, 122.4, 42.6, 23.3. 
Analytical data in accordance with literature.1 
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N-(2-(1H-indol-3-yl)ethyl)acetamide 34c 
 
General procedure A was followed. Eluent 100% EtOAc, the fractions containing product 
were combined and the solvent was evaporated under reduced pressure to give the title 
compound as a pale brown solid in 62% yield (0.125 g, 0.62 mmol). 1H NMR (300 MHz, CDCl3) δ 
8.2 (s, 1H, NH), 7.6 (ddt, J = 7.8, 1.5, 0.8 Hz, 1H, ArH), 7.4 (dt, J = 8.1, 1.0 Hz, 1H, ArH), 7.2 (ddd, 
J = 8.2, 7.0, 1.3 Hz, 1H, ArH), 7.1 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H, ArH), 7.1 – 7.0 (m, 1H, ArH), 5.5 (s, 
1H, NH), 3.6 (q, J = 6.5 Hz, 2H, CH2CH2NH), 3.0 (td, J = 6.7, 0.9 Hz, 2H, CH2CH2NH), 1.9 (s, 3H, CH3). 
13C NMR (75 MHz, CDCl3) δ 170.2, 136.5, 127.5, 122.4, 122.2, 119.7, 118.8, 113.1, 111.4, 77.4, 
39.9, 25.4, 23.6. 
Analytical data in accordance with literature.300 
N-Benzhydrylacetamide 34d 
 
General procedure A was followed. Eluent 20% EtOAc in CH2Cl2 the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as crystalline white solid in 70% yield (0.158 g, 0.70 mmol). 1H NMR (300 MHz, 
CDCl3) δ 7.3 (qt, J = 6.2, 1.8 Hz, 5H, ArH), 7.3 (s, 5H, ArH), 6.3 (d, J = 8.0 Hz, 1H, CH), 6.0 (s, 1H, 
NH), 2.1 (s, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 169.2, 141.6, 128.8, 127.6, 127.5, 57.1, 23.6. 
Analytical data in accordance with literature.301 
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N-Phenylacetamide 34e 
 
General procedure A was followed. Eluent 20% EtOAc in CH2Cl2 the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a pale yellow solid in 68% yield (0.92 g, 0.68 mmol). 1H NMR (300 MHz, CDCl3) 
δ 7.5 – 7.5 (m, 2H, ArH), 7.3 (t, J = 7.9 Hz, 2H, ArH), 7.2 – 7.1 (m, 1H, ArH), 2.2 (s, 3H, CH3). 13C 
NMR (75 MHz, CDCl3) δ 168.4, 138.0, 129.2, 124.5, 119.9, 24.8. 
Analytical data in accordance with literature.299 
N-methyl-N-phenylacetamide 34f 
 
General procedure A was followed. Eluent 30% EtOAc in CH2Cl2 the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a pale green solid in 60% yield (0.089 g, 0.60 mmol). 1H NMR (300 MHz, CDCl3) 
δ 7.4 (dd, J = 8.3, 6.5 Hz, 2H, ArH), 7.4 – 7.3 (m, 1H, ArH), 7.2 – 7.1 (m, 2H, ArH), 3.3 (s, 3H, NCH3), 
1.9 (s, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 170.7, 144.7, 129.9, 127.8, 127.2, 37.3, 22.6. 
Analytical data in accordance with literature.302 
Methyl 4-acetamidobenzoate 34g 
 
General procedure A was followed. Eluent 30% EtOAc in CH2Cl2 the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a pale yellow solid in 65% yield (0.126 g, 0.65 mmol). 1H NMR (300 MHz, CDCl3) 
δ 8.1 – 7.9 (m, 2H, ArH), 7.6 (d, J = 8.4 Hz, 2H, ArH), 7.4 (s, 1H, NH), 3.9 (s, 3H, CO2CH3), 2.2 (s, 
3H, CH3). 13C NMR (75 MHz, CDCl3) δ 168.6, 166.7, 142.2, 131.0, 125.7, 118.8, 52.2, 25.0. 
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Analytical data in accordance with literature.303 
N,N-dibutylacetamide 34h 
 
General procedure A was followed. Eluent 30% EtOAc in CH2Cl2 the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a clear oil in 90% yield (0.154 g, 0.90 mmol). 1H NMR (300 MHz, CDCl3) δ 3.3 
– 3.2 (m, 2H, NCH2), 3.2 – 3.2 (m, 2H, NCH2), 2.1 (s, 3H, CH3), 1.5 (dddd, J = 15.2, 9.2, 7.8, 5.4 Hz, 
4H, CH2CH2CH2), 1.3 (hept, J = 7.4 Hz, 4H, CH2CH2CH3), 0.9 (dt, J = 10.0, 7.3 Hz, 6H, 2x CH2CH3). 
13C NMR (75 MHz, CDCl3) δ 170.2, 48.7, 45.6, 31.1, 30.0, 21.7, 20.4, 20.2, 14.0, 14.0. 
Analytical data in accordance with literature.304  
1-(piperidin-1-yl)ethanone 34i 
 
General procedure A was followed. Eluent 20% EtOAc in CH2Cl2 the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a yellow oil in 95% yield (0.121 g, 0.95 mmol). 1H NMR (300 MHz, CDCl3) δ 3.6 
– 3.5 (m, 2H, NCHAX), 3.4 (dd, J = 6.2, 4.6 Hz, 2H, NCHEQ), 2.1 (s, 3H, CH3), 1.7 – 1.4 (m, 6H, 
CH2CH2CH2). 13C NMR (75 MHz, CDCl3) δ 168.9, 47.6, 42.6, 26.6, 25.6, 24.6, 21.7. 
Analytical data in accordance with literature.299 
1-(4-methylpiperazin-1-yl)ethanone 34j 
 
General procedure A was followed. Eluent 30% EtOAc in CH2Cl2 the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a yellow in 92% yield (0.131 g, 0.92 mmol). 1H NMR (300 MHz, CDCl3) δ 3.7 – 
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3.6 (m, 2H, AcNCHAX), 3.5 – 3.4 (m, 2H, AcNCHEQ), 2.4 (dt, J = 10.0, 5.2 Hz, 4H, CH2NCH3), 2.3 (s, 
3H, CH2NCH3), 2.1 (s, 3H, (C=O)CH3). 13C NMR (75 MHz, CDCl3) δ 169.1, 55.2, 54.7, 46.3, 46.1, 
41.4, 21.5. 
Analytical data in accordance with literature.305 
N,N-diallylacetamide 34k 
 
General procedure A was followed. Eluent 30% EtOAc in CH2Cl2 the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a yellow oil in 88% yield (0.122 g, 0.88 mmol). 1H NMR (300 MHz, CDCl3) δ 5.9 
– 5.6 (m, 2H, CH=CH2), 5.3 – 5.0 (m, 4H, CH=CH2), 4.0 (dt, J = 6.1, 1.4 Hz, 2H, NCHaHb), 3.9 (dt, J = 
4.9, 1.8 Hz, 2H, NCHaHb), 2.1 (s, 3H, CH3).13C NMR (75 MHz, CDCl3) δ 170.8, 133.4, 132.7, 117.4, 
116.7, 50.1, 47.9, 21.5. 
Analytical data in accordance with literature.304 
Benzyl acetate 39a 
 
General procedure B was followed. Eluent 5% EtOAc in pet ether the fractions 
containing product were combined and the solvent was evaporated under reduced pressure to 
give the title compound as a clear oil in 90% yield (0.135 g, 0.90 mmol). 1H NMR (300 MHz, CDCl3) 
δ 7.5 – 7.3 (m, 5H, ArH), 5.1 (s, 2H, CH2Ph), 2.1 (s, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 171.1, 
136.0, 128.7, 128.4, 66.5, 21.2. 
Analytical data in accordance with literature.306 
Pyridin-2-ylmethyl acetate 39b 
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General procedure B was followed. Eluent 5% EtOAc in pet ether the fractions 
containing product were combined and the solvent was evaporated under reduced pressure to 
give the title compound as a clear oil in 70% yield (0.105 g, 0.70 mmol). 1H NMR (300 MHz, CDCl3) 
δ 8.6 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H, ArH), 7.7 (td, J = 7.7, 1.8 Hz, 1H, ArH), 7.3 (d, J = 7.8 Hz, 1H, 
ArH), 7.3 (s, 1H, ArH), 5.2 (s, 2H, CH2), 2.2 (s, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 170.8, 155.8, 
149.7, 136.9, 123.0, 122.0, 67.0, 21.1. 
Analytical data in accordance with literature.307 
2-Bromophenethyl acetate 39c 
 
General procedure B was followed. Eluent 5% EtOAc in pet ether the fractions 
containing product were combined and the solvent was evaporated under reduced pressure to 
give the title compound as a clear oil in 76% yield (0.184 g, 0.76 mmol). 1H NMR (300 MHz, CDCl3) 
δ 7.6 (dt, J = 7.9, 0.9 Hz, 1H, ArH), 7.3 – 7.2 (m, 2H, ArH), 7.1 (ddd, J = 7.9, 5.1, 4.1 Hz, 1H, ArH), 
4.3 (t, J = 7.0 Hz, 2H, CH2OC(O)CH3), 3.1 (t, J = 7.0 Hz, 2H, ArCH2), 2.0 (s, 3H, CH3). 13C NMR (75 
MHz, CDCl3) δ 171.1, 137.3, 133.1, 131.2, 128.5, 127.6, 124.8, 63.5, 35.4, 21.1. 
Analytical data in accordance with literature.308 
[1,1'-biphenyl]-4-ylmethyl acetate 39d 
 
General procedure B was followed. Eluent 5% EtOAc in pet ether the fractions 
containing product were combined and the solvent was evaporated under reduced pressure to 
give the title compound as a white solid in 68% yield (0.153 g, 0.68 mmol). 1H NMR (300 MHz, 
CDCl3) δ 7.6 – 7.6 (m, 4H, ArH), 7.5 – 7.4 (m, 4H, ArH), 7.4 – 7.3 (m, 1H, ArH), 5.2 (s, 2H, CH2), 2.1 
(s, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 171.1, 141.4, 140.8, 135.0, 128.9, 127.6, 127.5, 127.3, 
66.2, 21.2. 
Analytical data in accordance with literature.309 
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3,7-Dimethyloct-6-en-1-yl acetate 39e 
 
General procedure B was followed. Eluent 5% EtOAc in pet ether the fractions 
containing product were combined and the solvent was evaporated under reduced pressure to 
give the title compound as a clear oil in 90% yield (0.178 g, 0.90 mmol). 1H NMR (300 MHz, CDCl3) 
δ 5.1 (tdt, J = 5.8, 3.0, 1.5 Hz, 1H, C=CH), 4.2 – 4.0 (m, 2H, CH2OAc), 2.0 (s, 3H, (C=O)CH3), 2.0 (dt, 
J = 15.0, 7.7 Hz, 2H, CH2), 1.7 – 1.6 (m, 4H, CH2), 1.6 (d, J = 1.4 Hz, 3H,CH3(C)CH3), 1.6 – 1.3 (m, 
3H, CH3(C)CH3), 1.2 (dddd, J = 13.5, 9.1, 7.5, 6.2 Hz, 1H, (CHCH3), 0.9 (d, J = 6.4 Hz, 3H, CHCH3). 
13C NMR (75 MHz, CDCl3) δ 171.4, 131.5, 124.7, 63.2, 37.1, 35.5, 29.6, 25.9, 25.5, 21.2, 19.5, 17.8. 
Analytical data in accordance with literature.307 
(rac)-1-phenylethyl acetate 39f 
 
General procedure B was followed. Eluent 5% EtOAc in pet ether the fractions 
containing product were combined and the solvent was evaporated under reduced pressure to 
give the title compound as a pale yellow oil in 77% yield (0.126 g, 0.77 mmol). 1H NMR (300 MHz, 
CDCl3) δ 7.4 – 7.3 (m, 5H, ArH), 5.9 (q, J = 6.6 Hz, 1H, CH), 2.1 (s, 3H, C(O)CH3), 1.5 (d, J = 6.6 Hz, 
3H, CHCH3). 13C NMR (75 MHz, CDCl3) δ 170.5, 141.8, 128.6, 128.0, 126.2, 72.5, 22.4, 21.5. 
Analytical data in accordance with literature.310 
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(4aR,6S,7S,8R,8aS)-6-Methoxy-2-phenylhexahydropyrano[3,2-d][1,3]dioxine-7,8-diyl 
diacetate 39g 
 
(4aR,6S,7S,8S,8aR)-6-Methoxy-2-phenylhexahydropyrano[3,2-d][1,3]dioxine-7,8-diol 
(0.282 g, 1.0 mmol) was added to phenylmethylene diacetate (0.582 g, 3.0 mmol) and K2CO3 
(0.270 g, 2.0 mmol) the reaction was stirred at 90 °C for 16 h. The crude reaction mixture was 
then directly purified by column chromatography to give the title compound. Eluent 5% EtOAc 
in pet ether, the fractions containing product were combined and the solvent was evaporated 
under reduced pressure to give the title compound as a white solid in 65% yield (0.238 g, 0.65 
mmol). 1H NMR (300 MHz, CDCl3) δ 7.4 (qd, J = 5.4, 4.5, 1.9 Hz, 2H, ArH), 7.4 (dt, J = 4.6, 2.8 Hz, 
3H, ArH), 5.6 (t, J = 9.6 Hz, 1H, CHOCH3), 5.5 (s, 1H, PhCH), 5.0 – 4.8 (m, 2H, 2 x CHC(O)CH3), 4.3 
(dd, J = 10.1, 4.7 Hz, 1H, CH2CH(O)CH(O)), 3.9 (td, J = 9.9, 4.7 Hz, 1H, CH2CH(O)CH(O)), 3.8 (t, J = 
10.2 Hz, 1H, OCHaHbCHO), 3.6 (t, J = 9.6 Hz, 1H, OCHaHbCHO), 3.4 (s, 3H, OCH3), 2.1 (s, 3H, 
C(O)CH3), 2.1 (s, 3H, C(O)CH3). 13C NMR (75 MHz, CDCl3) δ 170.6, 169.9, 137.0, 129.2, 128.4, 
126.3, 101.7, 97.7, 79.3, 71.7, 69.1, 69.0, 62.4, 55.5, 21.0, 20.9.  
Analytical data in accordance with literature.311 
(3aR,5R,6S,6aR)-5-((R)-2,2-Dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyltetrahydrofuro[2,3-
d][1,3]dioxol-6-yl acetate 39h 
 
General procedure B was followed. Eluent 5% EtOAc in pet ether the fractions 
containing product were combined and the solvent was evaporated under reduced pressure to 
give the title compound as a white solid in 70% yield (0.21 g, 0.69 mmol). [α]D20 = -32 in CHCl3. 
1H NMR (300 MHz, Chloroform-d) δ 5.9 (d, J = 3.7 Hz, 1H, OCHO), 5.2 (d, J = 2.4 Hz, 1H, 
OCHCHOC(O)CH3), 4.5 (d, J = 3.7 Hz, 1H, OCHC(O)CH2), 4.3 – 4.2 (m, 2H, OCH(CHOCH2O)C(O)CH3 
and CHC(O)CH3), 4.1 (tdd, J = 10.7, 7.0, 3.3 Hz, 2H, OCH2CHO), 2.1 (s, 3H, CHC(O)CH3), 1.5 (s, 3H, 
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OCO(CH3aCH3b)), 1.4 (s, 3H, OCO(CH3aCH3b)), 1.3 (s, 3H, OCO(CH3aCH3b)), 1.3 (s, 3H, 
OCO(CH3aCH3b)). 13C NMR (75 MHz, CDCl3) δ 169.8, 112.4, 109.5, 105.1, 83.4, 79.8, 76.3, 72.5, 
67.3, 27.0, 26.8, 26.3, 25.4, 21.1. 
Analytical data in accordance with literature.312 
Cinnamyl acetate 39i 
 
General procedure B was followed. Eluent 5% EtOAc in pet ether the fractions 
containing product were combined and the solvent was evaporated under reduced pressure to 
give the title compound as a clear oil in 83% yield (0.146 g, 0.83 mmol). 1H NMR (300 MHz, CDCl3) 
δ 7.3 (s, 5H, ArH), 6.7 (dt, J = 15.9, 1.4 Hz, 1H, CH=CHCH2), 6.3 (dt, J = 15.9, 6.5 Hz, 1H, CH=CHCH2), 
4.7 (dd, J = 6.5, 1.4 Hz, 2H, CH=CHCH2), 2.1 (s, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 171.0, 136.3, 
134.4, 128.7, 128.2, 126.7, 123.3, 65.2, 21.2. 
Analytical data in accordance with literature.313 
(E)-3,7-dimethylocta-2,6-dien-1-yl acetate 39j 
 
General procedure B was followed. Eluent 5% EtOAc in pet ether the fractions 
containing product were combined and the solvent was evaporated under reduced pressure to 
give the title compound as a waxy white solid in 89% yield (0.174 g, 0.89 mmol).1H NMR (300 
MHz, CDCl3) δ 5.3 (tq, J = 7.2, 1.3 Hz, 1H, C=CHCH2O), 5.1 (tq, J = 5.5, 1.5 Hz, 1H, C=CHCH2), 4.6 
(d, J = 7.1 Hz, 2H, CH2OAc), 2.2 – 2.0 (m, 7H, 2 x CH2 and (C=O)CH3), 1.7 (dd, J = 5.9, 1.3 Hz, 6H, 
CH3(C)CH3), 1.6 (d, J = 1.4 Hz, 3H, CH2C(CH3)=CH). 13C NMR (75 MHz, CDCl3) δ 171.3, 142.5, 132.0, 
123.9, 118.3, 61.6, 39.7, 26.4, 25.8, 21.2, 17.8, 16.6. 
Analytical data in accordance with literature.307 
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(S)-(4-(prop-1-en-2-yl)cyclohex-1-en-1-yl)methyl acetate 39k 
 
General procedure B was followed. Eluent 5% EtOAc in pet ether the fractions 
containing product were combined and the solvent was evaporated under reduced pressure to 
give the title compound as a clear oil in 85% yield (0.165 g, 0.85 mmol). [α]D20 = -65.5 in CHCl3.  
1H NMR (300 MHz, CDCl3) δ 5.8 (dd, J = 4.6, 2.4 Hz, 1H, CH2C=CH), 4.8 – 4.7 (m, 2H, C=CH2), 4.5 
(d, J = 1.7 Hz, 2H, CH2OAc), 2.2 – 2.0 (m, 7H, 2 x CH2 and (C=O)CH3), 2.0 – 1.8 (m, 2H, CH2), 1.7 (t, 
J = 1.1 Hz, 3H, CH3C=CH2), 1.5 – 1.4 (m, 1H, CH). 13C NMR (75 MHz, CDCl3) δ 171.2, 149.8, 132.7, 
126.0, 108.9, 68.7, 40.9, 30.6, 27.4, 26.5, 21.2, 20.9. 
Analytical data in accordance with literature.314 
2-Methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-yl acetate (mix of isomers) 39l 
 
General procedure B was followed. Eluent 5% EtOAc in pet ether the fractions 
containing product were combined and the solvent was evaporated under reduced pressure to 
give the title compound as a clear oil in 68% yield (0.132 g, 0.68 mmol). 1H NMR (300 MHz, CDCl3) 
δ 5.7 (dt, J = 5.3, 1.8 Hz, 1H), 5.6 (dq, J = 5.5, 1.8 Hz, 1H), 5.4 (d, J = 1.5 Hz, 1H), 5.3 – 5.2 (m, 1H), 
4.8 – 4.7 (m, 4H), 2.4 – 2.1 (m, 4H), 2.1 (d, J = 1.0 Hz, 6H), 2.0 – 1.8 (m, 3H), 1.7 (dt, J = 4.4, 1.1 
Hz, 5H), 1.7 (dd, J = 2.7, 1.4 Hz, 3H), 1.6 (dp, J = 2.5, 1.3 Hz, 3H), 1.6 – 1.5 (m, 1H), 1.5 – 1.4 (m, 
1H). 13C NMR (75 MHz, CDCl3) δ 171.1, 171.1, 148.9, 148.4, 133.0, 131.1, 128.1, 126.1, 109.5, 
109.3, 73.4, 70.8, 40.4, 35.9, 34.1, 33.7, 31.0, 30.9, 21.6, 21.4, 21.0, 20.8, 20.6, 19.0. 
Analytical data in accordance with literature.315 
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Phenylmethylene dipropionate 41a 
 
General procedure C was followed to afford the title compound as a clear oil in 97% 
yield (2.15 g, 9.12 mmol).1H NMR (300 MHz, CDCl3) δ 7.7 (s, 1H, CH(OCOEt)2), 7.5 (qd, J = 3.8, 1.5 
Hz, 2H, ArH), 7.4 (ddt, J = 4.3, 3.1, 1.6 Hz, 3H, ArH), 2.5 – 2.3 (m, 4H, 2 x CH2CH3), 1.2 (dt, J = 8.5, 
7.5 Hz, 6H, 2 x CH2CH3). 13C NMR (75 MHz, CDCl3) δ 172.4, 170.4, 135.8, 129.8, 128.7, 126.8, 89.7, 
28.9, 27.5, 8.9, 8.5. I.R (thinfilm) ν max (cm-1): 2983 (ArC-H), 1756 (C=O); HRMS (ESI): m/z 
calculated for C13H12O4: requires: 259.0946 for [M+Na]+; found: 259.0995. 
Phenylmethylene dibenzoate 41b 
 
General procedure C was followed to afford the title compound as a clear oil in 99% 
yield (3.09 g, 9.30 mmol). 1H NMR (300 MHz, CDCl3) δ 8.3 – 8.1 (m, 5H, CH and ArH), 7.8 – 7.6 
(m, 3H, ArH), 7.6 – 7.5 (m, 4H, ArH), 7.5 – 7.4 (m, 4H, ArH). 13C NMR (75 MHz, CDCl3) δ 164.6, 
162.5, 134.7, 133.7, 130.7, 130.2, 129.9, 129.2, 129.0, 128.9, 128.6, 126.9, 90.8. I.R (thinfilm) ν 
max (cm-1): 3064 (ArC-H), 1722 (C=O); HRMS (ESI): m/z calculated for C21H16O4: requires: 
355.0946 for [M+Na]+; found: 355.0929. 
Phenylmethylene diacrylate 41c 
 
General procedure C was followed to afford the title compound as a clear oil in 97% 
yield (2.12 g, 9.12 mmol). 1H NMR (300 MHz, Chloroform-d) δ 7.9 (s, 1H, CHPh), 7.7 – 7.5 (m, 2H, 
ArH), 7.5 – 7.4 (m, 3H, ArH), 6.5 (dd, J = 17.3, 1.4 Hz, 2H, CHaHb=CH), 6.3 – 6.0 (m, 2H, CHaHb=CH), 
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5.9 (dd, J = 10.5, 1.3 Hz, 2H, CHaHb=CH). 13C NMR (75 MHz, Chloroform-d) δ 164.0, 134.8, 132.8, 
129.9, 128.8, 127.6, 126.8, 90.1. I.R (thinfilm) ν max (cm-1): 3040 (ArC-H), 1732 (C=O); HRMS 
(ESI): m/z calculated for C13H12O4: requires: 255.0633 for [M+Na]+; found: 255.0667. 
Phenylmethylene dihexanoate 41d 
 
General procedure C was followed to afford the title compound as a clear oil in 96% 
yield (2.89 g, 9.02 mmol).1H NMR (300 MHz, CDCl3) δ 7.7 (s, 1H, CHPh), 7.5 – 7.5 (m, 2H, ArH), 
7.5 – 7.3 (m, 3H, ArH), 2.4 (td, J = 7.4, 2.3 Hz, 4H, 2 x (C=O)CH2CH2), 1.7 – 1.6 (m, 4H, 2 x 
(C=O)CH2CH2), 1.3 (dtq, J = 10.4, 7.0, 3.1 Hz, 8H, 2 x CH2CH2CH3), 0.9 – 0.9 (m, 6H, 2 x CH2CH2CH3). 
13C NMR (75 MHz, CDCl3) δ 171.8, 135.9, 129.8, 128.7, 126.8, 89.6, 35.4, 34.2, 31.3, 24.5, 22.4, 
14.0. I.R (thinfilm) ν max (cm-1): 2956 (ArC-H), 1752 (C=O); HRMS (ESI): m/z calculated for 
C19H28O4: requires: 343.1885 for [M+Na]+; found: 343.1898. 
Phenylmethylene bis(2-phenylacetate) 41e 
 
General procedure C was followed to afford the title compound as a clear oil in a 94% 
yield (3.18 g, 8.84 mmol). 1H NMR (250 MHz, CDCl3) δ 7.7 (s, 1H, CHPh), 7.4 – 7.2 (m, 15H, ArH), 
3.6 (s, 4H, 2 x CH2Ph). 13C NMR (75 MHz, CDCl3) δ 169.5, 135.3, 133.2, 129.9, 129.5, 129.4, 128.7, 
127.4, 126.7, 90.3, 41.1. I.R (thinfilm) ν max (cm-1): 3032, 2981 (ArC-H), 1759 (C=O); HRMS (ESI): 
m/z calculated for C23H20O4: requires: 383.1259 for [M+Na]+; found: 383.1259. 
Phenylmethylene bis(2,2,2-trifluoroacetate) 41f 
 
To a solution of benzaldehyde (0.50 g, 4.7 mmol) and trifluoroacetic anhydride (0.98 mL, 
7.08 mmol) was added trifluoroacetic acid (0.035 mL, 0.47 mmol) dropwise at rt. After 2 h the 
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reaction was concentrated en vacuo to give the title compound as a yellow oil in 95% yield (1.4 
g, 4.5 mmol). Taken forward to be used in subsequent steps without further purification. 1H NMR 
(300 MHz, CDCl3) δ 7.8 (s, 1H, ArH), 7.6 (dd, J = 7.8, 1.9 Hz, 2H, ArH), 7.6 – 7.5 (m, 3H, ArH). 13C 
NMR (75 MHz, CDCl3) δ 155.3 (q, 2JC-F = 44.7 Hz), 134.4, 131.8, 129.4, 127.0, 114.1 (q, 1JC-F = 
285.5 Hz), 93.8. I.R (thinfilm) ν max (cm-1): 1809 (C=O)    
N-benzylpropionamide 42a 
 
General procedure D was followed. Eluent 30% EtOAc in CH2Cl2 the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a fluffy white solid in 95% yield (0.155 g, 0.95 mmol). 1H NMR (300 MHz, 
CDCl3) δ 7.4 – 7.2 (m, 5H, ArH), 5.8 (s, 1H, NH), 4.4 (d, J = 5.7 Hz, 2H, CH2Ph), 2.2 (q, J = 7.6 Hz, 
2H, CH2CH3), 1.2 (t, J = 7.6 Hz, 3H, CH2CH3). 13C NMR (75 MHz, CDCl3) δ 173.7, 138.5, 128.8, 128.0, 
127.6, 43.7, 29.8, 10.0. 
Analytical data in accordance with literature.316  
N-benzylbenzamide 42b 
 
General procedure D was followed. Eluent 30% EtOAc in CH2Cl2 the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a cream solid in 87% yield (0.184 g, 0.87 mmol). 1H NMR (300 MHz, CDCl3) δ 
7.8 – 7.7 (m, 2H, ArH), 7.6 – 7.3 (m, 8H, ArH), 6.4 (s, 1H, NH), 4.7 (d, J = 5.6 Hz, 2H. CH2Ph). 13C 
NMR (75 MHz, CDCl3) δ 167.5, 138.3, 134.5, 131.7, 129.0, 128.8, 128.1, 127.8, 127.1, 44.3. 
Analytical data in accordance with literature.316 
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N-benzylacrylamide 42c 
 
General procedure D was followed. Eluent 30% EtOAc in CH2Cl2 the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a cream solid in 96% yield (0.154 g, 0.96 mmol). 1H NMR (300 MHz, CDCl3) δ 
7.4 – 7.3 (m, 5H, ArH), 6.3 (dd, J = 16.9, 1.5 Hz, 1H, CH=CHaHb), 6.1 (dd, J = 17.0, 10.2 Hz, 1H, 
CH=CHaHb), 5.9 (s, 1H, NH), 5.7 (dd, J = 10.2, 1.5 Hz, 1H, CH=CHaHb), 4.5 (d, J = 5.8 Hz, 2H, CH2Ph). 
13C NMR (75 MHz, CDCl3) δ 165.5, 138.1, 130.7, 128.9, 128.7, 128.7, 128.1, 128.0, 127.8, 127.0, 
126.8, 43.8. 
Analytical data in accordance with literature.317 
N-benzylhexanamide 42d 
 
General procedure D was followed. Eluent 30% EtOAc in CH2Cl2 the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a white solid in 91% yield (0.186 g, 0.91 mmol). 1H NMR (300 MHz, CDCl3) δ 
7.4 – 7.3 (m, 5H, ArH), 5.7 (s, 1H, NH), 4.4 (d, J = 5.7 Hz, 2H, CH2Ph), 2.2 (dd, J = 8.6, 6.7 Hz, 2H, 
(C=O)CH2CH2CH2), 1.7 – 1.6 (m, 2H, (C=O)CH2CH2CH2), 1.3 (dq, J = 7.2, 3.8, 3.2 Hz, 4H, 
(C=O)CH2CH2CH2CH2), 0.9 – 0.8 (m, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 173.1, 138.5, 128.9, 
128.0, 127.7, 43.7, 37.0, 31.6, 25.6, 22.6, 14.1. 
Analytical data in accordance with literature.318 
N-benzyl-2-phenylacetamide 42e 
 
General procedure D was followed. Eluent 30% EtOAc in CH2Cl2 the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
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title compound as a pale brown solid in a 79% yield (0.178 g, 0.79 mmol). 1H NMR (300 MHz, 
CDCl3) δ 7.3 (s, 8H, ArH), 7.2 – 7.1 (m, 2H, ArH), 5.7 (s, 1H, NH), 4.4 (d, J = 5.8 Hz, 2H, PhCH2NH), 
3.6 (s, 2H, PhCH2). 13C NMR (75 MHz, CDCl3) δ 171.0, 138.2, 134.9, 129.6, 129.2, 128.8, 127.6, 
127.6, 44.0, 43.7. 
Analytical data in accordance with literature.318 
N-benzyl-2,2,2-trifluoroacetamide 42f 
 
 
Benzylamine (0.107 g, 1.0 mmol) was added to phenylmethylene bis(2,2,2-
trifluoroacetate) (0.474 g, 1.5 mmol) the reaction was stirred at rt for 1 h. the crude reaction 
mixture was then directly purified by column chromatography to give the isolated title product. 
Eluent 30% EtOAc in CH2Cl2 the fractions containing product were combined and the solvent was 
evaporated under reduced pressure to give the title compound as a white solid in 91% yield 
(0.184 g, 0.91 mmol); 1H NMR (300 MHz, CDCl3) δ 7.4 – 7.3 (m, 3H, ArH), 7.32 – 7.27 (m, 2H, 
ArH), 6.6 (s, 1H, NH), 4.5 (d, J = 5.8 Hz, 2H, CH2). 13C NMR (75 MHz, CDCl3) δ 157.3 (q, 2JC-F = 37.2 
Hz), 135.9, 129.1, 128.4, 128.1, 116.0 (q, 1JC-F = 287.8 Hz), 44.0.   
Analytical data in accordance with literature.319 
Benzyl propionate 43a 
 
 
General procedure E was followed. Eluent 5% EtOAc in pet ether the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a clear oil in 94% yield (0.154 g, 0.94 mmol). 1H NMR (300 MHz, CDCl3) δ 7.4 
– 7.3 (m, 5H, ArH), 5.1 (s, 2H, CH2Ph), 2.4 (q, J = 7.6 Hz, 2H, CH2CH3), 1.2 (t, J = 7.6 Hz, 3H, CH2CH3). 
C NMR (75 MHz, CDCl3) δ 174.5, 136.3, 128.7, 128.3, 126.8, 66.3, 27.8, 9.3. 
Analytical data in accordance with literature.320 
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Benzyl benzoate 43b 
 
General procedure E was followed. Eluent 5% EtOAc in pet ether the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a clear oil in 78% yield (0.166 g, 0.78 mmol). 1H NMR (300 MHz, CDCl3) δ 8.2 
– 7.9 (m, 2H, ArH), 7.6 – 7.5 (m, 1H, ArH), 7.5 – 7.3 (m, 7H, ArH), 5.4 (s, 2H, CH2Ph). 13C NMR (75 
MHz, CDCl3) δ 166.6, 136.2, 133.2, 130.3, 129.8, 128.7, 128.5, 128.4, 128.3, 66.8. 
Analytical data in accordance with literature.320 
Benzyl acrylate 43c 
 
General procedure E was followed. Eluent 5% EtOAc in pet ether the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a clear oil in 81% yield (0.131 g, 0.81 mmol). 1H NMR (300 MHz, CDCl3) δ 7.4 
– 7.3 (m, 5H, ArH), 6.5 (dd, J = 17.3, 1.4 Hz, 1H, CH=CHaHb), 6.2 (dd, J = 17.3, 10.4 Hz, 1H, 
CH=CHaHb), 5.9 (dd, J = 10.4, 1.4 Hz, 1H, CH=CHaHb), 5.2 (s, 2H, CH2Ph). 13C NMR (75 MHz, CDCl3) 
δ 166.2, 136.0, 131.2, 128.7, 128.5, 128.4, 128.4, 66.5. 
Analytical data in accordance with literature.320 
Benzyl hexanoate 43d 
 
General procedure E was followed. Eluent 3% EtOAc in pet ether the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a clear oil in 70% yield (0.144 g, 0.70 mmol). 1H NMR (300 MHz, CDCl3) δ 7.4 
– 7.3 (m, 5H, ArH), 5.1 (s, 2H, CH2Ph), 2.4 (t, J = 7.5 Hz, 2H, (C=O)CH2CH2CH2CH2CH3), 1.7 – 1.6 
(m, 2H, (C=O)CH2CH2CH2CH2CH3), 1.3 (dq, J = 7.5, 3.8, 3.2 Hz, 4H, (C=O)CH2CH2CH2CH2CH3), 0.9 – 
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0.8 (m, 3H, (C=O)CH2CH2CH2CH2CH3). 13C NMR (75 MHz, CDCl3) δ 173.8, 136.3, 128.7, 128.3, 
126.8, 66.2, 34.4, 31.4, 24.8, 22.4, 14.0. 
Analytical data in accordance with literature.321  
Benzyl 2-phenylacetate 43e 
 
General procedure E was followed. Eluent 5% EtOAc in pet ether the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a clear oil in 62% yield (0.140 g, 0.62 mmol). 1H NMR (300 MHz, CDCl3) δ 7.4 
– 7.3 (m, 10H, ArH), 5.2 (s, 2H, PhCH2O), 3.7 (s, 2H, (C=O)CH2Ph). 13C NMR (75 MHz, CDCl3) δ 
171.5, 136.0, 134.0, 129.4, 128.7, 128.7, 128.3, 128.2, 127.2, 66.7, 41.5. 
Analytical data in accordance with literature.321 
Benzyl 2,2,2-trifluoroacetate 43f 
 
 
Benzyl alcohol (0.108 g, 1.0 mmol) was added to phenylmethylene bis(2,2,2-
trifluoroacetate) (0.474 g, 1.5 mmol) and K2CO3 (2.0 mmol, 0.270 g) the reaction was stirred at 
rt for 1 h. the crude reaction mixture was then directly purified by column chromatography to 
give the isolated title compound. Eluent 5% EtOAc in pet ether the fractions containing product 
were combined and the solvent was evaporated under reduced pressure to give the title 
compound as a clear oil in 89% yield (0.181 g, 0.89 mmol); 1H NMR (300 MHz, CDCl3) δ 7.4 (s, 
5H), 5.4 (s, 2H). 13C NMR (75 MHz, CDCl3) δ 157.5 (q, 2JC-F = 42.5 Hz), 133.4, 129.4, 129.0, 128.8, 
114.6 (q, 1JC-F = 285.8 Hz), 69.7. 
Analytical data in accordance with literature.322 
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(formyloxy)(phenyl)methyl acetate 44.2 
 
Copper(II) tetrafluoroborate hydrate (0.044 g, 1.80 mmol) was added to a mixture of 
benzladehyde (2.0 g, 18.0 mmol) and acetic formic anhydride (2.40 g, 27.0 mmol) at -20 °C  and 
stirred for 5 min. The reaction was then quenched with saturated Na2CO3 (10 mL) and diluted 
with Et2O (50 mL). The reaction was then washed with saturated Na2CO3 (3 x 20 mL). The 
organics were dried (MgSO4) and concentrated in vacuo. The resulting residue was purified by 
column chromatography (5% EtOAc in pet ether Rf = 0.56) to give the title compound as a clear 
oil in 59% yield. 
1H NMR (300MHz, CDCl3) δ = 8.12 (d, J = 0.9 Hz, 1H, (C=O)H), 7.77 (s, 1H, CHAr), 7.59 - 7.50 (m, 
2H, ArH), 7.47 - 7.41 (m, 3H, ArH), 2.16 (s, 3H, CH3), 13C NMR (75MHz, CDCl3) δ = 168.8, 158.7, 
134.7, 130.0, 128.7, 126.7, 89.2, 20.8, I.R (thinfilm) ν max (cm-1): 3040 (ArC-H), 1750, 1732 (C=O); 
HRMS (ESI): m/z calculated for C10H10O4: requires: 217.0471 for [M+Na]+; found: 217.0479. 
N-benzylformamide 47a 
 
General procedure F was followed. Eluent 30% EtOAc in CH2Cl2 the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as an off-white solid in 89% yield (0.24 g, 1.78 mmol). m.p. 60-61 °C 1H NMR (300 
MHz, CDCl3) δ 8.09 (s, 1 H, (C=O)H) (major), 8.00 (d, J = 11.9 Hz, 1H, (C=O)H) (minor), 7.34 - 7.06 
(m, 5H, ArH), 6.38 (br. s., 1H, NH), 4.34 (d, J = 6.0 Hz, 2H, CH2NH) (major), 4.27 (d, J = 6.6 Hz, 2H, 
CH2NH) (minor). 13C NMR (75 MHz, CDCl3) δ 164.7 (minor), 161.1 (major), 137.5, 128.8 (minor), 
128.6 (major), 127.8 (minor), 127.6 (major), 127.5 (major), 126.8 (minor), 45.5 (minor), 42.0 
(major). 
Analytical data in accordance with literature.80  
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N-(furan-2-ylmethyl)formamide 47b 
 
General procedure F was followed Eluent 25% EtOAc in CH2Cl2 the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a yellow oil in 80% yield (0.20 g, 1.60 mmol). 1H NMR (300 MHz, CDCl3) δ 8.19 
(s, 1H, (C=O)H) (major), 8.16 (d, J = 11.9 Hz, 1H, (C=O)H) (minor), 7.38 (dd, J = 0.8, 1.8 Hz, 1H, 
CHC(H)O) (minor), 7.35 (dd, J = 0.8, 1.9 Hz, 1H, CHC(H)O) (major), 6.32 (dd, J = 1.8, 3.3 Hz, 1H, 
CHC(H)O)), 6.24 (dd, J = 0.8, 3.2 Hz, 1H, CCH), 4.46 (d, J = 5.7 Hz, 2H, CH2NH) (major), 4.36 (d, J = 
6.4 Hz, 2H, CH2NH) (minor). 13C NMR (75 MHz, CDCl3) δ 164.6 (minor), 160.9 (major), 150.5, 142.8 
(minor), 142.3 (major), 110.4, 107.6 (major), 107.4 (minor), 38.8 (minor), 34.9 (major). 
Analytical data in accordance with literature.323 
N-(benzo[d][1,3]dioxol-5-ylmethyl)formamide 47c 
 
Gerneral procedure F was followed. Eluent 30% EtOAc in CH2Cl2 the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as an off-white crystalline solid in 82% yield (0.293 g, 1.64 mmol). m.p. 96-98 °C; 
1H NMR (300 MHz, CDCl3) δ 8.20 (s, 1H, (C=O)H) (major), 8.12 (d, J = 12.1 Hz, 1H, (C=O)H) (minor), 
6.79 - 6.66 (m, 3H, ArH), 6.18 (br. s., 1H, NH), 5.96 (s, 2H, OCH2O) (minor), 5.93 (s, 2H, OCH2O) 
(major), 4.35 (d, J = 5.8 Hz, 2H, CH2NH) (major), 4.29 (d, J = 6.4 Hz, 2H, CH2NH) (minor). 13C NMR 
(75 MHz, CDCl3) δ 164.5 (minor), 161.0 (major), 147.9, 147.0, 131.4, 121.0 (major), 120.3 (minor), 
108.4 (minor), 108.3 (major), 108.2 (major), 107.4 (minor), 101.2 (minor), 101.0 (major), 45.5 
(minor), 41.9 (major). 
Analytical data in accordance with literature.299  
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N-(2-(1H-indol-3-yl)ethyl)formamide 47d 
 
General procedure F was followed. Eluent 100% EtOAc the fractions containing product 
were combined and the solvent was evaporated under reduced pressure to give the title 
compound as pale brown viscous oil in 90% yield (0.339 g, 1.80 mmol). 1H NMR (300 MHz, CDCl3) 
δ 8.46 (br. s., 1 H, ArNH), 8.05 (s, 1 H, (C=O)H) (major), 7.84 (d, J = 12.1 Hz, 1 H, (C=O)H) (minor), 
7.60 (d, J = 7.9 Hz, 1 H, ArH) (major), 7.56 (d, J = 7.9 Hz, 1 H, ArH) (minor), 7.37 (d, J = 8.1 Hz, 1 
H, ArH), 7.28 - 7.09 (m, 3 H, ArH), 7.01 (d, J = 2.1 Hz, 1 H, ArHNH) (major), 6.96 (d, J = 2.3 Hz, 1 
H, ArHNH) (minor), 5.80 (br. s., 1 H, CH2NH), 3.63 (q, J = 6.5 Hz, 2 H, CH2NH) (major), 3.48 (q, J = 
6.5 Hz, 2 H, CH2NH) (minor), 3.02 - 2.90 (app m, 2 H, CH2CH2NH) (major and minor). 13C NMR (75 
MHz, CDCl3) δ 164.7 (minor), 161.3 (major), 136.4 (minor), 136.3 (major), 127.1 (major), 126.7 
(minor), 122.8 (minor), 122.2 (major), 122.2 (minor), 122.1 (major), 119.4 (minor), 119.4 (major), 
118.5 (major), 118.3 (minor), 112.2 (major), 111.5 (minor), 111.3 (major), 111.2 (minor), 41.9 
(minor), 38.3 (major), 27.2 (minor), 25.0 (major). 
Analytical data in accordance with literature.299 
N-(2,2-dimethoxyethyl)formamide 47e 
 
General procedure F was followed. Eluent 20% EtOAc in CH2Cl2 the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a pale yellow oil in 95% yield (0.253 g, 1.9 mmol). 1H NMR (300 MHz, CDCl3) δ 
8.17 (s, 1H, (C=O)H) (major), 8.02 (d, J = 12.1 Hz, 1H, (C=O)H) (minor), 6.03 (br. s., 1H, NH), 4.39 
(t, J = 5.2 Hz, 1H, CH(OMe)2) (major), 4.31 (t, J = 5.2 Hz, 1H, CH(OMe)2) (minor), 3.46 - 3.41 (m, 
2H CH2NH) (major), 3.40 (s, 6H, OCH3) (minor), 3.39 (s, 6H, OCH3) (major), 3.29 (dd, J = 5.1, 6.6 
Hz, 2H, CH2NH) (minor). 13C NMR (75 MHz, CDCl3) δ 164.9 (minor), 161.3 (major), 103.4 (minor), 
102.3 (major), 54.7 (minor), 54.4 (major), 43.6 (minor), 39.4 (major). I.R (thinfilm) ν max (cm-1): 
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3295 (N-H), 1658 (C=O); HRMS (ESI): m/z calculated for C5H11NO3: requires: 134.0817 for [M+H]+; 
found: 134.0824. 
N-benzhydrylformamide 47f 
 
General procedure F was followed. Eluent 20% EtOAc in CH2Cl2 the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as an off-white crystalline solid in 83% yield (0.35 g, 1.66 mmol). m.p. 133-134 
°C 1H NMR (300 MHz, CDCl3) δ 8.30 (s, 1H, (C=O)H) (major), 8.21 (d, J = 11.9 Hz, 1H, (C=O)H) 
(minor), 7.39 - 7.27 (m, 5H, ArH), 7.27 - 7.19 (m, 5H, ArH), 6.33 (d, J = 8.3 Hz, 1H, ArCH) (major), 
6.25 (br. s., 1H, NH), 5.77 (d, J = 8.3 Hz, 1H, ArCH) (minor). 13C NMR (75 MHz, CDCl3) δ 160.1, 
140.8, 128.9 (minor), 128.7 (major), 128.0 (minor), 127.6 (major), 127.3 (major), 127.2 (minor), 
55.6. 
Analytical data in accordance with literature.299 
(S)-methyl 2-formamido-3-methylbutanoate 47g 
 
General procedure F was followed. Eluent 30% EtOAc in CH2Cl2 the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a pale pink crystalline solid in 93% yield (0.296 g, 1.86 mmol). m.p. 68-69 °C; 
[α]D20 = -22 in EtOH; 1H NMR (300 MHz, CDCl3) δ 8.23 (s, 1H, (C=O)H) (major), 7.98 (d, J = 11.7 
Hz, 1H, (C=O)H) (minor), 6.53 (br. s., 1H, NH), 4.62 (ddd, J = 0.8, 4.9, 9.1 Hz, 1H, CHNH) (major), 
3.91 (dd, J = 5.1, 10.2 Hz, 1H, CHNH) (minor), 3.74 (s, 3H, OCH3) (minor), 3.72 (s, 3H, OCH3) 
(major), 2.23 - 2.08 (m, 1H, CH(CH3)2), 0.93 (d, J = 6.8 Hz, 3H, CH(CH3)2), 0.88 (d, J = 6.8 Hz, 3H, 
CH(CH3)2). 13C NMR (75 MHz, CDCl3) δ 172.1 (major), 171.3 (minor), 163.9 (minor), 161.0 (major), 
60.3 (minor), 55.5 (major), 52.4 (minor), 52.2 (major), 31.3 (minor), 31.1 (major), 19.0 (minor), 
18.8 (major), 17.5 (major), 17.0 (minor) 
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Analytical data in accordance with literature.87 
N-tert-butylformamide 47h 
 
General procedure F was followed. Eluent 20% EtOAc in CH2Cl2 the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a pale yellow oil in 53% yield (0.107 g, 1.06 mmol). 1H NMR (300 MHz, CDCl3) 
δ 8.26 (d, J = 12.4 Hz, 1H, (C=O)H) (minor), 8.03 (s, 1H, (C=O)H) (major), 6.15 (br. s., 1H, NH) 
(minor), 5.40 (br. s., 1H, NH) (major), 1.38 (s, 9H, CH3) (minor), 1.33 (s, 9H, CH3) (major). 13C NMR 
(75 MHz, CDCl3) δ 163.0 (major), 160.6 (minor), 51.3 (major), 50.3 (minor), 30.8 (major), 28.9 
(minor). 
Analytical data in accordance with literature.323 
N,N-dipropylformamide 47i 
 
General procedure F was followed. Eluent 20% EtOAc in CH2Cl2 the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a pale yellow oil in 74% yield (0.191 g, 1.48 mmol). 1H NMR (300 MHz, CDCl3) 
δ 8.04 (s, 1H, (C=O)H), 3.27 - 3.19 (m, 2H, CH2CH2CH3), 3.15 (t, J = 7.1 Hz, 2H, CH2CH2CH3), 1.63 - 
1.46 (m, 4H, CH2CH2CH3), 0.88 (dt, J = 2.2, 7.4 Hz, 6H, CH2CH2CH3). 13C NMR (75 MHz, CDCl3) δ 
162.8, 49.1, 43.6, 21.7, 20.4, 11.2, 10.8. 
Analytical data in accordance with literature.87 
N,N-diallylformamide 47j 
 
General procedure F was followed. Eluent 20% EtOAc in CH2Cl2 the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a pale yellow oil in 58% yield (0.145 g, 1.16 mmol). 1H NMR (300 MHz, CDCl3) 
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δ 8.10 (s, 1H, (C=O)H), 5.79 - 5.58 (m, 2H, CH2CH=CH2), 5.25 - 5.21 (m, 1H, CH2CH=CHaHb), 5.19 
(qd, J = 1.3, 4.1 Hz, 1H, CH2CH=CHaHb), 5.17 - 5.14 (m, 2H, CH2CH=CHaHb), 3.91 (td, J = 1.3, 5.9 
Hz, 2H, CH2CH=CH2), 3.79 (td, J = 1.2, 5.8 Hz, 2H, CH2CH=CH2). 13C NMR (75 MHz, CDCl3) δ 162.5, 
132.9, 131.9, 118.5, 118.0, 49.1, 44.1. I.R (thinfilm) ν max (cm-1): 1665 (C=O); HRMS (ESI): m/z 
calculated for C7H11NO: requires: 126.0918 for [M+H]+; found: 126.0932. 
4-phenylpiperazine-1-carbaldehyde 47k 
 
General procedure F was followed. Eluent 30% EtOAc in CH2Cl2 the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a pale pink crystalline solid in 96% yield (0.365 g, 1.92 mmol). m.p. 83-85 °C; 
1H NMR (300 MHz, CDCl3) δ 8.08 (s, 1H, (C=O)H), 7.33 - 7.21 (m, 2H, ArH), 6.97 - 6.87 (m, 3H, 
ArH), 3.74 - 3.63 (m, 2H CH2CH2NC(O)H), 3.56 - 3.44 (m, 2H, CH2CH2NC(O)H), 3.14 (td, J = 5.3, 
11.1 Hz, 4H, CH2CH2NC(O)H). 13C NMR (75 MHz, CDCl3) δ 160.6, 150.8, 129.1, 120.7, 116.9, 50.3, 
49.2, 45.3, 39.8 
Analytical data in accordance with literature.324 
N-phenylformamide 47l 
 
General procedure F was followed. Eluent 20% EtOAc in CH2Cl2 the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a yellow oil in 90% yield (0.218 g, 1.80 mmol). 1H NMR (300 MHz, CDCl3) δ 
8.98 (br. s., 1H, NH) (minor), 8.62 (d, J = 11.3 Hz, 1H, (C=O)H) (minor), 8.25 (d, J = 1.7 Hz, 1H, 
(C=O)H) (major), 8.13 (br. s., 1H, NH) (major), 7.51 - 7.42 (m, 1H, ArH), 7.30 - 7.17 (m, 2H, ArH), 
7.13 - 6.97 (m, 2H, ArH). 13C NMR (75MHz, CDCl3) δ 163.0 (major), 159.5 (minor), 136.9 (minor), 
136.7 (major), 129.6 (major), 129.0 (minor), 125.2 (major), 124.7 (minor), 120.0 (minor), 118.6 
(major) 
Analytical data in accordance with literature.80 
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N-(4-bromophenyl)formamide 47m 
 
General procedure F was followed. The reaction required the addition of 2 mL EtOAc 
and an extended reaction time of 24 h. The solvent was re-moved before purification. Eluent 
15% EtOAc in CH2Cl2 the fractions containing product were combined and the solvent was 
evaporated under reduced pressure to give the title compound as a white crystalline solid in 
95% yield (0.380 g, 1.90 mmol). m.p. 115-117 °C; 1H NMR (300 MHz, CDCl3) δ 8.67 (d, J = 11.3 
Hz, 1H, (C=O)H) (minor), 8.40 (d, J = 1.5 Hz, 1H, (C=O)H) (major), 8.09 (br. s., 1H, NH) (minor), 
7.52 - 7.47 (m, 2H, ArH), 7.46 (s, 4H, ArH) (major and minor), 7.32 (br. s., 1H, NH) (major), 7.02 - 
6.95 (m, 2H, ArH). 13C NMR (75 MHz, CDCl3) δ 162.5 (minor), 159.0 (major), 135.8 (major), 135.7 
(minor), 132.7 (minor), 132.1 (major), 121.5 (major), 120.2 (minor), 118.2 (minor), 117.4 (major) 
Analytical data in accordance with literature.87 
N-(4-chlorophenyl)formamide 47n 
 
General procedure F was followed. The reaction required the addition of 2 mL EtOAc 
and an extended reaction time of 24 h. The solvent was re-moved before purification. Eluent 
15% EtOAc in CH2Cl2 the fractions containing product were combined and the solvent was 
evaporated under reduced pressure to give the title compound as a beige crystalline solid in 94% 
yield (0.292 g, 1.88 mmol). m.p. 101-102 °C; 1H NMR (300 MHz, CDCl3) δ 8.59 (br. s., 1H, NH) 
(minor), 8.52 - 8.44 (m, 1H, (C=O)H) (minor), 8.19 (d, J = 1.9 Hz, 1H, (C=O)H) (major), 7.38 - 7.29 
(m, 2H, ArH), 7.63 (br. s., 1H, NH) (major), 7.19 - 7.07 (m, 4H, ArH), 6.93 - 6.82 (m, 2H, ArH). 13C 
NMR (75 MHz, CDCl3) δ 162.7 (minor), 159.2 (major), 135.4 (major), 135.2 (minor), 130.7, 129.8, 
129.1, 121.2, 120.0 
Analytical data in accordance with literature.323 
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Methyl 4-formamidobenzoate 47o 
 
General procedure F was followed. The reaction required the addition of 2 mL EtOAc 
and an extended re-action time of 24 h. The solvent was removed before purification. Eluent 
15% EtOAc in CH2Cl2 the fractions containing product were combined and the solvent was 
evaporated under reduced pressure to give the title com-pound as a white crystalline solid in 
87% yield (0.311 g, 1.74 mmol). m.p. 123-125 °C; 1H NMR (300 MHz, CDCl3) δ 8.87 (d, J = 11.1 
Hz, 1 H, (C=O)H) (minor), 8.66 (d, J = 11.1 Hz, 1H, NH) (minor), 8.44 (d, J = 1.7 Hz, 1H, (C=O)H) 
(major), 8.09 - 7.97 (m, 4H, ArH), 7.80 (br. s., 1H, NH) (major), 7.69 - 7.59 (m, 2H, ArH), 7.19 - 
7.12 (m, 2H, ArH), 3.92 (s, 3H, OCH3) (minor), 3.91 (s, 3H, OCH3) (major). 13C NMR (75 MHz, CDCl3) 
δ 166.5, 166.3, 162.0, 159.1, 140.9, 131.5, 130.9, 126.5, 126.1, 119.1, 117.1, 52.2, 52.1. 
Analytical data in accordance with literature.325 
N-methyl-N-phenylformamide 47p 
 
General procedure F was followed. Eluent 10% EtOAc in CH2Cl2 the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a pale brown oil in 91% yield (0.243 g, 1.82 mmol). 1H NMR (300 MHz, CDCl3) 
δ 8.28 (s, 1H, (C=O)H) (major), 8.17 (s, 1H, (C=O)H) (minor), 7.26 - 7.18 (m, 2H, ArH), 7.13 - 7.04 
(m, 1H, ArH), 7.02 - 6.95 (m, 2H, ArH), 3.16 (s, 3H, NCH3) (minor), 3.13 (s, 3H, NCH3) (major). 13C 
NMR (75 MHz, CDCl3) δ 162.1 (major), 162.0 (minor), 141.9, 129.4 (major), 128.8 (minor), 126.1 
(major), 126.0 (minor), 123.3 (minor), 122.0 (major), 36.6 (minor), 31.8 (major) 
Analytical data in accordance with literature.323  
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N-Formyl valine 49a 
 
General procedure G was followed. Recrystallized to give the title compound as a white 
solid in 78% yield (0.113 g, 0.78 mmol). [α]D20 = -11 in MeOH. 1H NMR (300 MHz, DMSO-d6) δ 
12.8 (s, 1H, OH), 8.3 (d, J = 8.7 Hz, 1H, NH), 8.1 (s, 1H, (C=O)H), 4.2 (dd, J = 8.8, 5.3 Hz, 1H, CHNH), 
2.1 (tq, J = 13.6, 6.8 Hz, 1H, CH(CH3)2), 0.9 (dd, J = 6.8, 4.7 Hz, 6H, CH(CH3)2). 13C NMR (75 MHz, 
DMSO-d6) δ 172.7, 161.2, 55.6, 29.9, 19.2, 17.7. 
Analytical data in accordance with literature80 
N-Formyl phenylalanine 49b 
 
General procedure G was followed. Recrystallized to give the title compound as a cream 
solid in 86% yield (0.166 g, 0.86 mmol). [α]D20 = +63 in MeOH. 1H NMR (500 MHz, DMSO-d6) δ 
12.8 (s, 1H, OH), 8.4 (d, J = 8.0 Hz, 1H, NH), 8.0 (dd, J = 1.7, 0.8 Hz, 1H, (C=O)H), 7.3 – 7.2 (m, 2H, 
ArH), 7.3 – 7.2 (m, 4H, ArH), 4.5 (dddd, J = 9.1, 8.2, 5.0, 0.9 Hz, 1H, CHNH), 3.1 – 2.8 (m, 2H, 
CH2Ph). 13C NMR (126 MHz, DMSO-d6) δ 172.5, 160.9, 137.3, 129.1, 128.2, 126.5, 51.9, 36.7. 
Analytical data in accordance with literature.80 
N-Formyl leucine 49c 
 
General procedure G was followed. Recrystallized to give the title compound as a white 
solid in a 74% yield (0.118 g, 0.74 mmol). [α]D20 = -19 in MeOH. 1H NMR (300 MHz, MeOD-d4) δ 
8.1 (s, 1H, (C=O)H), 4.5 (dd, J = 9.2, 5.1 Hz, 1H, CHNH), 1.8 – 1.5 (m, 3H, CH(CH3)2 and CH2CHNH), 
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1.0 (dd, J = 8.0, 6.1 Hz, 6H, CH(CH3)2). 13C NMR (75 MHz, MeOD-d4) δ 175.4, 163.6, 50.6, 41.9, 
26.0, 23.3, 21.8. 
Analytical data in accordance with literature.80 
N-Formyl methionine 49d 
 
General procedure G was followed. Recrystallized to give the title compound as a pale 
yellow solid in 81% yield (0.143 g, 0.81 mmol). [α]D20 = +7.5 in MeOH. 1H NMR (300 MHz, MeOD-
d4) δ 8.1 (s, 1H, (C=O)H), 4.6 (dd, J = 8.7, 4.7 Hz, 1H, CHNH), 2.7 – 2.4 (m, 2H, CH3SCH2), 2.2 – 2.1 
(m, 1H, CH3SCH2CHaHb), 2.1 (s, 3H, CH3), 2.0 (dtd, J = 14.1, 8.4, 5.8 Hz, 1H, CH3SCH2CHaHb). 13C 
NMR (75 MHz, MeOD-d4) δ 174.4, 163.6, 51.3, 32.4, 31.0, 15.2. 
Analytical data in accordance with literature.80 
N-Formyl alanine 49e 
 
General procedure G was followed. Recrystallized to give the title compound as a white 
solid in 89% yield (0.104 g, 0.89 mmol). [α]D20 = -35.5 in MeOH.  1H NMR (300 MHz, CDCl3) δ 8.1 
(s, 1H, (C=O)H), 4.5 (q, J = 7.3 Hz, 1H, CHCH3), 1.4 (d, J = 7.3 Hz, 3H, CHCH3). 13C NMR (75 MHz, 
CDCl3) δ 175.4, 163.3, 48.0, 18.0. 
Analytical data in accordance with literature.80 
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N-Formyl tryptophan 49f 
 
General procedure G was followed. Recrystallized to give the title compound as a pale 
brown solid in a 71% yield (0.165 g, 0.71 mmol). [α]D20 = -36 in MeOH.  1H NMR (300 MHz, MeOD-
d4) δ 8.0 (s, 1H, (C=O)H), 7.6 (d, J = 7.6 Hz, 1H, ArH), 7.3 (dd, J = 7.8, 1.2 Hz, 1H, ArH), 7.1 – 7.0 
(m, 2H, ArH), 7.1 – 6.9 (m, 2H, ArH), 4.8 (dd, J = 7.3, 5.1 Hz, 1H, CHNH), 3.4 – 3.3 (m, 1H, CHaHbAr), 
3.2 (dd, J = 14.7, 7.4 Hz, 1H, CHaHbAr). 13C NMR (75 MHz, MeOD-d4) δ 174.6, 163.6, 138.0, 128.8, 
124.4, 122.4, 119.8, 119.3, 112.2, 110.5, 53.2, 28.6. 
Analytical data in accordance with literature.80 
(S)-Methyl 2-((S)-2-((S)-2-formamido-4-(methylthio)butanamido)-4-methylpentanamido)-3-
phenylpropanoate (Formyl-methionine-leucine-phenylalanine-OMe) 56.6 
 
(6S,9S,12S)-methyl 12-benzyl-9-isobutyl-2,2-dimethyl-6-(2-(methylthio)ethyl)-4,7,10-
trioxo-3-oxa-5,8,11-triazatridecan-13-oate92 (0.80 g, 1.5 mmol) was dissolved in saturated 
methanolic HCl and stirred at rt for 1 h. The reaction was then concentrated in vacuo, the residue 
was suspended in EtOAc and neutralised with saturated NaHCO3. The aqueous layers was further 
extracted with EtOAc (3x 30 mL), the organics were combined dried (MgSO4) and concentrated 
in vacuo to give (S)-methyl 2-((S)-2-((S)-2-amino-4-(methylthio)butanamido)-4-
methylpentanamido)-3-phenylpropanoate which was taken forward to the next step without 
further purification.  
 
(formyloxy)(phenyl)methyl acetate (0.145 g, 0.75 mmol) was added to (S)-methyl 2-((S)-
2-((S)-2-amino-4-(methylthio)butanamido)-4-methylpentanamido)-3-phenylpropanoate (0.213 
g, 0.50 mmol) in EtOAc (4 mL) the reaction was stirred at rt for 5 h. The crude reaction mixture 
was diluted with EtOAc and washed with saturated NaHCO3, the organics were then dried 
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(MgSO4) and concentrated in vacuo. The residue was purified via recrystallization (MeOH/H2O) 
to give the title compound in 87% yield (0.20 g, 0.44 mmol); m.p. 133-135 °C, [α]D20 = -38 in 
MeOH. 1H NMR (300 MHz, MeOD-d4) δ 8.09 (s, 1H, (C=O)H), 7.34 - 7.15 (m, 5H, ArH), 4.64 (dd, 
J = 5.8, 8.5 Hz, 1H, PhCH2CH), 4.51 (dd, J = 5.5, 8.1 Hz, 1H, MeSCH2CH2CH), 4.41 (dd, J = 7.0, 8.1 
Hz, 1H, CH(CH3)2CH2CH), 3.68 (s, 3H, OCH3), 3.15 (dd, J = 5.8, 13.8 Hz, 1H, PhCHaHbCH), 3.00 (dd, 
J = 8.7, 13.9 Hz, 1H, PhCHaHbCH), 2.56 - 2.38 (m, 2H, MeSCH2CH2CH), 2.07 (s, 3H, SCH3), 2.03 - 
1.80 (m, 2H, MeSCH2CH2CH), 1.72 - 1.59 (m, 1H, CH(CH3)2CH2CH), 1.52 (t, J = 7.0 Hz, 2H, 
CH(CH3)2CH2CH), 0.92 (dd, J = 12.8, 6.4 Hz, 6H, CH(CH3)2CH2CH). 13C NMR (75 MHz, MeOD-d4) δ 
174.4, 173.2, 173.0, 163.7, 138.0, 130.3, 129.5, 127.9, 116.0, 55.2, 52.9, 52.7, 52.4, 41.9, 38.3, 
33.0, 30.8, 25.8, 23.4, 22.0, 15.2. I.R (thinfilm) ν max (cm-1): 3279 ((C=O)NH), 1738, 1664, 1632 
(C=O); HRMS (ESI): m/z calculated for C22H33N3O5S: requires: 452.2219 for [M+H]+; found: 
452.2245.  
 
(S)-2-((S)-2-((S)-2-formamido-4-(methylthio)butanamido)-4-methylpentanamido)-3-
phenylpropanoic acid (Formyl-methionine-leucine-phenylalanine-OH) 56.7 
 
2 M NaOH(aq) (1 mL) was added to a stirred solution of (S)-Methyl 2-((S)-2-((S)-2-
formamido-4-(methylthio)butanamido)-4-methylpentanamido)-3-phenylpropanoate (0.20 g, 
0.44 mmol) dissolved in MeOH (5mL). The reaction was stirred at rt for 2 h. The MeOH was 
removed under reduced pressure and the reaction was diluted with H2O, the aqueous solution 
was then extracted with Et2O (3x 15 mL). The aqueous layers was then acidified with 1 M HCl(aq) 
and extracted with EtOAc (3x 20 mL). The second organics were then dried (MgSO4) and 
concentrated in vacuo, the residue was then purified via recrystallization (MeOH/H2O) to give 
the title compound in 93% yield (0.179 g, 0.40 mmol); m.p. 208-210 °C, [α]D20 = -18 in MeOH/ -9 
in AcOH.  1H NMR (300 MHz, MeOD-d4) δ 8.08 (s, 1 H, (C=O)H), 7.33 - 7.14 (m, 5H, ArH), 4.69 - 
4.59 (m, 1H, PhCH2CH), 4.51 (dd, J = 5.7, 7.9 Hz, 1H, MeSCH2CH2CH), 4.42 (t, J = 7.7 Hz, 1H, 
CH(CH3)2CH2CH), 3.27 - 3.13 (m, 1H, PhCHaHbCH), 3.08 - 2.91 (m, 1H, PhCHaHbCH), 2.55 - 2.39 (m, 
2H, MeSCH2CH2CH), 2.06 (s, 3H, SCH3), 2.02 - 1.78 (m, 2H, MeSCH2CH2CH), 1.65 (dt, J = 6.6, 13.5 
Hz, 1H, CH(CH3)2CH2CH), 1.58 - 1.47 (m, 2H, CH(CH3)2CH2CH), 0.96 - 0.85 (m, 6H, CH(CH3)2CH2CH). 
13C NMR (75MHz, MeOD-d4) δ 174.5, 173.2, 163.8, 138.4, 130.5, 129.6, 128.0, 55.1, 53.1, 52.5, 
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42.1, 38.4, 33.1, 31.0, 25.9, 23.5, 22.1, 15.4. I.R (thinfilm) ν max (cm-1): 3284 ((C=O)NH), 1729, 
1634, 1621 (C=O); HRMS (ESI): m/z calculated for C21H31N3O5S: requires: 438.2062 for [M+H]+; 
found: 438.2080. 
2-Bromobenzyl alcohol formate 52a 
 
General procedure H was followed. Eluent 5% EtOAc in pet ether the fractions 
containing product were combined and the solvent was evaporated under reduced pressure to 
give the title compound as a yellow oil in 80% yield (0.172 g, 0.80 mmol). 1H NMR (500 MHz, 
CDCl3) δ 8.19 (s, 1H, (C=O)H), 7.61 (dd, J = 1.2, 8.1 Hz, 1H, ArH), 7.45 (dd, J = 2.0, 7.8 Hz, 1H, ArH), 
7.34 (dt, J = 1.2, 7.5 Hz, 1H, ArH), 7.25 - 7.20 (m, 1H, ArH), 5.31 (s, 2H, CH2). 13C NMR (126 MHz, 
CDCl3) δ 160.5, 134.5, 132.9, 130.1, 130.0, 127.6, 123.5, 65.2. I.R (thinfilm) ν max (cm-1): 1719 
(C=O); HRMS (ESI): m/z calculated for C8H7BrO2: requires: 214.9629 for [M+H]+; found: 214.9974. 
Citronellyl formate 52b 
 
General procedure H was followed. Eluent 5% EtOAc in pet ether the fractions 
containing product were combined and the solvent was evaporated under reduced pressure to 
give the title compound as a clear oil in 83% yield (0.153 g, 0.83 mmol). 1H NMR (300 MHz, CDCl3) 
δ 8.06 (s, 1H, (C=O)H), 5.19 - 4.98 (m, 1H, C=CH), 4.29 - 4.11 (m, 2H, CH2O(C=O)H), 2.12 - 1.83 
(m, 2H,), 1.81 - 1.64 (m, 4H), 1.61 (s, 3H, C=CCH3), 1.58 - 1.29 (m, 3H), 1.27 - 1.14 (m, 1H), 0.93 
(d, J = 6.4 Hz, 3H, CHCH3). 13C NMR (75 MHz, CDCl3) δ 161.2, 131.4, 124.5, 62.5, 36.9, 35.3, 29.4, 
25.7, 25.4, 19.3, 17.6. 
Analytical data in accordance with literature.326 
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Biphenyl-4-methanol formate 52c 
 
General procedure H was followed. Eluent 5% EtOAc in pet ether the fractions 
containing product were combined and the solvent was evaporated under reduced pressure to 
give the title compound as crystalline white solid in 80% yield (0.170 g, 0.80 mmol). 1H NMR (300 
MHz, CDCl3) δ = 8.18 (t, J = 0.9 Hz, 1H, (C=O)H), 7.65 - 7.57 (m, 4H, ArH), 7.50 - 7.42 (m, 4H, ArH), 
7.41 - 7.34 (m, 1H, ArH), 5.27 (s, 2H, CH2O(C=O)). 13C NMR (75 MHz, CDCl3) δ 160.8, 141.5, 140.5, 
134.1, 128.9, 128.8, 127.5, 127.4, 127.1, 65.5. I.R (thinfilm) ν max (cm-1): 1702 (C=O); HRMS (ESI): 
m/z calculated for C14H12O2: requires: 213.0915 for [M+H]+; found: 213.1055. 
4-Methoxy phenethyl alcohol formate 52d 
 
General procedure H was followed. Eluent 5% EtOAc in pet ether the fractions 
containing product were combined and the solvent was evaporated under reduced pressure to 
give the title compound as a clear oil in 71% yield (0.127 g, 0.71 mmol). 1H NMR (300 MHz, CDCl3) 
δ 8.05 (s, 1H, (C=O)H), 7.19 - 7.10 (m, 2H, ArH), 6.91 - 6.81 (m, 2H, ArH), 4.36 (t, J = 7.0 Hz, 2H, 
CH2(OC=O)), 3.81 (s, 3H, CH3), 2.93 (t, J = 7.2 Hz, 2H, CH2CH2(OC=O)). 13C NMR (75 MHz, CDCl3) δ 
161.0, 158.4, 129.8, 129.3, 113.9, 64.6, 55.2, 34.0. 
Analytical data in accordance with literature.326 
1-Phenylethanol formate 52e 
 
General procedure H was followed. Eluent 5% EtOAc in pet ether the fractions 
containing product were combined and the solvent was evaporated under reduced pressure to 
give the title compound as a pale yellow oil in 75% yield (0.112 g, 0.75 mmol). 1H NMR (300 MHz, 
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CDCl3) δ 8.11 (s, 1 H, (C=O)H), 7.42 - 7.28 (m, 5H, ArH), 6.18 - 5.85 (m, 1H, CH(OC=O)), 1.60 (d, J 
= 7.2 Hz, 3H, CH3). 13C NMR (75MHz, CDCl3) δ 160.4, 140.8, 128.6, 128.1, 126.1, 72.2, 22.1. 
Analytical data in accordance with literature.326 
Menthol formate 52f 
 
General procedure H was followed. Eluent 5% EtOAc in pet ether the fractions 
containing product were combined and the solvent was evaporated under reduced pressure to 
give the title compound as a yellow oil in 78% yield (0.143 g, 0.78 mmol). 1H NMR (300 MHz, 
CDCl3) δ 8.08 (d, J = 0.8 Hz, 1H, (C=O)H), 4.81 (dt, J = 4.3, 10.8 Hz, 1H, CH(OC=O)), 2.07 - 1.97 (m, 
1H, CH), 1.91 (dtd, J = 2.6, 7.0, 13.9 Hz, 1H, CH), 1.76 - 1.64 (m, 2H, CH2), 1.59 - 1.33 (m, 2H, CH2), 
1.14 - 0.98 (m, 2H, CH), 0.95 - 0.84 (m, 7H, CH & CH(CH3)2), 0.77 (d, J = 6.8 Hz, 3H, CH3). 13C NMR 
(75 MHz, CDCl3) δ 160.9, 74.1, 46.8, 40.8, 34.1, 31.4, 26.0, 23.2, 22.0, 20.7, 16.0. 
Analytical data in accordance with literature.327 
Perillyl alcohol formate 52g 
 
General procedure H was followed. Eluent 5% EtOAc in pet ether the fractions 
containing product were combined and the solvent was evaporated under reduced pressure to 
give the title compound as a yellow oil in 88% yield (0.159 g, 0.88 mmol). [α]D20 = -62.5 in MeOH. 
1H NMR (300 MHz, CDCl3) δ 8.11 (s, 1H, (C=O)H), 5.86 - 5.76 (m, 1H, CH2C=CH), 4.77 - 4.70 (m, 
2H, C=CH2), 4.57 (s, 2H, CH2O(C=O)), 2.26 - 2.06 (m, 4H, CH2), 2.05 - 1.94 (m, 1H, CH), 1.93 - 1.80 
(m, 1H, CH), 1.75 (s, 3H, CH3), 1.60 - 1.41 (m, 1H, CH). 13C NMR (75 MHz, CDCl3) δ 161.0, 149.4, 
132.0, 126.8, 108.8, 68.0, 40.7, 30.4, 27.2, 26.3, 20.7. I.R (thinfilm) ν max (cm-1): 1722 (C=O); 
HRMS (ESI): m/z calculated for C11H16O2: requires: 181.1228 for [M+H]+; found: 181.1210. 
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Carveol formate 52h 
 
General procedure H was followed. Eluent 5% EtOAc in pet ether the fractions 
containing product were combined and the solvent was evaporated under reduced pressure to 
give the title compound as a yellow oil in a 84% yield (0.150 g, 0.84 mmol) 
Product obtained as a mixture of diastereomers (1:1) in the same ratio as the starting material.  
1H NMR (300 MHz, CDCl3) δ 8.17 (d, J = 1.1 Hz, 1H, (C=O)H), 8.14 (s, 1H, (C=O)H), 5.82 - 5.75 (m, 
1H), 5.68 - 5.53 (m, 2H), 5.44 - 5.37 (m, 1H), 4.78 - 4.74 (m, 2H), 4.74 - 4.70 (m, 2H), 2.40 - 2.06 
(m, 5H), 2.04 - 1.82 (m, 4H), 1.76 - 1.68 (m, 10H), 1.68 - 1.63 (m, 3H), 1.61 - 1.56 (m, 1H). 13C 
NMR (75 MHz, CDCl3) δ 161.1 (α), 161.0 (β), 148.5 (α), 148.1(β), 132.1 (α), 130.2(β), 128.6 (α), 
126.5(β), 109.5 (α), 109.4(β), 73.1 (α), 70.5(β), 40.2 (α), 35.7(β), 33.9  (α), 33.7(β), 30.8 (α), 
30.7(β), 20.8 (α), 20.5(β), 20.5 (α), 18.8 (β). I.R (thinfilm) ν max (cm-1): 1717 (C=O); HRMS (ESI): 
m/z calculated for C11H16O2: requires: 181.1228for [M+H]+; found: 181.1190. 
Geranyl formate 52i 
 
General procedure H was followed. Eluent 5% EtOAc in pet ether the fractions 
containing product were combined and the solvent was evaporated under reduced pressure to 
give the title compound as a pale yellow oil in 85% yield (0.155 g, 0.85 mmol). 1H NMR (300 MHz, 
CDCl3) δ 8.08 (s, 1H, (C=O)H), 5.45 - 5.31 (m, 1H C=CHCH2O), 5.20 - 5.00 (m, 1H, C=CHCH2), 4.70 
(d, J = 7.2 Hz, 2H, CH2O(C=O)), 2.17-2.06 (m, 4H, CH2CH2), 1.76 - 1.71 (m, 3H CH3C(CH3)=CH), 1.71 
- 1.67 (m, 3H, CH3C(CH3)=CH), 1.61 (s, 3H, CH2C(CH3)=CH). 13C NMR (75 MHz, CDCl3) δ 161.1, 
143.2, 131.9, 123.6, 117.6, 60.8, 39.5, 26.2, 25.7, 17.7, 16.5. 
Analytical data in accordance with literature.328 
4-Methoxyphenol formate 52j 
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General procedure H was followed. Eluent 5% EtOAc in pet ether the fractions 
containing product were combined and the solvent was evaporated under reduced pressure to 
give the title compound as an orange oil in a 75% yield (0.114 g, 0.75 mmol). 1H NMR (300MHz, 
CDCl3) δ 8.30 (s, 1H, (C=O)H), 7.12 - 7.01 (m, 2H, ArH), 6.96 - 6.87 (m, 2H, ArH), 3.82 (s, 3H, CH3). 
13C NMR (75MHz, CDCl3) δ 159.7, 157.6, 143.3, 122.0, 114.6, 55. 
Analytical data in accordance with literature.329  
(S)-methyl 2-acetamido-3-hydroxypropanoate 53.2 
 
Serine methyl ester hydrochloride salt (0.5 g, 3.21 mmol) was suspended in acetone (3 
mL), to this was added NEt3 (0.42 mL, 3.21 mmol) dropwise. The mixture was stirred for 10 min 
and then filtered through a Celite® pad. The filtrate was concentrated in vacuo to give serine 
methyl ester which was used without further purification.  
General procedure A was followed. Eluent 5% MeOH in CH2Cl2 the fractions containing product 
were combined and the solvent was evaporated under reduced pressure to give the title 
compound as a brown oil in 83% yield (0.428 g, 2.56 mmol), [α]D20 = -9.5 MeOH; 1H NMR (500 
MHz, CDCl3) δ 6.5 (s, 1H, NH), 4.7 (dt, J = 7.3, 3.6 Hz, 1H, CHNH), 4.0 – 3.9 (m, 2H, CH2OH), 3.8 (s, 
3H, OCH3), 2.8 (s, 1H, OH), 2.1 (s, 3H, (C=O)CH3), 13C NMR (126 MHz, CDCl3) δ 171.1, 170.8, 63.6, 
54.9, 52.9, 23.3. [α]D20 = -9.5 in MeOH. I.R (thinfilm) ν max (cm-1): 3291 ((C=O)NH and OH), 1738, 
1648 (C=O); HRMS (ESI): m/z calculated for C6H11NO4: requires: 162.0766 for [M+H]+; found: 
162.0788. 
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(S)-methyl 2-acetamido-3-(formyloxy)propanoate 53.3 
 
General procedure H was followed. Eluent 5% MeOH in CH2Cl2 the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a white solid in 78% yield (0.377 g, 2.0 mmol); m.p. 95-97 °C, [α]D20 = -56 CHCl3. 
1H NMR (300 MHz, Chloroform-d) δ 8.0 (q, J = 0.9 Hz, 1H, (C=O)H), 6.3 (s, 1H, NH), 4.9 (dt, J = 7.1, 
3.3 Hz, 1H, CHNH), 4.6 – 4.4 (m, 2H, CH2O(C=O)H), 3.8 (s, 3H, OCH3), 2.1 (s, 3H, (C=O)CH3). 13C 
NMR (75 MHz, Chloroform-d) δ 170.0, 169.9, 160.3, 63.6, 53.2, 51.6, 23.2. I.R (thinfilm) ν max 
(cm-1): 3292 ((C=O)NH), 1727, 1713, 1703 (C=O); HRMS (ESI): m/z calculated for C7H11NO5: 
requires: 190.0715 for [M+H]+; found: 190.0739.  
2,4-diphenyl-1,3-dioxane 54.2 
 
General procedure I was followed. Eluent 5% EtOAc in pet ether, the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a clear oil in 85% yield. (0.204 g, 0.85 mmol); 1H NMR (300 MHz, CDCl3) δ 7.6 
– 7.5 (m, 2H, ArH), 7.5 – 7.3 (m, 8H, ArH), 5.7 (s, 1H, OCHO), 4.9 (dd, J = 11.4, 2.6 Hz, 1H, 
OCHCHaHb), 4.4 (ddd, J = 11.5, 5.0, 1.4 Hz, 1H, OCHaHb), 4.2 (td, J = 11.9, 2.5 Hz, 1H, OCHaHb), 2.3 
– 2.0 (m, 1H, OCHCHaHb), 1.8 (dtd, J = 13.5, 2.5, 1.4 Hz, 1H, OCHCHaHb), 13C NMR (75 MHz, CDCl3) 
δ 141.8, 138.8, 129.0, 128.6, 128.4, 127.9, 126.3, 126.0, 101.7, 79.2, 67.5, 33.6. I.R (thinfilm) ν 
max (cm-1): 2962, 2853 (Ar C-H); HRMS (ESI): m/z calculated for C16H16O2: requires: 263.1048 for 
[M+H]+; found: 263.1030.  
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4-methyl-2-phenyl-1,3-dioxane 57a 
 
General procedure I was followed. Eluent 5% EtOAc in pet ether, the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a clear oil in 80% yield. (0.142 g, 0.80 mmol); 1H NMR (300 MHz, CDCl3) δ 7.5 
– 7.4 (m, 2H, ArH), 7.4 – 7.3 (m, 3H, ArH), 5.5 (s, 1H, OCHO), 4.3 (ddd, J = 11.4, 5.0, 1.4 Hz, 1H, 
CHCH3), 4.1 – 3.8 (m, 2H, OCH2CHaHb), 1.8 (dddd, J = 13.4, 12.4, 11.0, 5.0 Hz, 1H, OCH2CHaHb), 
1.5 (dtd, J = 13.3, 2.5, 1.4 Hz, 1H, OCH2CHaHb), 1.3 (d, J = 6.2 Hz, 3H, CHCH3). 13C NMR (75 MHz, 
CDCl3) δ 138.9, 128.9, 128.4, 126.2, 101.5, 73.6, 67.2, 33.1, 22.0.  
Analytical data in accordance with literature.330 
2-phenyl-1,3-dioxane 57b 
 
General procedure I was followed. Eluent 5% EtOAc in pet ether, the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a clear oil in 80% yield. (0.131 g, 0.80 mmol); 1H NMR (300 MHz, CDCl3) δ 7.6 
– 7.4 (m, 2H, ArH), 7.4 – 7.3 (m, 3H, ArH), 5.5 (s, 1H, OCHO), 4.3 (ddt, J = 10.5, 5.0, 1.4 Hz, 2H, 2 
x OCHaHb), 4.1 – 3.9 (m, 2H, 2 x OCHaHb), 2.2 (dtt, J = 13.5, 12.4, 5.0 Hz, 1H, CH2HaHbCH2), 1.5 
(dtt, J = 13.5, 2.7, 1.4 Hz, 1H, CH2HaHbCH2). 13C NMR (75 MHz, CDCl3) δ 138.8, 128.9, 128.4, 126.1, 
101.8, 67.5, 25.9. 
Analytical data in accordance with literature.331 
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(2R,4R)-2,4-diphenyl-1,3-dioxolane 57c 
 
General procedure I was followed. Eluent 5% EtOAc in pet ether, the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a clear oil in 88% yield. (0.199 g, 0.88 mmol), [α]D20 = -100 in CHCl3. 1H NMR 
(300 MHz, CDCl3) δ 7.6 – 7.5 (m, 2H, ArH), 7.5 – 7.3 (m, 8H, ArH), 6.2 (s, 1H, OCHO), 5.2 (dd, J = 
7.7, 6.4 Hz, 1H, OCHCHaHb), 4.5 (dd, J = 8.3, 6.3 Hz, 1H, OCHCHaHb), 4.0 – 3.8 (m, 1H, OCHCHaHb). 
13C NMR (75 MHz, CDCl3) δ 139.5, 138.3, 129.4, 128.8, 128.6, 128.3, 126.5, 126.2, 104.7, 78.0, 
72.9., I.R (thinfilm) ν max (cm-1): 2965, 2848 (Ar C-H); HRMS (ESI): m/z calculated for C15H14O2: 
requires: 227.1072 for [M+H]+; found: 227.1068. 
4-methyl-2-phenyl-1,3-dioxolane 57d 
 
General procedure I was followed. Eluent 5% EtOAc in pet ether, the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a clear oil in 82% yield as a mix of diastereomers (2:3 syn:anti). (0.134 g, 0.82 
mmol); 1H NMR (300 MHz, CDCl3) δ 7.5 – 7.4 (m, 4H, ArH, syn and anti), 7.4 – 7.3 (m, 6H, ArH, 
syn and anti), 6.0 (s, 1H, OCHO, syn), 5.8 (s, 1H, OCHO, anti), 4.4 – 4.3 (m, 2H, CHCH3, syn and 
anti), 4.3 (dd, J = 7.8, 6.0 Hz, 1H, CHCHaHb, syn), 4.1 (dd, J = 7.5, 6.5 Hz, 1H, CHCHaHb, anti), 3.7 
– 3.5 (m, 2H, CHCHaHb, syn and anti), 1.4 (d, J = 6.1 Hz, 3H, CHCH3, anti), 1.4 (d, J = 6.1 Hz, 3H, 
CHCH3, syn). 13C NMR (75 MHz, CDCl3) δ 129.4, 129.2, 128.5, 126.7, 126.5, 104.2, 103.2, 73.6, 
72.5, 72.2, 71.6, 18.7, 18.5, mix of syn and anti. I.R (thinfilm) ν max (cm-1): 2961, 2868 (Ar C-H); 
HRMS (ESI): m/z calculated for C10H12O2: requires: 187.0735 for [M+Na]+; found: 187.0376. 
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4-(tert-butyl)-2-phenyl-1,3-dioxolane 57e 
 
General procedure I was followed. Eluent 5% EtOAc in pet ether, the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a clear oil in 78% yield, as a mixture of separateable diastereomers (0.161 g, 
0.78 mmol); Syn: 1H NMR (300 MHz, CDCl3)) δ 7.5 – 7.4 (m, 2H, ArH), 7.4 – 7.3 (m, 3H, ArH), 5.9 
(s, 1H, OCHO), 4.1 (dd, J = 8.0, 6.3 Hz, 1H, CHC(CH)3), 3.9 (dd, J = 8.1, 6.3 Hz, 1H, CHaHb), 3.8 (t, J 
= 8.1 Hz, 1H, CHaHb), 1.0 (s, 9H, CHC(CH)3). 13C NMR (75 MHz, CDCl3)) δ 138.9, 129.1, 128.5, 126.5, 
104.4, 84.2, 66.8, 33.5, 25.7. Anti: 1H NMR (300 MHz, CDCl3)) δ 7.6 – 7.5 (m, 2H, ArH), 7.4 – 7.3 
(m, 3H, ArH), 5.8 (s, 1H, OCHO), 4.0 – 3.9 (m, 3H, CHCH2), 1.0 (s, 9H, CHC(CH)3). 13C NMR (75 MHz, 
CDCl3)) δ 137.6, 129.5, 128.5, 127.0, 104.1, 84.8, 66.4, 33.1, 25.7. I.R (thinfilm) ν max (cm-1): 
2956, 2871 (Ar C-H); HRMS (ESI): m/z calculated for C13H18O2: requires: 205.1228 for [M-H]-; 
found: 205.1229. 
(4R,5R)-4,5-dimethyl-2-phenyl-1,3-dioxolane 57f 
 
General procedure I was followed. Eluent 5% EtOAc in pet ether, the fractions containing 
product were combined and the solvent was evaporated under reduced pressure to give the 
title compound as a clear oil in 84% yield. (0.150 g, 0.84 mmol), [α]D20 = -33 in CHCl3. 1H NMR 
(300 MHz, CDCl3) δ 7.5 – 7.5 (m, 2H, ArH), 7.4 – 7.3 (m, 3H, ArH), 5.9 (s, 1H, OCHO), 3.8 (dtt, J = 
7.4, 5.3, 2.7 Hz, 2H, 2 x CHCH3), 1.4 – 1.4 (m, 3H, CHCH3), 1.4 – 1.3 (m, 3H, CHCH3). 13C NMR (75 
MHz, CDCl3)) δ 138.7, 129.3, 128.5, 126.6, 102.8, 80.5, 78.8, 17.4, 17.1. 
Analytical data in accordance with literature.332, 333 
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(((phenylmethylene)bis(oxy))bis(methylene))dibenzene 57g 
 
Benzyl alcohol (0.216 g, 2.0 mmol) and acetic acid (0.65 μL, 0.01 mmol) were added to 
phenylmethylene diacetate (0.208 g, 1.0 mmol) in MeCN (3 mL) and heated to 40 °C for 12 h. 
The crude reaction mixture was concentrated under vacuum and the resulting residue was 
purified by column chromatography to give the isolated acetal. Eluent 5% EtOAc in pet ether, 
the fractions containing product were combined and the solvent was evaporated under reduced 
pressure to give the title compound as a clear oil in 66% yield (0.200 g, 0.66 mmol); 1H NMR (300 
MHz, DMSO-d6) δ 7.6 – 7.2 (m, 15H, ArH), 5.8 (d, J = 3.6 Hz, 1H, OCHO), 4.6 (s, 4H, CH2Ph). 13C 
NMR (75 MHz, DMSO-d6) δ 138.5, 138.1, 128.6, 128.3, 128.3, 127.6, 127.5, 126.6, 100.6, 67.1.    
Analytical data in accordance with literature.334 
Acetoxy(phenyl)methyl pivalate 58.3 
 
General procedure C was followed. Further purified by column chromatography, eluent 
5% EtOAc in pet ether, the fractions containing product were combined and the solvent was 
evaporated under reduced pressure to give the title compound as a clear oil a 60% yield (1.41 g, 
5.64 mmol). 1H NMR (300 MHz, CDCl3)) δ 7.7 (s, 1H, OCHO), 7.6 – 7.4 (m, 2H, ArH), 7.5 – 7.3 (m, 
3H, ArH), 2.1 (s, 3H, C(O)CH3), 1.2 (s, 9H, C(O)C(CH3)3). 13C NMR (75 MHz, CDCl3)) δ 176.4, 169.1, 
135.8, 129.7, 128.7, 126.7, 89.9, 39.0, 27.0, 21.1. 
Protecting Group Free Synthesis towards Polyketide Natural Products 
Enantiomeric excess analysis 
 Enantiomeric excess was determined by gas chromatography (GC), model Agilent 7890A 
fitted with three detectors. A flame ionisation detector (FID), a thermal conductivity detector 
(TCD) and an Agilent 5975C Mass Spec. The column used for analysis was a β-Dex 30 m long 
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0.530 mm in diameter. Method initial temperature: 80 °C held for 2 min, heated to 230 °C at a 
ramp of 10 °C min-1 and held at that final temperature for 2 min.   
Synthesis of (1E,3E)-1-ethoxy-2-methylpenta-1,3-diene 96.1 Route one 
 
Step 1: (E)-3-ethoxy-2-methylacrylaldehyde 94.2 
 N,N-Dimethylformamide (14 mL, 182.4 mmol) was added dropwise to phosphorus(V) 
oxychloride (15.6 mL, 167.2 mmol) at 0 °C with vigorous stirring. Propionaldehyde diethyl acetal 
94.1 (10 g, 12.3 mL, 76 mmol) was then slowly added to the reaction mixture ensuring that 
reaction temperature does not exceed 40 °C. Upon completion of addition the reaction was 
heated to 70 °C for 2 h, the reaction was then poured over ice (30 g) and left overnight. The 
solution was then basified with K2CO3 and extracted with Et2O (3x 100 mL), the combined organic 
layers were dried (MgSO4) and concentrated in vacuo to give the title compound as a pale yellow 
oil (2.6 g, 30%, 54.7 mmol). 1H NMR (300 MHz, CDCl3) δ 9.24 (s, 1H, C(O)H), 6.97 (d, J = 1.1 Hz, 
1H, CHOEt), 4.18 (q, J = 7.2 Hz, 2H, CH3CH3), 1.69 (d, J = 1.1 Hz, 3H, CH3), 1.40 (t, J = 7.2 Hz, 3H, 
CH2CH3). 13C NMR (75 MHz, CDCl3) δ 192.0, 167.9, 120.0, 71.0, 15.3, 6.4. I.R (thin film) ν max (cm-
1): 2983 (C=C-H), 1631 (C=O). HRMS (ESI): m/z calculated. C6H10O2: requires 115.075905 for 
[M+H]+; found: 115.0776; requires: 137.057849 for [M+Na]+; found: 137.0590. 
Step 2: (1E,3E)-1-ethoxy-2-methylpenta-1,3-diene 96.1 
 nBuLi (14.7 mL, 1.4 M in hexanes) was added slowly to a stirred solution of 
diisopropylamine (4.16 mL, 28.8 mmol) in THF (50 mL) at -78 °C and stirred for 10 min. The 
reaction was then warmed to 0 °C followed by the addition of ethyltriphenylphosphonium 
bromide (9.18 g, 25 mmol) the reaction was then allowed to warm to rt and stirred for 1 h. (E)-
3-ethoxy-2-methylacrylaldehyde 20.2 (2.35 g, 20.6 mmol) was added dropwise and stirred for 2 
h. The reaction was then diluted with H2O (100 mL) and extracted with Et2O (3x 50 mL), the 
combined organic layers were dried (MgSO4) and carefully concentrated in vacuo to give a crude 
mixture of product and triphenylphosphine oxide. The product was purified by kugelrohr 
distillation under reduced pressure to give the title compound as a yellow oil (2.08 g, 80%, 16.5 
mmol, B.P 75 °C at 40 milibar). (1E, 3E): 1H NMR (300 MHz, CDCl3) δ 6.15 - 6.07 (m, 1 H, CHOEt), 
5.96 (dd, J = 1.4, 15.4 Hz, 1 H, CHCHCH3), 5.45 (qd, J = 6.6, 15.1 Hz, 1 H, CHCHCH3), 3.83 (q, J = 
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7.2 Hz, 2 H, CH2CH3), 1.76 (dd, J = 1.3, 6.6 Hz, 3 H, CHCHCH3), 1.71 (d, J = 1.1 Hz, 3 H, EtOCHCH3), 
1.27 (t, J = 7.1 Hz, 3 H, OCH2CH3). (1E, 3Z): 1H NMR (300 MHz, CDCl3) δ 6.15 - 6.07 (m, 1 H, CHOEt), 
5.70 (app d, J = 11.3 Hz, 1 H, CHCHCH3), 5.31 (qd, J = 7.2, 11.7 Hz, 1 H, CHCHCH3), 3.83 (q, J = 7.0 
Hz, 2 H, CH2CH3), 1.76 (dd, J = 1.3, 6.6 Hz, 3 H, CHCHCH3), 1.69 (d, J = 1.1 Hz, 3 H, EtOCHCH3), 
1.28 (t, J = 7.1 Hz, 3 H, OCH2CH3). 13C NMR (75 MHz, CDCl3) δ 145.4, 130.8, 119.5, 114.3, 67.9, 
18.3, 15.3, 9.6. I.R (thinfilm) ν max (cm-1): 2978 (C=C-H), 2932 (C=C-H), 1650 (C=C), 1634 (C=C) 
Synthesis of (1E,3E)-1-ethoxy-2-methylpenta-1,3-diene 96.1 Route two 
 
Step 1: (E)-1,1-diethoxy-2-methylpent-2-ene 98.2 
 (E)-2-methylpentenal 98.1 (2 g, 2.4 mL, 20.36 mmol) was added to a stirred solution of 
triethylorthoformate (4.1 mL, 24.4 mmol) and ammonium nitrate (0.16 g, 2.04 mmol) in EtOH 
(15 mL) and stirred at rt for 18 h. The reaction was concentrated in vacuo the residues was then 
dissolved in Et2O (50 mL) and washed with H2O (3x 20 mL). The organic layer was then dried 
(MgSO4) and concentrated in vacuo to give the title compound as a yellow oil (3.33 g, 95%, 19.34 
mmol). 1H NMR (300 MHz, CDCl3) δ 5.52 (app t, J = 7.0 Hz, 1 H, CHCH2CH3), 4.58 (s, 1 H, (EtO)2CH), 
3.63 - 3.53 (m, 2 H, OCH2CH3), 3.50 - 3.39 (m, 2 H, OCH2CH3), 2.07 (ap quin, J = 7.4 Hz, 2 H, 
CHCH2CH3), 1.62 (s, 3 H, CH3), 1.29 - 1.17 (m, 6 H, 2 X OCH2CH3), 0.98 (t, J = 7.5 Hz, 3 H, CHCH2CH3). 
13C NMR (75 MHz, CDCl3) δ 132.0, 130.8, 106.1, 61.7, 20.6, 15.1, 13.9, 10.9. I.R (thin film) νmax 
(cm-1): 2974 (C=C-H), 1693 (C=C). HRMS (ESI): m/z calculated. C10H20O2: requires 195.135551 for 
[M+Na]+; found: 195.1206. 
Step 2: (1E,3E)-1-ethoxy-2-methylpenta-1,3-diene 96.1  
 nBuLi (11.7 mL, 1.5M in hexanes) was added dropwise to a mixture of KOtBu (2 g, 17.6 
mmol) in THF (20 mL) at -78 °C under a N2 environment. (E)-1,1-diethoxy-2-methylpent-2-ene 
98.2 (1.5 g, 1.7 mL, 8.8 mmol) was added dropwise to the reaction mixture to give a red mixture. 
The reaction was allowed to warm to rt and stirred for 24 h. The reaction was quenched with 
H2O (15 mL) and extracted with Et2O (3x 20 mL), the combined organic layers were dried (MgSO4) 
and carefully concentrated in vacuo to give crude product. The residue was purified by short 
path distillation under reduced pressure to give the title compound as a yellow oil (0.66 g, 60%, 
5.28 mmol, B.P 75 °C at 40 milibar). (1E, 3E): 1H NMR (300 MHz, CDCl3) δ 6.15 - 6.07 (m, 1 H, 
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CHOEt), 5.96 (dd, J = 1.4, 15.4 Hz, 1 H, CHCHCH3), 5.45 (qd, J = 6.6, 15.1 Hz, 1 H, CHCHCH3), 3.83 
(q, J = 7.2 Hz, 2 H, CH2CH3), 1.76 (dd, J = 1.3, 6.6 Hz, 3 H, CHCHCH3), 1.71 (d, J = 1.1 Hz, 3 H, 
EtOCHCH3), 1.27 (t, J = 7.1 Hz, 3 H, OCH2CH3). (1E, 3Z): 1H NMR (300 MHz, CDCl3) δ 6.15 - 6.07 
(m, 1 H, CHOEt), 5.70 (app d, J = 11.3 Hz, 1 H, CHCHCH3), 5.31 (qd, J = 7.2, 11.7 Hz, 1 H, CHCHCH3), 
3.83 (q, J = 7.0 Hz, 2 H, CH2CH3), 1.76 (dd, J = 1.3, 6.6 Hz, 3 H, CHCHCH3), 1.69 (d, J = 1.1 Hz, 3 H, 
EtOCHCH3), 1.28 (t, J = 7.1 Hz, 3 H, OCH2CH3). 13C NMR (75 MHz, CDCl3) δ 145.4, 130.8, 119.5, 
114.3, 67.9, 18.3, 15.3, 9.6. I.R (thinfilm) νmax (cm-1): 2978 (C=C-H), 2932 (C=C-H), 1650 (C=C), 
1634 (C=C) 
Step 2: (1E,3E)-1-ethoxy-2-methylpenta-1,3-diene 96.1  
 KOtBu (4.94 g, 44 mmol) was added to a solution of (E)-1,1-diethoxy-2-methylpent-2-
ene 98.2 (3 g, 3.4 mL, 17.6 mmol) in DMSO (15 mL). The stirred solution was heated at 80 °C 
under a N2 environment for 4 h. The reaction was quenched with H2O (15 mL) and extracted 
with Et2O (3x 20 mL), the combined organic layers were dried (MgSO4) and carefully 
concentrated in vacuo to give a crude product. The residue was purified by short path distillation 
under reduced pressure to give the title compound as a clear oil (1.77 g, 80%, 14.08 mmol, B.P 
75 °C at 40 milibar). (1E, 3E): 1H NMR (300 MHz, CDCl3) δ 6.15 - 6.07 (m, 1 H, CHOEt), 5.96 (dd, J 
= 1.4, 15.4 Hz, 1 H, CHCHCH3), 5.45 (qd, J = 6.6, 15.1 Hz, 1 H, CHCHCH3), 3.83 (q, J = 7.2 Hz, 2 H, 
CH2CH3), 1.76 (dd, J = 1.3, 6.6 Hz, 3 H, CHCHCH3), 1.71 (d, J = 1.1 Hz, 3 H, EtOCHCH3), 1.27 (t, J = 
7.1 Hz, 3 H, OCH2CH3). (1E, 3Z): 1H NMR (300 MHz, CDCl3) δ 6.15 - 6.07 (m, 1 H, CHOEt), 5.70 (app 
d, J = 11.3 Hz, 1 H, CHCHCH3), 5.31 (qd, J = 7.2, 11.7 Hz, 1 H, CHCHCH3), 3.83 (q, J = 7.0 Hz, 2 H, 
CH2CH3), 1.76 (dd, J = 1.3, 6.6 Hz, 3 H, CHCHCH3), 1.69 (d, J = 1.1 Hz, 3 H, EtOCHCH3), 1.28 (t, J = 
7.1 Hz, 3 H, OCH2CH3). 13C NMR (75 MHz, CDCl3) δ 145.4, 130.8, 119.5, 114.3, 67.9, 18.3, 15.3, 
9.6. I.R (thinfilm) νmax (cm-1): 2978 (C=C-H), 2932 (C=C-H), 1650 (C=C), 1634 (C=C) 
Synthesis of BINOL-Ti complex 106.3242 
 
 A 250 mL Schlenk tube was charged with powdered molecular sieves 4Å (15.0 g) and (R)-
(+)-binaphthol (0.859 g, 3.0 mmol). The Schlenk was then transferred into a glovebox where 
anhydrous CH2Cl2 (90 mL) was added and the reaction was stirred for 20 min. 
Diisopropoxytitanium(IV) chloride (0.711 g, 3.0 mmol) was added in one portion resulting in a 
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red brown reaction mixture. The reaction was removed from the glove box and allowed to stir 
at rt for 1 h.  The reaction mixture was then allowed to settle overnight. The reaction solution 
was transferred via cannula into a new Schlenk flask leaving the molecular sieves behind. The 
stirred reaction was evaporated at 0 °C under reduced pressure to afford a deep red/brown 
residue. The resulting residue is suspended in anhydrous pentane (50 mL) and stirred for 20 min. 
The pentane was decanted via syringe and the resulting precieptate was vacuum-dried to give 
the binaphthol-titanium complex in 90-95% yield and used as catalyst in subsequent reactions.  
Synthesis of ethyl 6-ethoxy-3,5-dimethyl-3,6-dihydro-2H-pyran-2-carboxylate 104.2 
 
 CH2Cl2 (3.0 mL) was added to binaphthol-titanium complex 106.3 (0.016 g, 0.04 mmol) 
under a N2 environment. Ethyl glyoxalate 50% in toluene (0.32 mL, 1.6 mmol) was added and 
the reaction cooled to -30 °C. (1E,3E)-1-ethoxy-2-methylpenta-1,3-diene 96.1 (0.1 g, 0.8 mmol) 
was added and the reaction was stirred at -30 °C for 4 h. The reaction was concentrated in vacuo 
to give a crude mixture which was purified by column chromatography (15% EtOAc in pentane 
Rf = 0.7) the fractions containing product were combined and concentrated in vacuo to give the 
title compound as a clear oil (0.118 g, 65%, 0.52 mmol). 1H NMR (500 MHz, CDCl3) δ = 5.71 - 5.68 
(m, 1 H, C=CH), 5.09 (s, 1 H, EtOCH), 4.34 (d, J = 3.5 Hz, 1 H, CHCO2CH2CH3), 4.28 - 4.22 (m, 2 H, 
CO2CH2CH3), 3.87 (dq, J = 9.6, 7.0 Hz, 1 H, OCHaHbCH3), 3.66 (dq, J = 9.5, 7.1 Hz, 1 H, OCHaHbCH3), 
2.48 - 2.42 (m, 1 H, CHCH3), 1.66 (s, 3 H, CH3C=C), 1.30 (t, J = 7.1 Hz, 3 H, CO2CH2CH3), 1.25 (t, J = 
7.1 Hz, 3 H, OCHaHbCH3), 1.01 (d, J = 6.9 Hz, 3 H, CHCH3). 13C NMR (75 MHz, CDCl3) δ = 170.0, 
132.9, 129.3, 100.3, 74.1, 62.8, 60.8, 31.7, 17.5, 15.2, 14.7, 14.3. I.R (thin film) ν max (cm-1): 2975 
(C=C-H), 1759 (C=O), 1730 (C=C). HRMS (ESI): m/z calculated. C12H20O4: requires 251.1259 for 
[M+Na]+; found: 251.1264. 
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Purification of ethyl glyoxalate  
 
 Commercially available ethyl glyoxalate 50% in toluene was concentrated to remove the 
toluene. The remaining glyoxalate is then distilled under reduced pressure to afford pure ethyl 
glyoxalate. The collection vessel is kept at -78 °C for the duration of the distillation. The pure 
ethyl glyoxalate was then diluted to a 50% solution with fresh anhydrous CH2Cl2 and transferred 
to a Schlenk flask. Allowing for freezer storage of the pure ethyl glyoxalate.   
Synthesis of ethyl 6-ethoxy-3,5-dimethyl-3,6-dihydro-2H-pyran-2-carboxylate 104.2 
 
 CH2Cl2 (3.0 mL) was added to binaphthol-titanium complex 106.3 (0.016 g, 0.04 mmol) 
under a N2 environment, ethyl glyoxalate 50% in CH2Cl2 (0.32 mL, 1.6 mmol) was added and the 
reaction cooled to -30 °C. (1E,3E)-1-ethoxy-2-methylpenta-1,3-diene 96.1 (0.1 g, 0.8 mmol) was 
added and the reaction was stirred at -30 °C for 4 h. The reaction was concentrated in vacuo to 
give a crude mixture which was purified by column chromatography (15% EtOAc in pentane Rf 
= 0.7). The fractions containing product were combined and concentrated in vacuo to give the 
title compound as a clear oil (0.118 g, 65%), [α]D20 = +114 (MeOH). 1H NMR (500 MHz, CDCl3) δ 
= 5.71 - 5.68 (m, 1 H, C=CH), 5.09 (s, 1 H, EtOCH), 4.34 (d, J = 3.5 Hz, 1 H, CHCO2CH2CH3), 4.28 - 
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4.22 (m, 2 H, CO2CH2CH3), 3.87 (dq, J = 9.6, 7.0 Hz, 1 H, OCHaHbCH3), 3.66 (dq, J = 9.5, 7.1 Hz, 1 
H, OCHaHbCH3), 2.48 - 2.42 (m, 1 H, CHCH3), 1.66 (s, 3 H, CH3C=C), 1.30 (t, J = 7.1 Hz, 3 H, 
CO2CH2CH3), 1.25 (t, J = 7.1 Hz, 3 H, OCHaHbCH3), 1.01 (d, J = 6.9 Hz, 3 H, CHCH3). 13C NMR (75 
MHz, CDCl3) δ 170.0, 132.9, 129.3, 100.3, 74.1, 62.8, 60.8, 31.7, 17.5, 15.2, 14.7, 14.3. I.R (thin 
film) νmax (cm-1): 2975 (C=C-H), 1759 (C=O), 1730 (C=C). HRMS (ESI): m/z calculated. C12H20O4: 
requires 251.1259 for [M+Na]+; found: 251.1264. 
 
Synthesis of ethyl 6-ethoxy-4-hydroxy-3,5-dimethyltetrahydro-2H-pyran-2-carboxylate 110.1 
 
 Borane dimethyl sulfide complex (0.2 mL, 1.75 mmol) was added dropwise to a stirred 
solution of ethyl 6-ethoxy-3,5-dimethyl-3,6-dihydro-2H-pyran-2-carboxylate 27.3 (0.2 g, 0.87 
mmol) in THF (5 mL) at  -5 °C the reaction was then placed in a freezer at -20 °C for 16 h. The 
reaction was warmed to -5 °C followed by the addition of H2O2 (30 % w/w) (0.548 mL) and NaOH 
(0.2 g, 4.35 mmol) the reaction was stirred for a further 1 h. The reaction was diluted with H2O 
(10 mL) and Et2O (20 mL) the layers were separated and the organics were washed with H2O (10 
mL X 3), dried (MgSO4) and concentrated in vacuo. The residue was purified via column 
chromatography (20% EtOAc in pentane Rf = 0.3). The fractions containing product were 
combined and concentrated in vacuo to give the title compound as a clear oil (0.18 g, 85%, 0.74 
mmol). [α]D20 = +21 (MeOH). 1H NMR (500 MHz, CDCl3) δ 4.76 (d, J = 3.5 Hz, 1H, EtOCH), 4.31 (d, 
J = 4.4 Hz, 1H, CHCO2CH2CH3), 4.24 (dq, J = 10.8, 7.1 Hz, 1H, CO2CHaHbCH3), 4.14 (dq, J = 10.8, 
7.1 Hz, 1H, CO2CHaHbCH3), 3.93 (t, J = 7.4 Hz, 1H, CHOH), 3.83 (dq, J =9.8, 7.0 Hz, 1H, OCHaHbCH3, 
3.45 (dq, J = 9.8, 7.0 Hz, 1H, OCHaHbCH3), 1.99 (app quin d, J = 7.3, 4.6 Hz, 1H, CH(CO2Et)CHCH3), 
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1.79 (app quin d, J = 7.2, 3.5 Hz, 1H, CH(OEt)CHCH3), 1.70 (br. s, 1H, OH), 1.30 (t, J = 7.3 Hz, 3H, 
CO2CH2CH3), 1.18 - 1.11 (m, 6H, OCH2CH3 and EtOCHCH3), 1.04 (d, J = 6.9 Hz, 3H, 
CH(CO2Et)CHCH3). 13C NMR (75 MHz, CDCl3) δ = 170.7, 102.3, 74.2, 72.5, 64.7, 60.6, 42.1, 39.6, 
14.7, 14.2, 12.7, 12.1. I.R (thin film) ν max (cm-1): 3505 (OH), 1736 (C=O). HRMS (ESI): m/z 
calculated. C12H22O5: requires: 269.1365 for [M+Na]+; found: 269.1355. 
Synthesis of ethyl 6-ethoxy-3,5-dimethyl-4-oxotetrahydro-2H-pyran-2-carboxylate 111.1 
 
 Oxalyl chloride (0.056 g, 0.44 mmol) was dissolved in anhydrous CH2Cl2 (5 mL) at -55 °C 
under N2. DMSO (0.062 g, 0.80 mmol) was added and the resulting solution was stirred for 2 
min. 6-ethoxy-4-hydroxy-3,5-dimethyltetrahydro-2H-pyran-2-carboxylate (0.10 g, 0.40 mmol) in 
CH2Cl2 (0.5 mL) was added dropwise to the solution to form a light yellow cloudy mixture, which 
was stirred for a further 15 mins at -55 °C. NEt3 (0.26 mL, 2.0 mmol) was then added and the 
resulting solution was stirred for 15 mins at -55 °C. The white slurry was then allowed to warm 
to rt and was quenched with H2O (10 mL). The layers were separated and the aqueous layer was 
extracted three times with CH2Cl2 (20 mL). The organics were combined and washed with 1 M 
HCl and saturated NaHCO3, before being dried (MgSO4) and concentrated under vacuum. The 
resulting residue was purified by column chromatography (5% EtOAc in pet ether). The fractions 
containing product were combined and concentrated under vacuum to give the title compound 
as a waxy oil (0.079 g, 80%, 0.32 mmol). 1H NMR (300 MHz, CDCl3)) δ 5.1 (d, J = 4.0 Hz, 1H, 
OCHOCH2CH3), 4.7 (d, J = 4.9 Hz, 1H, CHC(O)OCH2CH3), 4.2 (q, J = 7.1 Hz, 2H, CHC(O)OCH2CH3), 
3.9 (dq, J = 9.7, 7.1 Hz, 1H, OCHaHbCH3), 3.5 (dq, J = 9.7, 7.1 Hz, 1H, OCHaHbCH3), 2.9 – 2.8 (m, 2H, 
2 x CHCH3), 1.3 (t, J = 7.2 Hz, 3H, CHC(O)OCH2CH3), 1.2 – 1.1 (m, 6H, OCH2CH3 and CHCH3), 1.1 (d, 
J = 6.8 Hz, 3H, CHCH3). 13C NMR (75 MHz, CDCl3)) δ 207.5, 169.7, 102.8, 75.3, 64.5, 61.3, 47.9, 
45.5, 14.8, 14.2, 11.6, 9.6. I.R (thin film) νmax (cm-1): 2979, 2936 (C-H), 1727 (C=O). HRMS (ESI): 
m/z calculated. C12H20O5: requires: 267.1208 for [M+Na]+; found: 267.1259. 
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Synthesis of (2R,3S,4R,5R,6S)-ethyl 6-ethoxy-4-hydroxy-3,5-dimethyltetrahydro-2H-pyran-2-
carboxylate 111.2 
 
 Sodium borohydride (0.011 g, 0.30 mmol) was added to a stirred solution of ethyl 6-
ethoxy-3,5-dimethyl-4-oxotetrahydro-2H-pyran-2-carboxylate (0.065 g, 0.266 mmol) in EtOH (5 
mL) at 0 °C under a N2 environment. The reaction was allowed to reach rt and stirred for 1 h, the 
reaction was concentrated under vacuum. The resulting residue was partitioned between CH2Cl2 
and H2O, the layers were separated and the aqueous layer was further extracted with CH2Cl2 (20 
mL x 2), the organics were combined dried (MgSO4) and concentrated under vacuum to give the 
title compound as a clear oil (0.062 g, 95%, 0.25 mmol). 1H NMR (500 MHz, Chloroform-d) δ 4.6 
(d, J = 3.4 Hz, 1H, OCHOCH2CH3), 4.3 – 4.2 (m, 1H, C(O)OCHaHbCH3), 4.2 (d, J = 5.8 Hz, 1H, 
CHC(O)OCH2CH3), 4.2 – 4.1 (m, 1H, C(O)OCHaHbCH3), 3.8 (dq, J = 9.7, 7.1 Hz, 1H, OCHaHbCH3), 3.7 
– 3.6 (m, 1H, CHOH), 3.4 (dq, J = 9.7, 7.0 Hz, 1H, OCHaHbCH3), 2.2 (qdd, J = 7.3, 5.7, 3.7 Hz, 1H, 
CH(CH3)CHOH), 1.9 (qt, J = 7.2, 3.6 Hz, 1H, CH(CH3)CHC(O)OCH2CH3), 1.3 (td, J = 7.1, 0.6 Hz, 3H, 
C(O)OCH2CH3), 1.2 – 1.1 (m, 6H, OCH2CH3 and CHCH3), 1.1 – 1.0 (m, 3H, CHCH3). 13C NMR (126 
MHz, Chloroform-d) δ 172.0, 101.3, 73.6, 70.6, 64.7, 61.2, 39.2, 37.0, 14.8, 14.3, 12.7, 12.3. I.R 
(thin film) ν max (cm-1): 3480 (OH), 1739 (C=O). HRMS (ESI): m/z calculated. C12H22O5: requires: 
269.1365 for [M+Na]+; found: 269.1362. 
Synthesis of diethyl 2-hydroxy-3,5-dimethylhexanedioate 112.1 
 
 5% Pd/AlO3 (0.18 g, 0.088 mmol) was added to a solution of ethyl 6-ethoxy-3,5-dimethyl-
3,6-dihydro-2H-pyran-2-carboxylate (0.2 g, 0.87 mmol) in EtOH (3 mL) the reaction when then 
placed under a H2 environment and stirred at rt for 24 h. The reaction was filtered through 
Celite® and concentrated in vacuo. The residue was purified via column chromatography (20% 
EtOAc in pentane Rf = 0.15). The fractions containing product were combined and concentrated 
in vacuo to give the title compound as a clear oil (0.16 g, 75%, 0.066 mmol). 1H NMR (300 MHz, 
CDCl3) δ 4.34 - 4.20 (m, 2H, CH(CH3)CO2CH2CH3), 4.19 - 4.05 (m, 3H, CH(OH)CO2CH2CH3 and 
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CH(OH)CO2CH2CH3), 2.79 (d, J = 5.3 Hz, 1H, CO2EtCHCH3), 2.63 - 2.46 (m, 1H, CH(OH)CHCH3), 2.08 
- 1.93 (m, 1H, CH(CH3)CHaCHbCH(CH3)), 1.92 - 1.80 (m, 1H, CH(CH3)CHaCHbCH(CH3)), 1.29 (t, J = 
7.2 Hz, 3H, CH(OH)CO2CH2CH3), 1.26 (t, J = 7.2 Hz, 3H, CH(CH3)CO2CH2CH3),  1.19 (d, J = 7.0 Hz, 
3H, CH(OH)CHCH3), 0.83 (d, J = 6.6 Hz, 3H, CO2EtCHCH3). 13C NMR (75 MHz, CDCl3) δ 176.6, 174.8, 
73.3, 61.7, 60.2, 37.3, 37.2, 34.5, 17.9, 14.2, 14.2, 12.9. I.R (thin film) ν max (cm-1): 3505 (OH), 
1727 (C=O). HRMS (ESI): m/z calculated. C12H22O5: requires: 269.1365 for [M+Na]+; found: 
269.1431. 
Synthesis of ethyl 6-ethoxy-3,5-dimethyltetrahydro-2H-pyran-2-carboxylate 112.2 
 
 5% Pd/AlO3 (0.18 g, 0.088 mmol) was added to a solution of ethyl 6-ethoxy-3,5-dimethyl-
3,6-dihydro-2H-pyran-2-carboxylate 27.3 (0.2 g, 0.87 mmol) in EtOAc (3 mL), the reaction was 
then placed under a pressurised H2 environment (50 PSI) and stirred at rt for 24 h. The reaction 
was filtered through Celite® and concentrated in vacuo. The residue was purified via column 
chromatography (20% EtOAc in pentane Rf = 0.4). The fractions containing product were 
combined and concentrated in vacuo to give the title compound as a clear oil (0.17 g, 85%, 0.075 
mmol). [α]D20 = +48 (MeOH), +82 (CHCl3). 1H NMR (500 MHz, CDCl3) δ 4.56 (d, J = 3.2 Hz, 1H, 
EtOCH), 4.24 (qd, J = 7.1, 10.8 Hz, 1H, OCHaHbCH3), 4.18 - 4.08 (m, 1H, OCHaHbCH3), 4.04 (d, J = 
4.7 Hz, 1H, CHCO2CH2CH3), 3.82 (dq, J = 9.8, 7.1 Hz, 1H, CO2CHaHbCH3), 3.45 (dq, J = 9.8, 7.0 Hz, 
1H, CO2CHaHbCH3), 2.10 - 2.01 (m, 1H, CH(CO2Et)CHCH3), 1.90 - 1.84 (m, 1H, CH(OEt)CHCH3), 1.84 
- 1.75 (m, 1H, CH(CH3)CHaCHbCH(CH3)), 1.56 - 1.49 (m, 1H, CH(CH3)CHaCHbCH(CH3)), 1.31 (t, J = 
7.1 Hz, 3H, CO2CH2CH3), 1.15 (t, J = 6.9 Hz, 3H, OCH2CH3), 1.09 (d, J = 7.3 Hz, 3H, CH(OEt)CHCH3), 
0.94 (d, J = 6.6 Hz, 3H, CH(CO2Et)CHCH3). 13C NMR (75 MHz, CDCl3) δ 170.9, 101.6, 73.9, 64.3, 
60.3, 34.5, 32.2, 31.6, 16.9, 16.1, 14.7, 14.2. I.R (thin film) ν max (cm-1): 1739 (C=O). HRMS (ESI): 
m/z calculated. C12H22O4: requires: 253.1416 for [M+Na]+; found: 253.1407. 
Preparation of quaternary ammonium tetrakis(diperoxotungsto)phosphates (-3) 
[(C8H17)3NCH3]3PO4[W(O)(O2)2]4266 
Tungstic acid (2.5 g, 10.0 mmol) was suspended in 30% H2O2 (7 mL) and heated at 60 °C until the 
reaction becomes a clear solution. The reaction was then cooled to rt, 40% phosphoric acid (0.62 
mL, 2.5 mmol) was added and the reaction was diluted to 30 mL with H2O. Aliquat 336 (2.29 mL, 
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5 mmol) in CH2Cl2 (40 mL) was then added to the reaction and stirred at rt for 15 min. The organic 
layer was then separated, dried (Na2SO4) and concentrated to give the title compound as a clear 
viscous oil. Used without further purification.   
Synthesis of ethyl 2-ethoxy-1,5-dimethyl-3,7-dioxabicyclo[4.1.0]heptane-4-carboxylate 116.1 
 
Ethyl 6-ethoxy-3,5-dimethyl-3,6-dihydro-2H-pyran-2-carboxylate (0.2 g, 0.87 mmol) was 
added to a mixture of [(C8H17)3NCH3]3PO4[W(O)(O2)2]4 (0.028 g, 0.0087 mmol) in 30% H2O2 (0.155 
mL, 0.96 mmol) neutralised with 1 drop of 2M NaOH. The reaction was stirred at rt for 4 h. The 
reaction was diluted with NaHCO3(aq) (20 mL) and a Et2O/Pentane mix (10 mL 1:1). The layers 
were separated and the aqueous layer is further extracted with Et2O/Pentane 1:1 mix (3 X 10 
mL). The organic layers were then combined, dried (MgSO4) and concentrated under vacuum to 
give pure title compound as a colourless oil in 95% yield (0.201 g, 0.83 mmol). [α]D20 = +62.5 
(MeOH). 1H NMR (500 MHz, CDCl3) δ 4.8 (dd, J = 1.3, 0.5 Hz, 1H, EtOCHO), 4.2 (d, J = 3.3 Hz, 2H, 
OCHC(O)OEt), 4.2 (qd, J = 7.1, 2.4 Hz, 3H, C(O)OCH2CH3), 4.0 (dq, J = 9.6, 7.1 Hz, 1H, OCHaHbCH3), 
3.6 (dq, J = 9.6, 7.0 Hz, 1H, OCHaHbCH3), 3.0 (dd, J = 2.7, 1.2 Hz, 1H, C(CH3)OCH), 2.6 – 2.5 (m, 1H, 
CHCH3), 1.3 (s, 3H, C(CH3)OCH), 1.3 (t, J = 7.2 Hz, 3H, C(O)OCH2CH3), 1.2 (t, J = 7.0 Hz, 3H, 
OCHaHbCH3), 1.0 (d, J = 7.1 Hz, 3H, CHCH3). 13C NMR (126 MHz, CDCl3) δ 170.6, 100.2, 69.7, 65.5, 
63.0, 61.0, 58.2, 32.0, 18.6, 15.2, 14.4, 10.9. I.R (thin film) νmax (cm-1): 2977, 2935 (C-H), 1758 
(C=O). HRMS (ESI): m/z calculated. C12H20O5: requires: 245.1388 for [M+H]+; found: 245.1370. 
Synthesis of 2-ethoxy-6-(hydroxymethyl)-3,5-dimethyltetrahydro-2H-pyran-3-ol 118.1 
 
2-ethoxy-1,5-dimethyl-3,7-dioxabicyclo[4.1.0]heptane-4-carboxylate (0.1 g, 0.41 mmol) in 
anhydrous THF (5 mL) was added dropwise to a stirred suspension of LiAlH4 (0.063 g, 0.82 mmol) 
in anhydrous THF (5 mL) at 0 °C. The reaction was stirred at 0 °C for 1 h and then poured into a 
saturated solution of NH4Cl (20 mL). The reaction was extracted with Et2O (3 x 20 mL), the 
organic layers were combined, dried (MgSO4) and concentrated under vacuum to give pure title 
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compound as a pale yellow oil in 90% yield (0.075 g, 0.37 mmol). [α]D20 = +44 (MeOH). 1H NMR 
(300 MHz, CDCl3) δ 4.8 (d, J = 1.0 Hz, 1H, OCHOCH2CH3), 4.0 (dq, J = 9.7, 7.1 Hz, 1H, 
OCHOCHaHbCH3), 3.7 – 3.5 (m, 4H, OCHOCHaHbCH3, OCHCH2OH and OCHCH2OH), 2.9 (dd, J = 2.0, 
1.1 Hz, 1H, CHaHbCHCH3), 2.3 (s, 1H, CHaHbCHCH3), 2.2 – 2.1 (m, 1H, CHaHbCHCH3), 1.3 (s, 3H, 
C(OH)CH3), 1.3 (t, J = 7.1 Hz, 3H, CH2CH3), 1.0 (d, J = 7.2 Hz, 3H, CHCH3). 13C NMR (75 MHz, CDCl3) 
δ 99.6, 71.3, 65.4, 63.5, 63.4, 57.7, 30.8, 18.7, 15.3, 11.4. I.R (thin film) νmax (cm-1): 3446 (OH), 
2974, 2931 (C-H). HRMS (ESI): m/z calculated. C10H20O4: requires: 205.1440 for [M+H]+; found: 
205.1431. 
Synthesis of ethyl 5-bromo-6-ethoxy-4-hydroxy-3,5-dimethyltetrahydro-2H-pyran-2-
carboxylate 119.1 
 
NBS (0.052 g, 0.43 mmol) was added to a mixture of ethyl 6-ethoxy-3,5-dimethyl-3,6-
dihydro-2H-pyran-2-carboxylate (0.1 g, 0.43 mmol) in acetone/H2O 1:1 (6 mL). The reaction was 
stirred at 10 °C for 2 h and then concentrated under vacuum. The residue was dissolved in EtO2 
(30 mL) and washed with NaHCO3(aq) (3 x 20 mL). The organics were dried (MgSO4) and 
concentrated under vacuum to give the crude product. The residue was purified via column 
chromatography (20% EtOAc in pentane Rf = 0.2) the fractions containing product were 
combined and concentrated in vacuo to give the title compound as a white solid (0.11 g, 86%, 
0.37 mmol). [α]D20 = +38 (MeOH). 1H NMR (500 MHz, CDCl3) δ 4.6 (s, 1H, OCHOCH2CH3), 4.4 (d, J 
= 8.3 Hz, 1H, OCHC(O) OCH2CH3), 4.3 – 4.3 (m, 1H, CHOH), 4.3 – 4.1 (m, 2H, C(O)CH2CH3), 3.9 – 
3.8 (m, 1H, OCHaHbCH3), 3.6 (dq, J = 9.8, 7.0 Hz, 1H, OCHaHbCH3), 2.3 – 2.2 (m, 1H, CHCH3), 2.2 
(d, J = 3.4 Hz, 1H, OH), 1.8 (s, 3H, C(Br)CH3), 1.3 (t, J = 7.2 Hz, 3H C(O)OCH2CH3), 1.3 (d, J = 7.2 Hz, 
3H, CHCH3), 1.2 (t, J = 7.1 Hz, 3H, OCH2CH3). 13C NMR (126 MHz, CDCl3) δ 170.0, 103.9, 74.2, 65.9, 
60.7, 51.4, 37.2, 23.8, 14.5, 14.3 14.2, 13.7. I.R (thin film) ν max (cm-1): 3467 (OH), 2971, 2942 
(C-H), 1726 (C=O). HRMS (ESI): m/z calculated. C12H21BrO5: requires: 347.0470 for [M+Na]+; 
found: 347.0473. 
 
NMR experiment to show that the epoxide formed from bromohydrin ring closure is the same 
as the epoxide formed directly from dihydropyran 104.2 
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Comparison of epoxide 1H NMR 
Synthesis of ethyl 6-ethoxy-4,5-dihydroxy-3,5-dimethyltetrahydro-2H-pyran-2-carboxylate 
122.1 
 
 AD-mix-α (or AD-mix-β) (1.4 g) was dissolved in 1:1 tert-butanol:water (10 mL) and 
stirred at rt to produce two clear phases. Methanesulfonamide (0.095 g, 1.0 mmol) was added 
and the reaction was cooled to 0 °C. Ethyl 6-ethoxy-3,5-dimethyl-3,6-dihydro-2H-pyran-2-
carboxylate (0.22 g, 1.0 mmol) was then added and the reaction was vigorously stirred at 0 °C 
for 4 d. Sodium sulphite was added and the reaction was allowed to warm to rt and stirred for a 
further 1 h. The reaction mixture was extracted with CH2Cl2 (3 x 10 mL). The organics were 
combined, washed with 2 M KOH(aq), dried (MgSO4) and concentrated under vacuum. The 
resulting residue was purified via column chromatography (20% EtOAc in pentane Rf = 0.3) to 
give the title compound as a clear oil (0.118 g, 45%, 0.45 mmol) [α]D20 = +32 MeOH. 1H NMR (300 
MHz, CDCl3) δ 4.6 (s, 1H, CHCH2CH3), 4.6 (d, J = 3.6 Hz, 1H, OCHC(O) OCH2CH3), 4.2 (qt, J = 6.9, 
3.5 Hz, 2H, C(O)CH2CH3), 4.0 (dq, J = 9.7, 7.1 Hz, 1H, OCHaHbCH3), 3.7 (d, J = 3.5 Hz, 1H, CHOH), 
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3.5 (dq, J = 9.6, 7.0 Hz, 1H, OCHaHbCH3), 2.4 (qt, J = 7.5, 3.6 Hz, 1H, CHCH3), 1.3 – 1.3 (m, 6H, 
C(OH)CH3 and C(O)CH2CH3), 1.2 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.0 (d, J = 7.6 Hz, 3H, CHCH3). 13C 
NMR (75 MHz, CDCl3) δ 170.3, 103.1, 77.3, 73.8, 71.4, 65.6, 61.0, 37.4, 20.5, 15.1, 14.4, 13.0. I.R 
(thin film) ν max (cm-1): 3473 (OH), 2979, 2933 (C-H), 1737 (C=O). HRMS (ESI): m/z calculated. 
C12H22O6: requires: 285.1314 for [M+Na]+; found: 285.1290. 
Synthesis of ethyl 4-ethoxy-2,2,3a,7-tetramethyltetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-6-
carboxylate 123.1 
 
 p-Toluenesulfonic acid (0.001 g, 0.0053 mmol) was added to a stirred solution of ethyl 
6-ethoxy-4,5-dihydroxy-3,5-dimethyltetrahydro-2H-pyran-2-carboxylate (0.03 g, 0.11 mmol) in 
2,2-dimethoxypropane (2 mL) and acetone (2 mL). The reaction was stirred at rt for 2 h, the 
reaction was then concentrated under vacuum, dissolved in Et2O and extracted with saturated 
Na2CO3. The organics were dried (MgSO4) and concentrated under vacuum to give the title 
compound as a pale yellow solid (0.031 g, 95%, 0.0050 mmol), mpt = 56-59 °C, [α]D20 = +57 
MeOH. 1H NMR (300 MHz, CDCl3) δ 4.5 – 4.4 (m, 2H, OCHOCH2CH3 and CHC(O)OCH2CH3), 4.2 (q, 
J = 7.2 Hz, 2H, CHC(O)OCH2CH3), 4.0 (dq, J = 9.4, 7.1 Hz, 1H, OCHaHbCH3), 3.8 (d, J = 1.8 Hz, 1H, 
CHOC(CH3)2), 3.6 (dq, J = 9.4, 7.0 Hz, 1H, OCHaHbCH3), 2.5 (qdd, J = 7.5, 3.1, 1.8 Hz, 1H, CHCH3), 
1.5 (s, 3H, CH3C(O)C(O)), 1.4 (s, 3H, OC(CH3)a(CH3)bO), 1.3 (s, 3H, OC(CH3)a(CH3)bO), 1.3 – 1.2 (m, 
3H, C(O)OCH2CH3), 1.3 – 1.2 (m, 3H, OCH2CH3), 1.0 (d, J = 7.5 Hz, 3H, CHCH3). 13C NMR (75 MHz, 
CDCl3) δ 170.0, 108.1, 104.6, 84.5, 78.4, 73.6, 65.7, 61.2, 33.8, 28.5, 26.9, 17.7, 15.0, 14.4, 12.3. 
I.R (thin film) ν max (cm-1): 2979, 2933, 2879 (C-H), 1753 (C=O). HRMS (ESI): m/z calculated. 
C15H26O6: requires: 325.1627 for [M+Na]+; found: 325.1657. 
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Synthesis of (2S,3S,6S)-ethyl 6-ethoxy-3,5-dimethyl-3,6-dihydro-2H-pyran-2-carboxylate 
104.3 
 
 Potassium tert-butoxide (0.02 g, 0.16 mmol) in THF (0.5 mL) was added dropwise to a 
stirred solution of (2R,3S,6S)-ethyl 6-ethoxy-3,5-dimethyl-3,6-dihydro-2H-pyran-2-carboxylate 
(0.20 g, 0.8 mmol) in THF (4 mL) at 0 °C. The reaction as stirred at 0 °C for 2 h, 1 M NaHSO4(aq) 
(0.4 mL) was added and the reaction was warmed to rt. The reaction was diluted with Et2O (20 
mL) and extracted with H2O and brine. The aqueous layers were extracted with Et2O, the 
organics were combined, dried (MgSO4) and concentrated under vacuum to give the title 
compound as a clear oil (0.192 g, 96%, 0.77 mmol). [α]D20 = +20.5 MeOH. 1H NMR (300 MHz, 
Chloroform-d) δ 5.4 (d, J = 2.3 Hz, 1H, C=CH), 4.8 (s, 1H, OCHOCH2CH3), 4.3 (q, J = 7.1 Hz, 2H, 
C(O)OCH2CH3), 4.0 (d, J = 10.4 Hz, 1H, CHC(O)OCH2CH3) 3.8 (dq, J = 9.9, 7.1 Hz, 1H, CHaHbCH3), 
3.6 (dq, J = 9.8, 7.1 Hz, 1H, CHaHbCH3), 2.5 (ddtt, J = 9.2, 5.6, 2.1, 1.1 Hz, 1H, CHCH3), 1.7 (q, J = 
1.9 Hz, 3H, CH3C=C), 1.3 (t, J = 7.1 Hz, 3H, C(O)OCH2CH3), 1.2 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.0 (d, 
J = 7.1 Hz, 3H, CHCH3). 13C NMR (75 MHz, Chloroform-d) δ 171.2, 131.5, 128.6, 97.3, 72.9, 64.3, 
61.2, 32.4, 18.8, 16.7, 15.4, 14.4. I.R (thin film) νmax (cm-1): 2974, 2876 (C-H), 1740 (C=O). HRMS 
(ESI): m/z calculated. C12H20O4: requires 251.1259 for [M+Na]+; found: 251.1263. 
Computational results 
Entry Compound I/TS Description G/Hartrees 
ΔG 
(kcal/mol) 
1 
 
I CO2Et up, eq. -770.177310 2.3 
2 
 
I CO2Et up, ax. -770.173262 4.8 
3 
 
I CO2Et down, eq. -770.180908 0 
4 
 
I CO2Et down, ax. -770.177082 2.4 
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Synthesis of ethyl 2-ethoxy-1,5-dimethyl-3,7-dioxabicyclo[4.1.0]heptane-4-carboxylate 128.1 
 
Ethyl 6-ethoxy-3,5-dimethyl-3,6-dihydro-2H-pyran-2-carboxylate (0.1 g, 0.44 mmol) was 
added to a mixture of [(C8H17)3NCH3]3PO4[W(O)(O2)2]4 (0.014 g, 0.0044 mmol) in 30% H2O2 (0.078 
mL, 0.48 mmol) neutralised with 1 drop of 2M NaOH. The reaction was stirred at rt for 4 h. The 
reaction was diluted with NaHCO3(aq) (20 mL) and a Et2O/Pentane mix (10 mL 1:1). The layers 
were separated and the aqueous layer is further extracted with Et2O/Pentane 1:1 mix (3x 10 
mL). The organic layers were then combined, dried (MgSO4) and concentrated under vacuum to 
give pure title compound as a colourless oil in a 96% yield (0.101 g, 0.42 mmol). 1H NMR (300 
MHz, CDCl3) δ 4.9 (s, 1H, CHOCH2CH3), 4.2 (q, J = 7.2 Hz, 2H, C(O)OCH2CH3), 3.9 (d, J = 10.4 Hz, 
1H, OCHaHbCH3), 3.8 (dt, J = 9.8, 7.1 Hz, 1H, CHC(O)OCH2CH3), 3.6 (dq, J = 9.8, 7.0 Hz, 1H, 
OCHaHbCH3), 2.9 (s, 1H, CHO (epoxide)), 2.4 – 2.2 (m, 1H, CHCH3), 1.3 (s, 3H, CO(CH3)), 1.3 (dt, J 
= 13.2, 7.2 Hz, 6H, CHOCH2CH3 and C(O)OCH2CH3), 1.1 (d, J = 7.3 Hz, 3H, CHCH3). 13C NMR (75 
MHz, CDCl3) δ 170.6, 97.7, 70.3, 64.5, 62.0, 61.4, 55.1, 30.8, 18.0, 15.8, 15.2, 14.3. I.R (thin film) 
ν max (cm-1): 2985, 2940 (C-H), 1731 (C=O). HRMS (ESI): m/z calculated. C12H20O5: requires: 
245.1388 for [M+H]+; found: 245.1370. 
Synthesis of (E)-1-ethoxy-2-methylbuta-1,3-diene 130.1 
 
nBuLi (14.7 mL, 1.4 M in hexanes) was added slowly to a stirred solution of 
diisopropylamine (4.16 mL, 28.8 mmol) in THF (50 mL) at -78 °C and stirred for 10 min. The 
reaction was then warmed to 0 °C followed by the addition of methyltriphenylphosphonium 
bromide 8.93 g, 25.0 mmol) the reaction was then allowed to warm to rt and stirred for 1 h. (E)-
3-ethoxy-2-methylacrylaldehyde 20.2 (2.35 g, 20.6 mmol) was added dropwise and stirred for 2 
h. The reaction was then diluted with H2O (100 mL) and extracted with Et2O (3x 50 mL), the 
combined organic layers were dried (MgSO4) and carefully concentrated in vacuo to give a crude 
mixture of product and triphenylphosphine oxide. The product was purified by distillation under 
reduced pressure to give the title compound as a clear oil (1.61 g, 70%, 14.42 mmol). 1H NMR 
(300 MHz, CDCl3) δ 6.3 (dd, J = 17.2, 10.7 Hz, 1H, CH=CH2), 6.2 (s, 1H, CHOCH2CH3), 5.0 (ddd, J = 
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17.2, 1.4, 0.7 Hz, 1H, CH=CHaHb), 4.8 (dd, J = 10.7, 1.4 Hz, 1H, CH=CHaHb), 3.9 (q, J = 7.1 Hz, 2H, 
OCH2CH3), 1.7 (d, J = 1.3 Hz, 3H, CH3C=C), 1.3 (t, J = 7.1 Hz, 3H, OCH2CH3). 13C NMR (75 MHz, 
CDCl3) δ 148.0, 137.0, 114.7, 107.9, 68.3, 15.5, 9.0. I.R (thinfilm) νmax (cm-1): 2980, 2939, 2880 
(C=C-H), 1651 (C=C). 
Synthesis of (ethoxymethyl)triphenylphosphonium chloride  
 
 Triphenylphosphine (20.0 g, 0.076 mol) and chloromethyl ethyl ether (7.9 g, 0.084 mol) 
were dissolved in CH2Cl2 and heated at 42 °C for 12 h. The reaction was concentrated under 
vacuum, the solid residue was washed with pet ether to give the title compound as a white solid 
(27.0 g, 99%, 0.0752 mol). 1H NMR (300 MHz, CDCl3) δ 7.7 (s, 9H, ArH), 7.6 (dddq, J = 7.7, 6.2, 
3.7, 1.2 Hz, 6H, ArH), 5.8 (d, J = 4.0 Hz, 2H, CH2OCH2CH3), 3.9 (q, J = 7.0 Hz, 2H, CH2OCH2CH3), 1.1 
(t, J = 7.0 Hz, 3H, CH2OCH2CH3). 31P NMR (122 MHz, CDCl3) δ 18.6. 
Analytical data in accordance with literature.335 
Synthesis of (1E,3E)-1-ethoxypenta-1,3-diene 131.2 
 
nBuLi (14.7 mL, 1.4 M in hexanes) was added slowly to a stirred solution of 
diisopropylamine (4.16 mL, 28.8 mmol) in THF (50 mL) at -78 °C and stirred for 10 min. The 
reaction was then warmed to 0 °C followed by the addition of 
(ethoxymethyl)triphenylphosphonium chloride (8.92 g, 25.0 mmol) the reaction was then 
allowed to warm to rt and stirred for 1 h. Freshly distilled crontonaldehyde (1.44 g, 20.6 mmol) 
was added dropwise and stirred for 2 h. The reaction was then diluted with H2O (100 mL) and 
extracted with Et2O (3x 50 mL), the combined organic layers were dried (MgSO4) and carefully 
concentrated in vacuo to give a crude mixture of product and triphenylphosphine oxide. The 
product was purified by distillation under reduced pressure to give the title compound as a clear 
oil (1.73 g, 75%, 15.45 mmol). As a mixture of (E, E) and (E, Z). 1H NMR (300 MHz, CDCl3) δ 6.5 – 
6.4 (m, 1H), 6.4 (dddt, J = 12.6, 2.7, 1.8, 1.0 Hz, 1H), 6.0 – 5.9 (m, 1H), 5.9 – 5.8 (m, 1H), 5.6 – 5.4 
(m, 3H), 5.0 (dd, J = 10.8, 6.2 Hz, 1H), 3.8 (dq, J = 21.3, 7.1 Hz, 4H), 1.8 – 1.7 (m, 6H), 1.3 (t, J = 
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7.1 Hz, 6H). 13C NMR (75 MHz, CDCl3) δ 148.5, 144.1, 127.4, 125.6, 124.3, 123.5, 106.9, 106.8, 
68.2, 65.3, 18.4, 18.3, 15.4, 14.9. 
Synthesis of ethyl 6-ethoxy-5-methyl-3,6-dihydro-2H-pyran-2-carboxylate 132.2 
 
CH2Cl2 (3.0 mL) was added to binaphthol-titanium complex 106.3 (0.016 g, 0.04 mmol) 
under a N2 environment, ethyl glyoxalate 50% in CH2Cl2 (0.32 mL, 1.6 mmol) was added and the 
reaction cooled to -30 °C. (1E,3E)-1-ethoxypenta-1,3-diene (0.09 g, 0.8 mmol) was added and 
the reaction was stirred at -30 °C for 4 h. The reaction was concentrated in vacuo to give a crude 
mixture which was purified by column chromatography (10% EtOAc in pentane Rf = 0.45). The 
fractions containing product were combined and concentrated in vacuo to give the title 
compound as a clear oil (0.116 g, 68%), [α]D20 = +88 (MeOH). 1H NMR (500 MHz, CDCl3) δ 5.6 
(ddddd, J = 3.7, 2.8, 2.2, 1.5, 0.7 Hz, 1H, C=CH), 4.9 (s, 1H, OCHOCH2CH3), 4.5 – 4.4 (m, 1H, 
CHC(O)OCH2CH3), 4.2 (qd, J = 7.1, 3.2 Hz, 2H, CHC(O)OCH2CH3), 3.9 (dq, J = 9.9, 7.1 Hz, 1H, 
OCHaHbCH3), 3.6 (dq, J = 9.8, 7.0 Hz, 1H, OCHaHbCH3), 2.3 – 2.2 (m, 2H, C=CHCH2), 1.7 (q, J = 2.0 
Hz, 3H, CH3C=C), 1.3 (t, J = 7.1 Hz, 3H, CHC(O)OCH2CH3), 1.2 (t, J = 7.1 Hz, 3H, OCH2CH3). 13C NMR 
(75 MHz, CDCl3) δ 171.7, 132.7, 121.5, 97.9, 65.9, 64.2, 61.2, 27.9, 19.1, 15.4, 14.4. I.R (thin film) 
ν max (cm-1): 2977, 2897 (C-H), 1736 (C=O). HRMS (ESI): m/z calculated. C11H18O4: requires 
237.1103 for [M+Na]+; found: 237.1168. 
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Synthesis of ethyl 6-ethoxy-3-methyl-3,6-dihydro-2H-pyran-2-carboxylate 133.1 
 
CH2Cl2 (3.0 mL) was added to binaphthol-titanium complex 106.3 (0.016 g, 0.04 mmol) 
under a N2 environment, ethyl glyoxalate 50% in CH2Cl2 (0.32 mL, 1.6 mmol) was added and the 
reaction cooled to -30 °C. (E)-1-ethoxy-2-methylbuta-1,3-diene (0.09 g, 0.8 mmol) was added 
and the reaction was stirred at -30 °C for 4 h. The reaction was concentrated in vacuo to give a 
crude mixture which was purified by column chromatography (10% EtOAc in pentane Rf = 0.45). 
The fractions containing product were combined and concentrated in vacuo to give the title 
compound as a clear oil (0.094 g, 55%), [α]D20 = +73 (MeOH). 1H NMR (300 MHz, CDCl3) δ 6.0 
(ddd, J = 10.1, 5.3, 1.5 Hz, 1H, CH=CHCHCH3), 5.6 (dt, J = 10.1, 1.2 Hz, 1H, CH=CHCHCH3), 5.2 (dt, 
J = 2.6, 1.4 Hz, 1H, OCHOCH2CH3), 4.4 (d, J = 3.5 Hz, 1H, CHC(O)OCH2CH3), 4.3 (qd, J = 7.1, 1.0 Hz, 
2H, CHC(O)OCH2CH3), 4.0 (dq, J = 9.4, 7.1 Hz, 1H, OCHaHbCH3), 3.6 (dq, J = 9.4, 7.1 Hz, 1H, 
OCHaHbCH3), 2.6 – 2.4 (m, 1H, CHCH3), 1.3 (t, J = 7.2 Hz, 3H, CHC(O)OCH2CH3), 1.2 (t, J = 7.1 Hz, 
3H, OCH2CH3), 1.0 (d, J = 7.0 Hz, 3H, CHCH3). 13C NMR (75 MHz, CDCl3) δ 170.0, 134.6, 126.7, 
98.5, 74.0, 63.8, 61.1, 31.7, 15.4, 14.8, 14.4. I.R (thin film) νmax (cm-1): 2977, 2897 (C-H), 1759 
(C=O), 1731 (C=C). HRMS (ESI): m/z calculated. C11H18O4: requires 237.1103 for [M+Na]+; found: 
237.1138. 
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Synthesis of ethyl 6-ethoxy-4-hydroxy-5-methyltetrahydro-2H-pyran-2-carboxylate 134.1 
 
Borane dimethyl sulfide complex (0.2 mL, 1.75 mmol) was added dropwise to a stirred 
solution of ethyl 6-ethoxy-5-methyl-3,6-dihydro-2H-pyran-2-carboxylate (0.18 g, 0.87 mmol) in 
THF (5 mL) at  -5 °C the reaction was then placed in a freezer at -20 °C for 16 h. The reaction was 
warmed to -5 °C followed by the addition of H2O2 (30 % w/w) (0.548 mL) and NaOH (0.2 g, 4.35 
mmol) the reaction was stirred for a further 1 h. The reaction was diluted with H2O (10 mL) and 
Et2O (20 mL) the layers were separated and the organics were washed with H2O (3x 10 mL), dried 
(MgSO4) and concentrated in vacuo. The residue was purified via column chromatography (20% 
EtOAc in pentane, Rf = 0.35) the fractions containing product were combined and concentrated 
in vacuo to give the title compound as a clear oil (0.131 g, 65%). [α]D20 = +63.5 (MeOH). 1H NMR 
(300 MHz, CDCl3) δ 4.8 (d, J = 2.8 Hz, 1H), 4.4 (dd, J = 7.0, 4.5 Hz, 1H), 4.3 – 4.0 (m, 2H), 4.0 (td, J 
= 6.7, 3.7 Hz, 1H), 3.9 (dq, J = 9.7, 7.1 Hz, 1H), 3.5 (dq, J = 9.7, 7.1 Hz, 1H), 2.2 (ddd, J = 13.5, 7.2, 
3.7 Hz, 1H), 1.9 – 1.7 (m, 2H), 1.3 (t, J = 7.1 Hz, 3H), 1.2 (t, J = 7.1 Hz, 3H), 1.0 (d, J = 6.9 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 171.8, 101.2, 70.4, 68.3, 65.0, 61.2, 41.3, 32.8, 15.0, 14.3, 11.4. I.R 
(thin film) ν max (cm-1): 3466 (OH), 2979, 2933 (C-H), 1736 (C=O). HRMS (ESI): m/z calculated. 
C11H20O5: requires 255.12084 for [M+Na]+; found: 255.1233. 
Synthesis of ethyl 2-ethoxy-1-methyl-3,7-dioxabicyclo[4.1.0]heptane-4-carboxylate 
135.1/135.2 
 
Ethyl 6-ethoxy-5-methyl-3,6-dihydro-2H-pyran-2-carboxylate (0.18 g, 0.87 mmol) was 
added to a mixture of [(C8H17)3NCH3]3PO4[W(O)(O2)2]4 (0.028 g, 0.0087 mmol) in 30% H2O2 (0.155 
mL, 0.96 mmol) neutralised with 1 drop of 2M NaOH. The reaction was stirred at rt for 4 h. The 
reaction was diluted with NaHCO3(aq) (20 mL) and a Et2O/Pentane mix (10 mL 1:1). The layers 
were separated and the aqueous layer is further extracted with Et2O/Pentane 1:1 mix (3x 10 
mL). The organic layers were then combined, dried (MgSO4) and concentrated under vacuum to 
give pure title compound as a colourless oil in a 80% yield (0.160 g, 0.69 mmol). [α]D20 = +61 
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(MeOH). 1H NMR (300 MHz, CDCl3) δ 4.8 (s, 1H), 4.3 – 4.1 (m, 3H), 4.0 (dq, J = 9.6, 7.1 Hz, 1H), 
3.6 (dqd, J = 9.6, 7.0, 4.4 Hz, 1H), 3.3 – 3.1 (m, 1H), 2.3 (ddd, J = 14.7, 5.2, 2.5 Hz, 1H), 2.3 – 2.1 
(m, 2H), 1.3 (d, J = 2.0 Hz, 3H), 1.3 (t, J = 7.1 Hz, 3H), 1.3 – 1.2 (m, 3H). 13C NMR (75 MHz, CDCl3) 
δ 171.5, 99.8, 98.0, 66.9, 65.3, 61.3, 56.9, 27.0, 18.2, 15.1, 14.2. I.R (thin film) ν max (cm-1): 2979, 
2932 (C-H), 1756 (C=O). HRMS (ESI): m/z calculated. C12H20O5: requires: 245.1388 for [M+H]+; 
found: 245.1378. 
Synthesis of ethyl 6-ethoxy-4-hydroxy-3-methyltetrahydro-2H-pyran-2-carboxylate and ethyl 
6-ethoxy-5-hydroxy-3-methyltetrahydro-2H-pyran-2-carboxylate 136.1/136.2 
 
Borane dimethyl sulfide complex (0.22 mL, 1.86 mmol) was added dropwise to a stirred 
solution of ethyl 6-ethoxy-5-methyl-3,6-dihydro-2H-pyran-2-carboxylate (0.20 g, 0.93 mmol) in 
THF (5 mL) at  -5 °C the reaction was then placed in a freezer at -20 °C for 16 h. The reaction was 
warmed to -5 °C followed by the addition of H2O2 (30 % w/w) (0.548 mL) and NaOH (0.2 g, 4.35 
mmol) the reaction was stirred for a further 1 h. The reaction was diluted with H2O (10 mL) and 
Et2O (20 mL) the layers were separated and the organics were washed with H2O (3x 10 mL), dried 
(MgSO4) and concentrated in vacuo. The residue was purified via column chromatography (20% 
EtOAc in pentane, Rf = 0.37 and 0.35). The fractions containing product were combined and 
concentrated in vacuo to give ethyl 6-ethoxy-4-hydroxy-3-methyltetrahydro-2H-pyran-2-
carboxylate as a clear oil (0.097 g, 45%) and ethyl 6-ethoxy-5-hydroxy-3-methyltetrahydro-2H-
pyran-2-carboxylate as a mix of diastereomers (0.064 g, 30%). 
Ethyl 6-ethoxy-4-hydroxy-3-methyltetrahydro-2H-pyran-2-carboxylate 136.1 
1H NMR (500 MHz, CDCl3) δ 4.3 – 4.2 (m, 2H, C(O)OCH2CH3), 4.2 (d, J = 2.7 Hz, 1H, CHOCH2CH3), 
4.2 (d, J = 7.7 Hz, 1H, CHC(O)OCH2CH3), 4.1 (dq, J = 10.2, 7.3 Hz, 1H, OCHaHbCH3), 3.7 (ddd, J = 
12.3, 7.7, 5.1 Hz, 1H, CHOH), 3.6 – 3.5 (m, 1H, OCHaHbCH3), 2.4 (qdt, J = 7.4, 5.1, 2.6 Hz, 1H, 
CHCH3), 2.0 (ddd, J = 13.1, 5.1, 2.3 Hz, 1H, CHaHbCHOH), 1.8 – 1.7 (m, 1H, CHaHbCHOH), 1.3 – 1.3 
(m, 3H, C(O)OCH2CH3), 1.3 – 1.2 (m, 3H, CHOCH2CH3), 1.0 (d, J = 7.2 Hz, 3H, CHCH3). 13C NMR 
(126 MHz, CDCl3) δ 169.7, 106.0, 77.1, 65.9, 65.4, 61.1, 36.4, 31.9, 15.2, 14.4, 13.9. I.R (thin film) 
ν max (cm-1): 3484 (OH), 2976, 2934 (C-H), 1735 (C=O). HRMS (ESI): m/z calculated. C11H20O5: 
requires: 255.12084 for [M+Na]; found: 255.1219. 
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Ethyl 6-ethoxy-5-hydroxy-3-methyltetrahydro-2H-pyran-2-carboxylate 136.2 
1H NMR (500 MHz, CDCl3) δ 4.3 – 4.2 (m, 2H, CHOCH2CH3 and CHC(O)OCH2CH3), 4.0 – 3.8 (m, 1H, 
CHOH), 3.6 – 3.5 (m, 2H, C(O)OCH2CH3), 3.4 (dt, J = 9.4, 3.0 Hz, 1H, CHaHbCH3), 3.3 (ddd, J = 9.4, 
7.9, 3.4 Hz, 1H, CHaHbCH3), 2.3 (dtdt, J = 12.1, 7.5, 5.2, 2.6 Hz, 1H, CHCH3), 1.7 – 1.5 (m, 1H, 
CHaHbCHOH), 1.5 – 1.4 (m, 1H, CHaHbCHOH), 1.3 (td, J = 7.1, 2.2 Hz, 3H, C(O)OCH2CH3), 1.2 (td, J 
= 7.0, 0.8 Hz, 3H, CHOCH2CH3), 0.9 (dd, J = 6.9, 2.3 Hz, 3H, CHCH3). 13C NMR (126 MHz, CDCl3) δ 
175.2, 110.2, 75.4, 75.1, 74.3, 72.4, 68.6, 67.7, 66.9, 66.8, 61.9, 61.8, 36.7, 36.5, 33.8, 33.2, 15.3, 
14.4, 14.1, 13.2. I.R (thin film) ν max (cm-1): 3466 (OH), 2971, 2932 (C-H), 1737 (C=O). HRMS (ESI): 
m/z calculated. C11H20O5: requires: 255.12084 for [M+Na]; found: 255.1260. 
Synthesis of 1-tert-butyl 8-ethyl 7-hydroxy-2,4,6-trimethylocta-2,4-dienedioate 138.2 
 
5 M HCl (1.2 mL in 0.4 mL of H2O) was added to a stirred solution of (2R,3S,6S)-ethyl 6-
ethoxy-3,5-dimethyl-3,6-dihydro-2H-pyran-2-carboxylate (0.20 g, 0.8 mmol) in THF (10 mL) at rt. 
The reaction was heated to 50 °C and heated for 1.5 h. the reaction was cooled and quenched 
with NaHCO3(aq) (10 mL). The reaction was extracted with Et2O (3x 30 mL) and the organics 
were combined, dried (MgSO4) and concentrated en vacuo to give the synthetic sugar. The 
material was carried forward as the crude product for the next step. The residue was dissolved 
in toluene (5 mL) and stirred at rt. To this was added benzoic acid (0.005 g, 0.04 mmol) and tert-
butyl 2-(triphenylphosphoranylidene)propanoate (0.344 g, 0.88 mmol). The reaction was heated 
to reflux and stirred for 8 h. The reaction was then cooled and concentrated, the resulting 
residue was purified by column chromatography (20% EtOAc in pet ether Rf = 0.2) to give the 
title compound as a pale yellow wax in a 70% yield (0.175 g, 0.56 mmol) as a mixture of E/Z 
isomers.   
E isomer  
1H NMR (300 MHz, Chloroform-d) δ 7.1 (d, J = 1.9 Hz, 1H, (CO2tBu)C=CHC=CH), 5.4 (dq, J = 10.2, 
1.5 Hz, 1H, (CO2tBu)C=CHC=CH), 4.3 – 4.2 (m, 2H, CH2CH3), 4.0 (dd, J = 6.3, 3.7 Hz, 1H, CHOH), 
2.8 – 2.6 (m, 1H, CHCH3), 1.8 (s, 3H, (CO2tBu)CH3C=C-(CH3)C=C), 1.8 (d, J = 1.4 Hz, 3H, 
(CO2tBu)CH3C=C-(CH3)C=C), 1.5 (s, 9H, C(CH3)3), 1.3 – 1.3 (m, 3H, CH2CH3), 0.9 (d, J = 6.8 Hz, 3H, 
CHCH3). 
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Z isomer 
1H NMR (300 MHz, Chloroform-d) δ 7.1 – 7.0 (m, 1H, (CO2tBu)C=CHC=CH), 5.5 (d, J = 9.8 Hz, 1H, 
(CO2tBu)C=CHC=CH), 4.4 – 4.2 (m, 2H, CH2CH3), 4.1 (dd, J = 6.4, 4.1 Hz, 1H, CHOH), 3.0 – 2.9 (m, 
1H, CHCH3), 2.0 (d, J = 1.5 Hz, 3H, (CO2tBu)CH3C=C-(CH3)C=C), 1.9 (d, J = 1.4 Hz, 3H, 
(CO2tBu)CH3C=C-(CH3)C=C), 1.5 (s, 3H, C(CH3)3), 1.3 (dd, J = 7.1, 5.4 Hz, 3H, CH2CH3), 1.0 (d, J = 6.9 
Hz, 3H, CHCH3). 
13C NMR (75 MHz, Chloroform-d) δ 174.4, 168.4, 167.7, 141.5, 137.7, 135.5, 133.1, 132.8, 131.4, 
130.3, 130.1, 128.0, 80.5, 80.3, 74.1, 74.0, 62.0, 61.8, 37.5, 37.2, 28.3, 23.3, 16.8, 14.9, 14.5, 
14.4, 14.3, 14.3, 14.2. I.R (thin film) νmax (cm-1): 3497 (OH), 2977, 2933 (C-H), 1730, 1702 (C=O). 
HRMS (ESI): m/z calculated. C17H28O5: requires 313.20149 for [M]+; found: 313.2001. 
6-Ethoxy-3,5-dimethyl-3,6-dihydro-2H-pyran-2-yl)methanol 137.1 
 
LiAlH4 (2.4 M in THF, 4.0 mL) was added dropwise to a solution of (2R,3S,6S)-ethyl 6-
ethoxy-3,5-dimethyl-3,6-dihydro-2H-pyran-2-carboxylate (1.0 g, 4.8 mmol) in THF (10 mL) at 0 
°C. The reaction was stirred at 0 °C for 1 h and then poured into a solution of saturated NH4Cl 
(20 mL). The reaction mixture was then extracted with Et2O (3x 30 mL) and the organics were 
combined, dried (MgSO4) and concentrated en vacuo to give pure title compound as a clear oil 
in 95% yield (0.85 g, 4.56 mmol). [α]D20 = +71 (MeOH). 1H NMR (300 MHz, CDCl3) δ 5.6 (dp, J = 
4.4, 1.5 Hz, 1H, C=CH), 4.9 (dt, J = 2.0, 1.0 Hz, 1H, CHCH2CH3), 3.9 – 3.8 (m, 2H, CHCH2CH3), 3.8 – 
3.5 (m, 2H, CHCH2OH), 2.5 (br s, 1H, CHCH2OH), 2.4 (tdd, J = 7.1, 3.9, 2.0 Hz, 1H, CHCH3), 1.7 (td, 
J = 1.8, 0.9 Hz, 3H, C=CCH3), 1.3 (t, J = 7.1 Hz, 3H, CHCH2CH3), 1.0 (d, J = 7.2 Hz, 3H, CHCH3). 13C 
NMR (75 MHz, CDCl3) δ 131.7, 129.7, 98.4, 75.3, 63.8, 63.1, 30.8, 18.3, 15.4, 14.8. I.R (thin film) 
νmax (cm-1): 3423 (OH), 2970, 2930, 2875 (C-H). HRMS (ESI): m/z calculated. C10H18O3: requires 
209.1153 for [M+Na]+; found: 209.1162. 
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6-Ethoxy-3,5-dimethyl-3,6-dihydro-2H-pyran-2-yl)methyl 4-methylbenzenesulfonate 141.1 
 
NEt3 (0.19 mL, 1.48 mmol) was added to a solution of 6-Ethoxy-3,5-dimethyl-3,6-
dihydro-2H-pyran-2-yl)methanol (0.25 g, 1.34 mmol) and tosyl chloride (0.28 g, 1.48 mmol) in 
CH2Cl2 (10 mL) at 0 °C. The reaction was allowed to warm to rt and stirred for 16 h. The reaction 
was diluted with 1 M NaOH and extracted with Et2O (3x 30 mL) and the organics were combined, 
dried (MgSO4) and concentrated en vacuo, the resulting residue was purified by column 
chromatography (10% EtOAc in pet ether Rf = 0.4) to give the title compound as a clear oil in a 
82% yield (0.374 g, 1.10 mmol). 1H NMR (300 MHz, CDCl3) δ 7.9 – 7.7 (m, 2H, ArH), 7.4 – 7.3 (m, 
2H, ArH), 5.5 (dp, J = 4.5, 1.5 Hz, 1H, C=CH), 4.9 (s, 1H, CHOCH2CH3), 4.2 – 3.9 (m, 3H, 
CHCH2OSO2Ts and CHCH2OSO2Ts), 3.7 (dq, J = 9.5, 7.1 Hz, 1H, CHOCHaHbCH3), 3.5 (dq, J = 9.6, 7.1 
Hz, 1H, CHOCHaHbCH3), 2.4 (s, 3H, CH3Ar), 2.2 (dddt, J = 9.3, 5.8, 4.0, 2.1 Hz, 1H, CHCH3), 1.6 (q, J 
= 1.3 Hz, 3H, C=CCH3), 1.2 (td, J = 7.1, 2.3 Hz, 3H, CHOCHaHbCH3), 0.9 (d, J = 7.1 Hz, 3H, CHCH3). 
13C NMR (75 MHz, CDCl3) δ 145.0, 144.0, 132.8, 130.0, 129.0, 128.1, 99.4, 71.9, 69.8, 63.4, 30.7, 
21.8, 17.9, 15.3, 14.1. I.R (thin film) νmax (cm-1): 2971, 2879 (C-H). HRMS (ESI): m/z calculated. 
C17H24O3S1: requires 363.1242 for [M+Na]+; found: 363.1246. 
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X-Ray Crystallography Data  
 
 
Name 
rslc-2-127 
Formula C12 H21 Br O5 
M / g mol-1 325.20 
T (K), radiation 150, Cu Kα 
Space Group P21/c 
a (Å) 13.7446(2) 
b (Å) 12.37620(10) 
c (Å) 8.59960(10) 
α (o) 90 
β (o) 104.2950(10) 
γ (o) 90 
Volume (Å3) 1417.55(3) 
Z 4 
ρcal/ Mg cm-3 
1.524 
μ/mm-1 4.067 
θ range/° 4.878-66.601 
Completeness 100 % 
Refln. Collected 14324 
Independent 2502 
Refln (obs.I>2σ(I)) 2456 
Rint 0.0234 
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Parameters 247 
GooF 0.947 
R1 (obs) 0.0216 
R1 (all) 0.0219 
wR2 (all) 0.0585 
ρmax,min/e Å-3 
0.304,-0.338 
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